DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           1 
CONFIDENTIAL  
 A Phase 2 Multi -Center, Prospective, Randomized, Double -Blind 
Study to Assess the Clinical and Antiviral Efficacy and Safety of 
Nitazoxanide for the Treatment of Norovirus in Hematopoietic Stem 
Cell and Solid Organ Transplant Recipi[INVESTIGATOR_270515] r: 16-0092  
DMID Funding Mechanism: Contract # HHSN272201600016C  
Pharmaceutical Support Provided by: [CONTACT_270612], L.C.  
Other Identifying Numbers: NIAID -DMID -NIH-AI-2014028  
IND Sponsor: National Institute of Al lergy and Infectious D iseases, Division of Microbiology 
and Infectious Diseases  
Lead Principal Investigator: [INVESTIGATOR_68020] G Ison, MD, MS   
DMID Clinical Protocol Manager : Gabriele Feolo , RN, MSN  
DMID Scientific Lead:  Rodolfo M. Alarcón, PhD  
DMID Medical Officer: John Beigel , MD  
DMID Medical Monitor:  Jorge  Mejia -Galvis,  M.D.  [C]  
Version Number: 4.0 
21 January, 2020  
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           2 
CONFIDENTIAL  
 STATEMENT OF COMPLIANCE  
The study  trial will be carried out in accordance with Good Clinical Practice (GCP) and as 
required by [CONTACT_716] : 
• [LOCATION_002] Code of Federal Regulations (CFR) 45 CFR Part 46: Protection of Human 
Subjects  
• Food and Drug Administration (FDA) Regulations, as applicabl e: 21 CFR Part 50 
(Protection of Human Subjects), 21 CFR Part 54 (Financial Disclosure by [CONTACT_1615]) , 21 CFR Part 56 (Institutional Review Boards), 21 CFR Part 11, and 21 
CFR Part 312 (Investigational New Drug Application), 21 CFR 812 (Investi gational 
Device Exemptions)  
• International Conference on Harmonis ation : Good Clinical Practice (ICH E6); 62 Federal 
Register [ZIP_CODE] (1997); and future revisions  
• Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects 
of Researc h, Report of the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research  
• National Institutes of Health (NIH) Office of Extramural Research, Research Involving 
Human Subjects, as applicable  
• National Institute of Allerg y and Infectious Diseases (NIAID) Clinical Terms of Award , 
as applicable  
• Applicable Federal, State, and Local Regulations and Guidance  
All key personnel (all individuals responsible for the design and conduct of this study) have 
completed Human Subjects Pr otection Training.  
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           3 
CONFIDENTIAL  
 SIGNATURE [CONTACT_140180], including all statements regarding confidentiality, and 
according to local legal and r egulatory requirements and applicable US federal regulations and 
ICH E6 Good Clinical Practice (GCP) guidelines.  
 
I agree to conduct the study in compliance with GCP and applicable regulatory requirements.  
 
I agree to conduct the study in accordance with t he current protocol and will not make changes to 
the protocol without obtaining the sponsor’s approval and IRB/IEC approval, except when 
necessary to protect the safety, rights, or welfare of subjects.  
 
Site Investigator  Signature : 
 
[INVESTIGATOR_14586]:   Date:   
    
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329805] 
Administration  ................................ ................................ ................................ .. 48 
5.3.4  Handling of Withdrawals  ................................ ................................ .................  49 
5.3.5  Termination of Study  ................................ ................................ .......................  50 
6 Study Intervention/Investigational Product  ................................ ................................ .............  [ADDRESS_329806] Storage and Stability  ................................ ................................ ..........  52 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           5 
CONFIDENTIAL  
 6.2 Dosage, Preparation and Administration of Study Intervention/Investigational 
Product  ................................ ................................ ................................ ...........................  53 
         6.3       Modifiction of Study Intervention/Investigational Product for a Participant…...… 53 
6.4 Accountability Procedures for the Study Intervention/Investigational Product(s)  ... [ADDRESS_329807] Compliance with Study Intervention/Investigational 
Product  ................................ ................................ ................................ ...........................  54 
6.6 Concomitant Medications/Treatments  ................................ ................................ .........  54 
7      Study  Schedule……………………………………………... ……………………………… 56 
7.1 Screening/Baseline/Treatment Phase  ................................ ................................ ..........  57 
7.2 Follow -up ................................ ................................ ................................ ......................  62 
7.3 Final Study Visit  ................................ ................................ ................................ ...........  63 
7.4 Early Termination Visit  ................................ ................................ ................................  63 
7.5 Unscheduled Visit  ................................ ................................ ................................ .........  63 
8 Study Procedures/Evaluations  ................................ ................................ ................................ .. 64 
8.1 Clinical  Evaluations  ................................ ................................ ................................ ...... 64 
8.2 Laboratory Evaluations  ................................ ................................ ................................  64 
8.2.1  Clinical Laboratory Evaluations  ................................ ................................ ...... 64 
8.2.2  Special Assays or Procedures  ................................ ................................ ..........  67 
8.2.3  Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007]  ................................ .............  70 
9 Assessment of Safety  ................................ ................................ ................................ ................  73 
9.1 Specification of Safety Parameters  ................................ ................................ ..............  73 
9.2 Methods and Timing for Assessing, Recording, and Ana lyzing Safety 
Parameters  ................................ ................................ ................................ .....................  73 
9.2.1  Adverse Events  ................................ ................................ ................................ . 73 
9.2.2  Serious Adverse Events  ................................ ................................ ...................  75 
9.3 Reporting Procedures  ................................ ................................ ................................ ... 77 
9.3.1  Serious Adverse Events  ................................ ................................ ...................  77 
9.3.2  Regulatory Reporting for Studies Conducted Under DMID -Sponsored 
IND ................................ ................................ ................................ ....................  78 
9.3.3  Reporting of Pregnancy  ................................ ................................ ...................  78 
9.4 Type and Duration of Follow -up of Subjects after  Adverse Events  ..........................  79 
9.5 Halting Rules  ................................ ................................ ................................ .................  79 
9.6 Safety Oversight (ISM plus SMC or DSMB)  ................................ .............................  [ADDRESS_329808] (DSMB)  ................................ ..................  80 
10 Clinical Monitoring  ................................ ................................ ................................ ...................  82 
10.1  Site Monitoring Plan  ................................ ................................ ................................ ..... 82 
11 Statistical Considerations  ................................ ................................ ................................ ..........  83 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           6 
CONFIDENTIAL  
 11.1  Study Hypotheses  ................................ ................................ ................................ .........  83 
11.2  Sample Si ze Considerations  ................................ ................................ .........................  83 
11.3  Planned Interim Analyses  ................................ ................................ .............................  84 
11.3.1  Safety Review  ................................ ................................ ................................ ... 84 
11.3.2  Efficacy Review  ................................ ................................ ...............................  84 
The DSMB will review available clinical and virologic efficacy data, however no 
formal hypothesis testing is planned.  ................................ ................................ ..........  84 
11.4  Final Analysis Plan  ................................ ................................ ................................ ....... 84 
11.4.1  Gener al Principles  ................................ ................................ ............................  84 
11.4.2  Analysis Populations  ................................ ................................ ........................  84 
                     11.4.3  Efficay Analysis…………………………………………………………… 85 
11.4.4  Safety Analyses  ................................ ................................ ................................  87 
11.4.5  Exploratory Analyses  ................................ ................................ .......................  87 
12 Source Documents and Access to Source Data/Documents  ................................ ...................  93 
13 Quality Control and Quality Assurance  ................................ ................................ ...................  94 
14 Ethics/Protection of Human Subjects ................................ ................................ .......................  [ADDRESS_329809] ................................ ................................ ...........................  95 
14.3  Informed Consent Process  ................................ ................................ ............................  96 
14.3.1  Informed Consent/Assent Process (in Case of a Minor)  ................................  97 
14.4  Exclusion of Women, Minorities, and Children (Special Popul ations)  ....................  [ADDRESS_329810] Keepi[INVESTIGATOR_007]  ................................ ................................ ......................  101 
15.1  Data Management Responsibilities  ................................ ................................ ...........  101 
15.2  Data Capture Methods  ................................ ................................ ................................  101 
15.3  Types of Data  ................................ ................................ ................................ ..............  101 
15.4  Timing/Reports  ................................ ................................ ................................ ...........  102 
15.5  Study Records Retention  ................................ ................................ ............................  102 
15.6  Protocol Deviations  ................................ ................................ ................................ .... 102 
16 Publication Policy ................................ ................................ ................................ ....................  103 
17 Literature References  ................................ ................................ ................................ ..............  104 
18 Appendix  A: Schedule of Events  ................................ ................................ ................................  112 
         Appendix B: Laboratory Reference Ranges and Toxicity Grading… ……… ……….. ………... .…115 
         Appendix C: Patient Diary Component……………………...…………… ……….. …………...… [ADDRESS_329811] OF TABLES  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           7 
CONFIDENTIAL  
  
Table 1 
Cause of Diarrhea in Hospi[INVESTIGATOR_270516] a Single Center …………...……………….. 27 
 
Table 2 
Approved and Experimental Therapi[INVESTIGATOR_270517] …………………...……… .….29  
 
Table 3 
Plasma Pharmacokinetic Values Following a Single Oral Dose of Nitazoxanide …… ....………. [ADDRESS_329812] Enteric Viruses in Cell Culture ……..…… ….33 
 
Table 5 
Protocol PRO Completion Guide …………………………………………………………… ..….64 
 
Table 6 
Specimen Collection, Preparation, Processing and Storage …..…………. …..…… ……….…....[ADDRESS_329813] OF FIGURES  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           8 
CONFIDENTIAL  
 Figure 1 
Norovirus Capsid & Genome  
(3)……………… …… ……… …..………………………… …………………………… ….….25 
 
Figure 2 
HBGA Biosynthesis  
(4)…………………………………………………………………… …………………….. …..25 
 
Figure 3 
Nitazoxanide Metabolism ……………………… ..……………… .…...………… .………. …...32 
 
 
  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329814] OF ABBREVIATIONS  
AE Adverse Event/Adverse Experience  
AIDS  Acquired Immune Deficiency S yndrome  
ALC  Absolute Lymphocyte Count  
BID Twice Daily  
CBC  Complete Blood Count  
CFR  Code of Federal Regulations  
CKD  Chronic Kidney Disease  
COR  Contracting Officer’s Representative  
CRF  Case Report Form  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH, DHHS  
DSMB  Data and Safety Monitoring Board  
eCRF  Electronic Case Report Form  
EIA Enzyme immunoassay  
FDA  Food and Drug Administration  
FWA  Federal Wide Assurance  
GCP  Good Clinical Practice  
GVHD  Graft Versus Host Disease  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HSCT  Hematopoietic Stem Cell Transplantation  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
ICMJE  International Committee of Medical Journal Editors  
ICU Intensive Care Unit  
IND Investigational New Drug Application  
IRB Institutional Review Board  
JAMA  Journal of the American Medical Association  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_19737])  
NEJM  New England Journal of Medicine  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
NUCTC  Northwestern University Comprehensive Transplant Center  
OCRA  Office of Clinical Research Affairs, DMID, NIAID, NIH, DHHS  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           10 
CONFIDENTIAL  
 OHRP  Office for Human Research Protections  
OHSR  Office for Human Subjects Research  
ORA  Office of Regulatory Affairs, DMID, NIAID, NIH, DHHS  
PHI Protected Health Information  
PI [INVESTIGATOR_270518]-PCR  Reverse Transcription Polymerase Chain R eaction  
SAE  Serious Adverse Event/Serious Adverse Experience  
SDCC  Statistical Data and Coordinating Center  
SOP Standard Operating Procedure  
SOT  Solid Organ Transplant  
UGI Upper Gastro Intestinal  
UNOS  United Network for Organ Sharing  
US [LOCATION_002]  
WHO  World Health Organization  
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           11 
CONFIDENTIAL  
 PROTOCOL SUMMARY  
Title:  A Phase  2 Multi -Center, Prospective, Randomized, Double -
Blind Study  to Assess the Clinical and Antiviral Efficacy and 
Safety of Nitazoxanide  for the Treatment of  Norovirus  in 
Hematopoietic Stem Cell and Solid Organ Transplant Recipi[INVESTIGATOR_270519]:  Phase 2 
Population:  Sample Size : 160 male or female Hematopoietic  Stem Cell or 
Solid Organ transplant recipi[INVESTIGATOR_840], equal to or greater than 12 
years of age with diagnosis of Norovirus . 
Number of Sites:  12 
Study Duration:  Approximately [ADDRESS_329815] Participation 
Duration:  Approximat ely 6 months  
Description of Agent or 
Intervention:  1. Nitazoxanide Arm: All subjects age ≥ 12 years:  500 mg (one 
tablet) Nitazoxanide by [CONTACT_270613] 56 
consecutive dose s. 
2. Placebo Arm: All subjects age ≥ 12 years:  Placebo (one 
tablet) by [CONTACT_270613] 56 consecutive 
doses  
 
Objectives : 
 Primary Objective:    
1. To assess the clinical efficacy  of nitazoxanide for the 
management of acute and chronic Norovirus in transplant 
recipi[INVESTIGATOR_840].  
Secondary Objectives:  
1. To assess the virologic efficacy  of nitazoxanide . 
2. To assess the safety  of nitazoxanide for the management of 
acute and chronic Norovirus in transplant recipi[INVESTIGATOR_840] . 
 
Exploratory Objectives:  
1. To assess initial clinical improvement  in Norovirus Disease 
through 28 and 180 days.  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           12 
CONFIDENTIAL  
 2. To assess markers of virologic improvement  of Norovi rus 
Disease through 28 and180 days . 
3. To assess the contribution of immunologic response  to 
Norovirus to the clinical course of disease in treated and 
untreated subjects . 
4. To define the pharmacokinetics and dose response 
relationships  of nitazoxanide . 
5. To defi ne the natural history of Norovirus in nitazoxanide 
treated and untreated subjects . 
 
Outcome Measures  Primary Outcome:  
1. Time from randomization until initial clinical resolution of 
Norovirus symptoms for at least [ADDRESS_329816]  and will be defined as cessation of vomiting and 
no stools classified by [CONTACT_270614] 
(Type 6 or 7) . 
Secondary Outcomes:  
Virologic Efficacy  
1. Time from the randomization  to first negative viral load 
through 180 days.  
2. The change in viral titer between Day 1 and 180 . 
Safety  
3. Incidence of unsolicited non -serious adverse events (see 
section 9 for details) through 60 days . 
4. Incidence of laboratory adverse events (WB C, Hemoglobin, 
Platelet count, Creatinine, Alkaline Phosphatase, ALT, AST, 
BUN and Bilirubin) through 60 days.  
5. Incidence of protocol -specified serious adverse events (see 
section 9 for details) through 60 days.  
6. Incidence of Hospi[INVESTIGATOR_151400] 60 days .  
Exploratory Outcomes:  
Clinical Improvement:  
1. Time from randomization  to initial clinical improvement in 
Norovirus disease through [ADDRESS_329817] 48 
hours, as defined by:  
a. 50% reduction in number of epi[INVESTIGATOR_270520],  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           13 
CONFIDENTIAL  
 b. Improvement in PO intake, as judged by [CONTACT_270615], 
c. 50% reduction in the number of  epi[INVESTIGATOR_270521] 6 or 7 bowel movements,  
2. Time from randomization  to initial cessation of vomiting 
through Day 180 (recurrent vomiting will be considered 
disease recurrence unless determined to be due to another 
etiology [i.e. GVHD]) . 
3. Time from randomization  to subject report of no loss of 
appetite that is maintained fo r 48 hours through Day180 
(measure will be first time that the subject reports that they 
have no “loss of appetite” on their daily diary).  
4. Time from randomization  to initial cessation of diarrhea 
through Day 180 classified by [CONTACT_270616] 
6 or 7 bowel movements (recurrent diarrhea will be 
considered disease recurrence unless determined to be due to 
another etiology [i.e. GVHD]).  
5. Time from randomization  to 50% reduction in the amount of 
antimotility agents utilized by [CONTACT_270617] 180.  
6. Number of days of diarrhea  through Day 28  and 180 . 
7. Number of stools classified by [CONTACT_270618] 
6 or 7 bowel movements  through Day 28.  
8. Number of days of IV hydration or total parenteral nutrition 
(TPN) therapy through Day 28 . 
9. Total number of days of hospi[INVESTIGATOR_270522] 28  and 
180. 
10. Change in patient -reported quality of life as measured by 
[CONTACT_270619] -5 (global) and IBSQOL  (diarrhea specific) [adult] 
or Euro QOL -5 Peds (global) and  PedsQL  GI Module  
PedsQL [children]  from baselin e to Day 180 . 
11. Change in patient -reported physical function as measured by 
[CONTACT_270620] (Adult)  Pediatric Global 
Health (Peds)  from baseline to Day 180 . 
12. Change in patient -reported emotional distress as measured by 
[CONTACT_270621], Anxiety, Fatigue  (Adult and 
Peds)  from baseline to Day 180 . 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           14 
CONFIDENTIAL  
 13. Change in patient -reported gastrointestinal symptoms as 
measured by [CONTACT_270622] (Adult and Peds) 
sympt oms (6 of 8 subscales)  from baseline to Day 180.  
14. The effect of co -pathogens, as determined by [CONTACT_270623], on the primary outcome measure . 
15. Time from randomization until initial clinical resolution of 
Norovirus symptoms for at least [ADDRESS_329818] and will be defined as cessation of vomiting 
and no stools classified by [CONTACT_270614] 
(Type 6 or 7) from the total population c ompared to  the 
subgroup of subjects who do not report chromaturia 
(discoloration of urine) based on unsolicited self -reporting.   
16. Incidence of  unsolicited non -serious adverse events (see 
section 9 for details) through 60 days,  laboratory adverse 
events (WBC, Hemoglobin, Platelet count, Creatinine, 
Alkaline Phosphatase, ALT, AST, BUN and Bilirubin) 
through 60 days,  protocol -specified serious adverse events 
(see section 9 for details) through 60 days, 
and Hospi[INVESTIGATOR_151400] 60 days  from the tot al 
population compared to  the subgroup of subjects who do not 
report chromaturia (discoloration of urine) based on 
unsolicited self -reporting.  
 
Virologic Improvement:  
17. Time to ≥ [ADDRESS_329819] negative viral load 
through 180 days and the change in viral titer between Day 1 
and 180  from the total population compared to  the subgroup 
of subjects who do not report chromaturia (discoloration of 
urine) based on unsolicited self -reporting.  
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           15 
CONFIDENTIAL  
 Immunologic Response:  
22. Change in Norovirus -specific serum  and stool  IgA, IgM and 
IgG between Day 1 and  Days  28 and 60 (stool only) . 
23. Association  between change in total lymphocyte count and T 
cell subsets at Day 1 and 180 and clinical resolution of 
Norovirus symptoms.  
24. Association  between change in total lymphocyte count and T 
cell subsets at Day 1 and 180 and undetectable quantitative 
Norovirus PCR . 
25. Association  between change in Norovirus -specific serum and 
stool IgA, IgM and IgG  from  Day 1 to Days 28 and 60  (stool 
only)  and clinical resolution of symptoms . 
26. Association  between change in Norovirus -specific serum  and 
stool  IgA, IgM and IgG from Day 1 to Days 28 and 60 (stool 
only) and undetectable quantitative Norovirus PCR.  
 
Pharmacokinetics and Dose Response:  
27. For subjects consenting to PK draws, concentrations of 
nitazoxanide metabolites (tizoxanide and tizoxanide 
glucuronide) [ADDRESS_329820] dose on Day 7 and 10 
minutes before the second dose on Day 21 . 
 
 
 
Natural History of Disease  
28. Time to Allograft rejection as per each center team .  
29. Time to allograft loss as reported to UNOS.  
30. Time to death.  
31. Time to withdrawal from the study because of intolerance or 
due to drug -related adverse events . 
32. Correlation of secretor status as defined by [CONTACT_270624], separately, and clinical resolution of Norovirus as 
defined by [CONTACT_53229] . 
 
Description of Study Design:   
A total  of 160 subjects  ≥ 12 years of age will be selected 
according to the inclusion and exclusion criteria .  Upon 
enrollment in the study, subjects  will be randomized into two 
treatment groups:  active nitazoxanide and placebo.  
Randomization will be str atified  by [CONTACT_551] ( pediatric (12 -17  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           16 
CONFIDENTIAL  
 years) vs. adult ≥ 18 years ), chronicity of Norovirus -associated 
symptoms (acute  (<14 days)  vs. chronic  (≥14 days) ) and 
transplant type ( solid organ  (SOT)  vs. hematopoietic stem cell 
transplant  (HSCT) ).  Enrolled subjects will participate in 2 
phases of the study:  Treatment Phase, which will include dosing 
with the assigned study agent for 28 days and study visits on 
study Day 1, 7 ± 3 days, 14 ± 3 days, 2 1 ± 3 days, and 28 + 3 
days; Longitudinal Monitoring Phase which will include 
telephone call on Days 35 ± 3 days , 53 ± 7 days, 113 ± 7 days, 
173 ± 7 days.  study visits on study Day 60 ± 14 days, 120 ± 14 
days and 180 ± 14 day s.  If symptoms recur after co mpletion of 
the Treatment Phase, subjects can resume any therapy  excluding 
nitazoxanide  at the discretion of the principal investigator [INVESTIGATOR_113610]/her designee.  Nitazoxanide can be used after Day 28 if the 
local PI [INVESTIGATOR_270523] e nitazoxanide 
because the patient is experiencing severe or life -threatening 
disease.  Although nitazoxanide can be used if it is felt critical to 
the subjects care, its use should be avoided until Day 180 
whenever felt to be safe to do so by [CONTACT_24099] . Additional stool 
specimens should be collected prior to initiation of therapy for 
testing in the central lab.  
 
Estimated Time to Complete 
Enrollment:  60 months .  
  
 
 
 
 
 
 
 
 
 
Schematic of Study Design : 
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           17 
CONFIDENTIAL  
  
 
 
 
 

DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           18 
CONFIDENTIAL  
 1 KEY ROLES  
Individuals:   
Principal Investigator:    
 
 
 
 
 
[INVESTIGATOR_71445] : 
 Michael G Ison, MD MS  
Professor, Divisions of Infectious Diseases and Organ  
Transplantation  
Northwestern University Feinberg School of Medicine  
Address: [ADDRESS_329821], 19th Floor,  
Chicago, IL [ZIP_CODE]  
Phone#: (312) 695 -4186  
[EMAIL_5230]  
 
 
Gabriele Feolo, RN, MSN  
EHDB/DMID/NIAID/NIH  
[ADDRESS_329822],  
Room: 8F56  
Bethesda, MD [ZIP_CODE] - 9825 
([PHONE_5636]  
[EMAIL_5231]  
 
DMID Scientific Lead:    
 
 
 
 
 
 
 
DMID Medical Officer:  
 
 
 
 
 
 
 
DMID Medical Monitor:  
 Rodolfo M. Alarcón, PhD  
EHDB/DMID/NIAID/NIH  
[ADDRESS_329823] , 
Room #8F45  
Bethesda, MD [ZIP_CODE] - 9825  
(240) 292 -0871  
[EMAIL_5232]  
 
John Beigel, MD  
Associate Director for Clinical Research  
Division of Microbiology and Infectious Diseases  
National Institute of Allergy and Infectious Diseases (NIAID)  
Phone: (1) 301 -451-9881  
 [EMAIL_5233]  
 
 
 
Jorge  Mejia -Galvis,  M.D.  [C]  
OCRA /DMID/NIAID/NIH   
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329824], 7E56  
Rockville, MD [ZIP_CODE] -9826  
Phone : [PHONE_5637]  
 Jorge.mejia -[EMAIL_5234]  
 
 
 
  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           20 
CONFIDENTIAL  
 Institutions:  PARTICIPATING SITES  
Cincinnati Children’s Hospi[INVESTIGATOR_270524] : Cincinnati Children’s Hospi[INVESTIGATOR_29349]  
[ADDRESS_329825]  
ML 7017  
Cincinnati, Ohio [ZIP_CODE] -3039  
Site PI:  [INVESTIGATOR_270525] -Isakov, MD , MPH  
Phone#:  [PHONE_5638]  
Email : Lara.Danziger -[EMAIL_5235]  
 
Johns Hopkins University  
Address : School of Medicine/Division of Infectious Diseases  
The Johns Hopkins University  
[ADDRESS_329826]./Room 44 9  
Baltimore, MD [ZIP_CODE]  
Site PI:  [INVESTIGATOR_270526], MD  
Phone#:  [PHONE_5639]  
Email : [EMAIL_5236]  
 
University of Kansas  
Address : University of Kansas Medical Center Research   
Institute, Inc.  [ADDRESS_329827], MSN 1039, Kansas City, 
KS [ZIP_CODE] -2937  
Site PI:  [INVESTIGATOR_270527], MD  
Phone#: [PHONE_5640]  
Email : [EMAIL_5237]  
 
University of Michigan  
Address: University of Michigan  
Int Med -Infectious Diseases  
[ADDRESS_329828]  
Ann Arbor, MI [ZIP_CODE] -5378  
Site PI:  [INVESTIGATOR_270528], MD  
Phone#:  [PHONE_5641]  
Email : [EMAIL_5238]  
 
University of Nebraska  
Address : University of Nebraska Medical Center  
985400 Nebraska Medical Center, Omaha, NE [ZIP_CODE] -5400  
Site PI:  [INVESTIGATOR_270529],  MD 
Phone#:  [PHONE_5642]  
Email : [EMAIL_5239]  
 
University of [LOCATION_007] Southwestern Medical Center  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           21 
CONFIDENTIAL  
 Address : Division of Infectious Diseases  
[ADDRESS_329829]., Suite Y7.312C  
Dallas, TX [ZIP_CODE] -9113  
Site PI:  [INVESTIGATOR_270530] , MD  
Phone#:  [PHONE_5643]  
Email : [EMAIL_5240]  
 
University of Pi[INVESTIGATOR_270531] : Division of Infectious Diseases  
Scaife Hall, Suite [ADDRESS_329830]  
Pi[INVESTIGATOR_9109], PA  [ZIP_CODE] -1816  
Site PI:  [INVESTIGATOR_270532] -Hong Nguyen,  MD 
Phone#:  [PHONE_5644]  
Email : [EMAIL_5241]  
 
Children’s Hospi[INVESTIGATOR_270533] : University of Pi[INVESTIGATOR_9109], Pediatrics  
Children’s Hospi[INVESTIGATOR_270534]  
[ADDRESS_329831], Faculty Pavilion 6135  
Pi[INVESTIGATOR_68321] [ZIP_CODE]  
Site Co-PI: [INVESTIGATOR_270535], MPH  
Phone#: [PHONE_5645]  
Email : [EMAIL_5242]  
 
Address:  [ADDRESS_329832]  
AOB Suite 2200  
Pi[INVESTIGATOR_68321] [ZIP_CODE]  
Site Co PI:  [INVESTIGATOR_270536] G Michaels MD, MPH  
Phone #:  [PHONE_5646]  
 
E-mail:   [EMAIL_5243]  
 
University of Washington  
Address : University of Washington  
[ADDRESS_329833].  
Box 356174  
Seattle, WA [ZIP_CODE]  
Site PI:   [INVESTIGATOR_270537], MD , MPH  
Phone#:  [PHONE_5647]  
Email : [EMAIL_5244]  
 
Fred Hutchinson Cancer Research Center  
Address : Fred Hutchinson Cancer Research Center  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329834], N, E4 -100 
Seattle, WA [ZIP_CODE].  
Site PI:  [INVESTIGATOR_270538],  MD, MPH  
Phone#:  (206) 667 -7538  
Email : [EMAIL_5245]  
 
 
COLLABORATORS  
Mount Sinai  Hospi[INVESTIGATOR_70858] : Icahn School of Medicine at Mount Sinai  
CAM Building  
[ADDRESS_329835], 5th floor  
[LOCATION_001], NY [ZIP_CODE]  
Collaborator: Laurie Keefer, PhD  
Phone#:  [PHONE_5648]  
Email : [EMAIL_5246]  
 
Protocol Manager:   
Address: [ADDRESS_329836]. Clair, 19-073 
Chicago, IL [ZIP_CODE]  
Name: [CONTACT_270677], CCRC, CAPM  
Phone#:312 -694-0259  
Email: [EMAIL_5247]  
 
Statistician:   
Address: [ADDRESS_329837]  
Chicago, IL [ZIP_CODE]  
Name: [CONTACT_270678], PhD  
Phone#:312 -503-7230  
Email: [EMAIL_5248]  
 
NU Institutional Review Board Contact [CONTACT_7171]:  
Arthur Rubloff Building, 7th Floor  
[ADDRESS_329838].  
Chicago, IL [ZIP_CODE]  
Phone: (312) 503 -9338  
[EMAIL_630]  
Safety and 
Pharmacovigilance 
Contractor   
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support 
(CROMS)  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329839]., Suite 650  
Bethesda, MD 2081 7 
SAE Hot Line: 1 -[PHONE_889] (US)  
SAE Fax: 800 -275-7619 (US)  
SAE Email: [EMAIL_1393]  
 
Data Coordinating Center:  
 The Emmes Company, LLC  
[ADDRESS_329840]  
Rockville, MD [ZIP_CODE]  
Group E -mail: [EMAIL_5249]  
 
Project Manager:  Carey Rodeheffer Petrie , PhD   
[PHONE_2269] x10803  
[EMAIL_5250]  
 
Proto col Statistician: Jill El -Khorazaty  
[PHONE_2269] x [ZIP_CODE]  
[EMAIL_5251]  
  
Laboratories  Cincinnati Children’s Hospi[INVESTIGATOR_270524]:  Division of Infectious Diseases, S8.[ADDRESS_329841]  
Cincinnati, OH [ZIP_CODE]  
Collaborator:  Xi Jason Jian, PhD  
Phone#:  [PHONE_5649]  
Email: [EMAIL_5252]  
 
Cincinnati Chi ldren’s Hospi[INVESTIGATOR_270524]:  Diagnostic Infectious Diseases Testing Laboratory  
Department of Patholog y and Laboratory Medicine  
[ADDRESS_329842], B4.252, MLC 1010  
Cincinnati, OH [ZIP_CODE] -3026  
Collaborator:  Joel Mortensen, PhD  
Phone#:  [PHONE_5650]  
Email:  [EMAIL_5253]  
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           24 
CONFIDENTIAL  
 Industry Representative  Romark, L.C.  
Addresses: [ADDRESS_329843]: Mathew Bardi n, PharmD , BCPS  
Phone#: (813) 282 -8544  
Email: [EMAIL_5254]  
 
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329844] 
common cause of severe diarrhea in infants and young children.(3, 5) In the US, Norovirus is 
estimated to be responsible for 19 –21 million e pi[INVESTIGATOR_270539] 56,000 –71,000 
hospi[INVESTIGATOR_230240].(1) Increasingly, Norovirus is recognized as a common  cause of chronic 
gastroenteritis in immunocompromised patients. Prolonged diarrhea can lead to dehydration, 
allograft dysfunction, renal insufficiency and rarely death in these patients.(3, 6-11) 
Noroviruses are 
small, non -enveloped, 
single -stranded RNA 
viruses that are 
members of the 
Caliciviridae (Figure 
1). (3, 12)  Of the five 
genogroups (GI -GV), 
GI, GII  and GIV are 
known to be human 
pathogens, although 
most are caused by [CONTACT_270625], which can be 
further classified into 
[ADDRESS_329845] common cause 
of outbreaks of 
Norovirus infections 
globally. (13, 14) 
Norovirus is highly  
contagious as transmission is highly efficient with a median infectious dose of 18 viruses. There 
is generally high titers of virus within stool (105 to 1010 genome copi[INVESTIGATOR_270540]); (15, 16)  Figure 1:Nor ovirus Capsid & Genome (3)  

DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329846] with infected feces and vomit, fecally -contaminated food, water and surfaces 
are common sources of infection.(17, 18 , 15, 16)Norovirus is also highly stable with retained 
infectivity under environmental conditions that would generally inactivate other viruses, 
including c hlorine at concentrations used in drinking water.(19, 20) 
 
The Norovirus  genome encodes 2 major structural proteins (VP1 and VP2) and 7 nonstructural 
proteins responsible for viral replication.  The viral VP1 protruding 2 (P2) do main binds 
saccharides of the human ABO, secretor (H), and Lewis families histo -blood group antigens  to 
facilitate viral entry into the 
epi[INVESTIGATOR_270541].(4, 20, 21)  
Carbohydrate antigen 
expression on gastrointestinal 
epi[INVESTIGATOR_270542], FUT2 and FUT3 
alleles in humans .  Only 70 -
80% of individuals have a 
functional copy of the FUT2 
(“secretor”) gene required for 
gut HBGA expression 
(Figure 2 ); these individuals 
are known as “secretors.” 
“Non -secretors” have 
inactivated FUT2 alleles 
typi[INVESTIGATOR_270543] G428A nons ense mutation or A385T missense mutation.  Non -
secretors appear to have reduced susceptibility or outright resistance to symptomatic infection . 
(22-25) Further, in vitro work suggests that A and B blood group blood type B patients have 
reduced susceptibility to infection.(26) However, it remains unclear if these proteins serve only as 
attachment ligands on host cells or are functional receptors that enable entry into the cells.  
   
While significant progress has been made in understanding host factors that modulate the risk of 
developi[INVESTIGATOR_270544], our understanding of the immune response to Norovirus es 
remains limited.(20) Adaptive immunity appears to play an incomplete role in the prevention and 
control of Norovirus  infections.  There appears to be short and long -term immunity to infection 
based on data from challenge studies. Re -challenge with the same serotype withi n 6-14 weeks of 
initial infection generally prevents recurrent infections but not infection with heterotypic 
viruses.(27) Long -term immunity is more complex and re -challenge with the same virus 27 -42 Figure 2.  HBGA Biosynthesis  (4)
 
Figure 2: HBGA Biosynthesis (4)  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329847], data 
suggests that patients without pre -challenge antibodies are less likely to deve lop symptoms. 
Local mucosal IgA responses appear to be protective.  More recently, HBGA carbohydrate -
blocking antibodies that block Norovirus  VLPs to H type 1 or H type 3 glycans appear to be 
protective.(20, 28)  Cell-mediated responses, including bot h T- and B -cell responses, are critical for 
clearance of Norovirus .  Following challenge with VLPs and Snow Mountain virus, there is a 
robust T -helper type 1 (Th -1) response with significant increases in interferon -α and IL -2, but 
not IL -4, IL -6, or IL -10.(29) Depletion of CD4+ cells results in reduced interferon production.(29) 
In a mouse model, CD4+ and CD8+ cells were required for clearance of murine Norovirus  in the 
intestine.(30) Likewise, patients with defective T cell function more commonly have prolonged 
shedding and clearance of shedding in patients with chronic infectio n has been shown to be 
associated with the recovery of T cells.(31, 32)  
 
Cell-mediated responses, including both T - and B -cell and B -cell responses, are critical for 
clearance of Norovirus .  Following challenge with VLPs and Snow Mountain virus, there is a 
robust T -helper type 1 (Th -1) response with significant increases in interferon -, IL-2 but not IL -
4, IL -6, or IL -10.(29)  Depletion of CD4+ cells results in reduced interferon production.(29) Further, 
in a mouse model, CD4+ and CD8+ cells were required for clearance of murine Norovirus  in the 
intestine.(30)  Likewise, patients with de fective T cell function more commonly have prolonged 
shedding and clearance of shedding in patients with chronic infection has been shown to be 
associated with the recovery of T cells.(31, 32)  Norovirus  appears to evolve rapi[INVESTIGATOR_270545] (3.3% amino acid substitutions per year in chronic shedders) (3). 
 
Norovirus  infections typi[INVESTIGATOR_270546], with an 
incubation period of 10 to 51 ho urs. Symptoms include nausea, vomiting, watery non -bloody 
diarrhea, abdominal cramps and occasionally low -grade fever, muscle aches, chills and 
headache,(20) usually lasting from 24 to 60 hour s. (33) While the acute phase of illness is typi[INVESTIGATOR_270547] -lived, asymptomatic patients may continue to shed the virus for up to two weeks.(12, 20, 34) 
Unfortunate ly, approximately 570 –[ADDRESS_329848] of fatal cases occurring in immunocompromised hosts.(35) 
Immunocompromised patients such as those with congenital immunodeficiencies , human 
immunodeficiency virus (HIV) -infected patients, solid organ transplant recipi[INVESTIGATOR_840], hematopoietic 
stem cell transplant patients and oncology  patients undergoing chemotherapy can develop 
chronic Norovirus  infections. (3, 36 -41) Copi[INVESTIGATOR_270548] 3 –4 months or 
longer. (1, 37)  As a result, dehydration and elevated calcineurin inhibitor levels are common in 
patients at the time of initial diagnosis.  
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           28 
CONFIDENTIAL  
 Chronic Norovirus  infection is common in hematopoietic stem cell transplant recipi[INVESTIGATOR_840].(6, 11, 36, 
38, 42 -45)  In one study, 18% of hematopoietic stem cell transplant patients developed Norovirus  
infection post -transplant, with prolonged shedding detected in most of these patients (median 3 
months, range 0.5 – 14 months).(38) Half had severe weight loss as the result of Norovirus  
gastroenteritis; one patient died of malnutrition attributed to Norovirus  infection.  In another 
retrospec tive study in pediatric hematopoietic stem cell recipi[INVESTIGATOR_840], 16.3% of patients with 
diarrhea were proven to have Norovirus  infections.  Norovirus  developed at a median of 36.[ADDRESS_329849] -transplantation (range, 5 -517 days) with prolonged shedding in most pat ients (median 
145, range 13 - 263). (11) A more recent study demonstrated prolonged shedding of virus in sera 
(mean of 33.6 days) and in stool (mean of 61.6 days) in adult HSCT recipi[INVESTIGATOR_270549].(44) 
 
Solid organ transplant re cipi[INVESTIGATOR_270550].(7, 10, 36, 39, 
40, 46 -48)  One of the earliest studies documented Norovirus  in 17% of renal transplant patients 
who shed virus for [ADDRESS_329850] to sequence Norovirus es and 
demonstrated accumulation of mutations in several of the patients over time, resulting in amino 
acid chang es predominantly in the P2 and P1 -2 region.(40) Recently, our g roup conducted a 
retrospective study of solid organ transplant recipi[INVESTIGATOR_270551].  In 
this study of [ADDRESS_329851] 
common documented cause of diarrhea after C. dif ficile  (Table 1 ).(7)  Norovirus  was more 
common among individuals who had community -acquired diarrhea.   
 
 
Recently, we expanded on our initial study to assess the epi[INVESTIGATOR_270552] 1: Cause of Diarrhea in Hospi[INVESTIGATOR_270516] a Single Center  
 
 
 

DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           29 
CONFIDENTIAL  
 solid organ transplant patients with Norovirus.(49) We retrospectively reviewed data from 67 SOT 
recipi[INVESTIGATOR_270553] 67 randomly selected S OT 
recipi[INVESTIGATOR_270554].  From this data, 35% of all patients 
evaluated for diarrhea had Norovirus, which was the most common infectious diagnosis among 
patients with diarrhea; C. difficile  was the second most common d iagnosis in 25% of patients.  
We found that nearly half of patients with Norovirus were diagnosed without the need for 
hospi[INVESTIGATOR_059].  Diarrheal duration was significantly protracted in Norovirus patients with an 
average of 241 days versus 75 days in the  control (p=0.[ZIP_CODE]); 22.4% of Norovirus patients 
were still having diarrhea at the time of last evaluation suggesting that we are likely 
underestimating  the duration of symptoms. There were [ADDRESS_329852] year after the onset of diarrhea and 30% of Norovirus 
patients had a ≥ 20% increase in creatinine within [ADDRESS_329853] (58%) of the 
Norovirus -infected patients required intravenous hydration on diagnosis and 81% had s upra-
therapeutic tacrolimus levels at diagnosis.   
 
In another recent study of 116 pediatric solid organ and hematopoietic stem cell transplant 
recipi[INVESTIGATOR_270549], 22% had documented Norovirus infection, making it the most 
commonly identified enterop athogen.(50) Over half of these patients had prolonged diarrhea with 
a median duration of 12.5 days (range 1 -324 days) and 29% developed recurrent epi[INVESTIGATOR_1865](s) of 
Norovirus -associate d diarrhea. Patients with Norovirus were more likely to require ICU 
admission (27% vs. 0%, p  = 0.02), had a greater rise in serum creatinine (median 0.3 vs. 
0.2 mg/dL, p = 0.01), and experienced greater weight loss (median 1.6 vs. 0.6  kg, p < 0.01).  
 
Diagn osis of Norovirus generally relies upon detection of Norovirus RNA or antigens in stool 
since cell culture is not available and direct visualization via electron microscopy is 
impractical.(34, 51)  Enzyme immunoassay (EIA) detection methods are also available 
commercially. Although simpler to perform, EIA assays have reduced sensit ivity (58 –93%) and 
specificity (85 –100%) compared to RT -PCRs.(36, 51)  Qualitative or quantitative PCRs can be run 
on stool, vomitus, foods, and environmental specimens.(34) PCR methods generally use primers 
directed at highly conserved regions of ORFs 1, 2, and 3, including the POL region in ORF 1.(20, 
52) Sequencing the products of RT -PCRs al lows tracking of individual strains, which may be 
useful in outbreaks.(14) Several multiplex panels that detect Norovirus, among other common 
gastrointestinal pathogens, have recently become widely available.(36) 
 
The current mainstay of therapy for Norovirus is supportive.(53, 54)  Reduction of 
immunosu ppression is commonly practiced since diarrhea is a common adverse effect of many 
immunosuppressive drugs, including mycofenolate mofetil. It remains unclear, however, if 
reduction of immunosuppression alone significantly improves clearance of Norovirus.  There are 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329854] that substitution of one of the immunosuppressive agents with one 
of the mTOR inhibitors may speed recovery, but the strength of this data is limited.(6, 47)  In these 
two cases, symptoms improved within days, and viral shedding was undetectable within weeks 
of changing to an mTOR inhibitor.  
Oral and intravenous 
immunoglobulins have 
been tried in 
immunosuppressed 
patients with variable 
success.  While there 
have been several case 
series that demonstrated 
improvement in 
diarrheal symptoms 
within 2 –[ADDRESS_329855] of 
hospi[INVESTIGATOR_270555].(55-57) 
Likewise, breast milk 
has had variable results 
and is currently undergoing study as a potential treatment of Norovirus (ClinicalTrials .gov 
Identifier:  [STUDY_ID_REMOVED]).  Systemic administration of immunoglobulin has provided 
conflicting evidence of clinical impact on Norovirus infection.(1, 3)  A novel monoclonal 
Norwalk -virus specific antibody has been developed and found to be effective in a chimpanzee 
model of infection, but efficacy in humans remains unproven.(58) A number of drugs that are 
currently approved, including nitazoxanide, ribavirin, suramin and human inter feron -α have 
activity against Norovirus (Table 2). Several drugs including favipi[INVESTIGATOR_270556] (Table 2).(1, 3, 36)  
 Table 2 .  Approved and Experimental Therapi[INVESTIGATOR_270557] (1) 
Table 2: Approved and Experimental Therapi[INVESTIGATOR_270558] 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           31 
CONFIDENTIAL  
 Nitazox anide (2 -acetyloxy -N-(5-nitro -2-thiazolyl)  benzamide Alinia®) is a thiazolide compound 
that is rapi[INVESTIGATOR_270559], tizoxanide, which has broad activity against 
bacteria, parasites and viruses.(59)  Nitazoxanide is approved by [CONTACT_270626] (age ≥ 1 year) and a 500 mg tablet (age ≥ 12 years) for 
treating  diarrhea caused by [CONTACT_270627]. The nitazoxanide 
table contains 500 mg of nitazoxanide and the following inactive ingredients: maize starch, 
pregelatinized corn starch, hydroxypropyl methylcellulose, sucrose, sodium starch g lycolate, 
talc, magnesium stearate, soy lecithin, polyvinyl alcohol, xanthan gum, titanium dioxide, FD&C 
Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, and FD&C Blue No. 2 
Aluminum Lake.  
 
Pharmacology of Nitazoxanide  
After oral administrati on, maximum plasma concentrations of the active metabolites tizoxanide 
and tizoxanide glucuronide are observed within 1 -4 hours. The active metabolite elimination 
half-life is 7.3 hours.  The parent nitazoxanide is not detected in plasma.  Key pharmacokine tic 
parameters are summarized in Table 3.  From this data, it is clear that the oral suspension is not 
bioequivalent to the tablet formulation.  The relative bioavailability of the suspension compared 
to the tablet is 70%.  
 
Table 3: Plasma Pharmacokinetic Values Following a Single Oral Dose of Nitazoxanide   
1Mean (± SD). 2Mean (Range)  
1Mean (± SD). 2Mean (Range)  
  Formulation  Dose  Age 
(Yrs)  Tizoxanide  Tizoxanide Glucuronide  
Cmax1 
(µg/mL) Tmax2 
(Hr) AUC1 
(μg•hr/mL) Cmax1 
(µg/mL)  Tmax2 
(Hr) AUC1 
(μg•hr/m
L) 
Tablet  500mg  12-17 9.1 (6.1)  4.0 (1 -4) 39.5 (24.2)  7.3 (1.9)  4.0 (2 -8) 46.5 (18.2)  
500mg  ≥18 10.6 (2.0)  3.0 (2 -4) 41.9 (6.0)  10.5 (1.4)  4.5 (4 -6) 63.0 (12.3)  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329856] 50%.  Likewise, 
administration of the suspension with food 
increases the AUC t of tizoxanide and 
tizoxanide glucuronide by [CONTACT_2902] 45 -50% and 
the C max by ≤10%.  It is r ecommended to 
always take nitazoxanide with food to ensure 
maximal delivery of the active drug.  Repeat 
dosing of nitazoxanide every 12 hours for 7 
consecutive days failed to demonstrate 
significant accumulation of nitazoxanide metabolites tizoxanide or ti zoxanide glucuronide 
detected in plasma.  
 
In plasma, the parent drug, nitazoxanide is generally not detected while 99% of tizoxanide is 
bound to proteins.  Following oral administration in humans, nitazoxanide is rapi[INVESTIGATOR_270560],  tizoxanide (desacetyl -nitazoxanide). Tizoxanide then undergoes 
conjugation, primarily by [CONTACT_12075].  In vitro  metabolism studies have demonstrated that 
tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes. (Alinia® 
(nitazoxanid e) Prescribing Information. Romark, L.C., Tampa, FL. November 2013)  
 
Tizoxanide is excreted in the urine, bile and feces, and tizoxanide glucuronide is excreted in 
urine and bile. Approximately two -thirds of the oral dose of nitazoxanide is excreted in the  feces 
and one - third in the urine.  The pharmacokinetics of nitazoxanide in pediatric patients less than 
one year of age and geriatric patients has not been studied.  Data in patients with impaired 
hepatic and renal function is limited . (60) The PK of nitazoxanide has been studied in patients 
given a single dose of nitazoxanide 600mg with mild renal impairment [eGFR 60 -89 
mL/min/1.73 m2], moderate renal impairment [eGFR 30 -59 mL/min/1.73 m2],  severe renal 
impairment [eGFR 15 -29 mL/min/1.73 m2]  and end stage renal disease requiring dialysis  (6 
subjects in each group) . Terminal half -life and time to peak concentration for tizoxanide, the 
active metabolite, were similar between renal impaired patients and healthy subjects. There was 
a trend to inc reasing.  Cmax and AUCs for tizoxanide glucuronide , a non -active metabolite, 
increased with the degree of renal impairment.  There were no treatment emergent adverse 
events that were related to the study drug  (Nitazoxanide Investigator’s Brochure, March 1,  
2018) .  Similarly, there was a small phase I study of single dose nitazoxanide 600mg in patients 
with normal, mild (Child -Pugh Class A), moderate (Child -Pugh Class B) and severe hepatic Figure 3: Nitazoxanide Metabolism  

DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           33 
CONFIDENTIAL  
 impairment (Child -Pugh Class C) (6 subjects in each arm).  N o clear r elationships between 
tizoxanide and tizoxanide glucuronide PK parameters and hepatic function parameters (Child -
Pugh classification and the individual components serum albumin, serum bilirubin and INR) 
were apparent.  There were no treatment emergent adver se events  (Nitazoxanide Investigator’s 
Brochure, March 1, 2018) . 
 
Nitazoxanide has been extensively studied in multiple animal models to assess safety, 
pharmacokinetics and efficacy, as summarized in the attached IB.  To date, 4,[ADDRESS_329857] has been marketed for 
approximately nine years in the [LOCATION_002] and sixteen years in Latin America with more than 
70 million people treated.  While nitazoxanide is specifically approved for twice daily dosing for 
3 days duration, there is extensive experience with more prolonged dosing, including dosing 
beyond 30 days (Alinia® (nitazoxanide) Prescribing Information. Romark, L.C., Tampa, FL. 
November 2013).  
 
Adverse reactions to nitazoxanide are re lated primarily to the gastrointestinal tract with mild and 
transient abdominal pain (6.6 -7.8%), diarrhea (2.1 -4.2%), headache (1.1 -3.1%), nausea (3.0%) 
and vomiting (1.1%) being the most common adverse events reported. Mild and transient yellow 
discolorat ion of the urine and sclera have also been reported, particularly in patients receiving 
doses higher than 500 mg bid for extended durations.  Other rare adverse events occurring in less 
than 1% of patients include:  asthenia, fever, pain, allergic reaction , pelvic pain, back pain, chills, 
infection, malaise, flu syndrome, dizziness, somnolence, insomnia, tremor, hyperesthesia, 
dyspepsia, anorexia, flatulence, constipation, appetite increase, enlarged salivary glands, dry 
mouth, thirst, dysuria, amenorrhea, metrorrhagia, kidney pain, edema labia, increased creatinine, 
increased alanine aminotransferase (ALT), anemia, leukocytosis,  rash, pruritus, sweating, ear 
ache, epi[INVESTIGATOR_3940], lung disease, pharyngitis, rhinitis, tachycardia, syncope, hypertension, myalgia, 
leg cramps, and spontaneous bone fracture. No drug -related serious adverse events have been 
reported during post -marketing experience with nitazoxanide.(61-70) 
 
While nitazoxanide has not shown signs of reproductive toxicity in animal studies, no adequate 
and well -controlled clinical studies have been conducted in pregnant or lactating females. It is 
not known whether nitazoxanide is excreted in breast milk.  The drug is classified as pregnancy 
category B by [CONTACT_55257].  No cases of overdose of nitazoxanide have been reported. Single 
doses of up to [ADDRESS_329858] 
of symptomatic and supportive therapy.  
 
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329859] -regulated processes involved 
in viral replication which leads to an inhibition of viral protein synthesis.(71-75) The relative 
activity of nitazoxanide and tizoxanide against enteric viruses is detailed in Table 4.  Of great 
interest, the IC 50 and IC 90 for tizoxanide in a Norovirus G1 replicon -assay system using an HG -
23 cell line were 0.5 and 1.2 µg/mL respectively.(75)  While the precise mechanism of action of 
nitazoxanide has not been fully defined for Nor ovirus, tizoxanide appears to inhibit the 
maturation of rotavirus viral protein 7 (VP7), a glycoprotein that forming the outer part of the 
virion and one of the six structural glycoproteins involved in rotavirus replication, in addition to 
altering viropla sm formation and interfering with viral morphogenesis.(74)  Nitazoxanide has also 
been shown to potentiate the production of type I interferons. The significance of this activity is 
not fully understood, but it could contribute to the antiviral ac tivity of nitazoxanide by [CONTACT_270628].(75) 
 
Table 4: Activity of Nitazoxanide and Tizoxanide against Enteric Viruses in Cell Culture  
Virus  TIZ EC 50  TIZ CC 50  
Simian rotavirus SA11 - G3P (72, 74)  0.5 µg/ml  >50  
Human rotavirus Wa - G1P (74) 1.0 µg/ml  >50 
Norovirus G1 (75) 0.5 µg/ml  14 
 
EC 50 = drug concentration at which a 2 -fold depression of viral DNA or RNA (relative to the 
average levels in untreated cultures) was observed.  CC 50 = drug concentration at with a [ADDRESS_329860] studied in Egypt.(72)  Children hospi[INVESTIGATOR_270561] 7·5 mg/kg nitazoxanide as an oral suspension or placebo twice a day 
for 3 days.  Patients were monitored in the hospi[INVESTIGATOR_34092] 7 days.  Of the 47 patients included in the 
efficacy analysis, 38 patients had rotavirus, 4 patients had a denovirus, 4 patients had rotavirus 
and adenovirus, and 1 patient had rotavirus and Norovirus at baseline.  The median time to 
resolution of illness was 31 h (IQR 22 –73) for the nitazoxanide -treated group compared with 75 
h (51 –124) for the placebo group ( p=0·0137).  Two adverse events were reported in patients 
randomized to the placebo group, one was a case of bronchitis and the other was a case of mild 
otitis media.   
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329861] of nitazoxanide tablets for the treatment of viral 
gastroenteritis caused by [CONTACT_270629], rotavirus, or adenovirus in patients over the age of 12.(76) Of 
the [ADDRESS_329862] dose to resolution of symptoms was 1.5 days in the nitazoxanide treated 
patients and 2.5 days for the placebo group ( P=0.0001). Time to symptom resolution was faster 
in nitazoxanide treated subject s who were infected with rotavirus (1.5 vs. 2.5 days, P=0.0052) 
and Norovirus (1.5 vs. 2.5 days, P=0.0295). The medication was well tolerated with no serious 
adverse events reported during this study.  
 
Given the severity of Norovirus in immunosuppressed pa tients, there has been significant interest 
in using nitazoxanide to improve outcomes.  One of the first published cases involved a 43-year-
old male with relapsed refractory acute myelogenous leukemia who had undergone 
hematopoietic stem cell transplantati on and had biopsy -proven cutaneous and pulmonary graft -
versus -host disease.  Shortly after initiating ponatinib for management of his AML, he presented 
with Norovirus infection associated with 8 – 12 daily epi[INVESTIGATOR_270562], non -dysenteric 
watery di arrhea but without fever, chills, or any associated abdominal pain or tenesmus. He was 
significantly lymphopenic on admission.  He was also clinically unstable with tachycardia (115 
bpm) and hypotensive (88/55 mm  Hg).  Stool studies were negative for all t ested pathogens other 
than Norovirus.  He failed to respond to antimotility treatment and octreotide but, within 24 
hours of starting nitazoxanide 500mg twice daily, he had marked clinical improvement from 10 
to 2 bowel movements per day.  He had normal co nsistency and frequency of his bowel 
movements within 4 days of starting nitazoxanide.  Clinical resolution of acute gastroenteritis 
was achieved with a 7 day course of nitazoxanide but the patient continued to asymptomatically 
shed Norovirus in his stools  for over 30 days.(77) 
 
Recently, o ne of the largest experiences of nitazoxanide for the treatment of Norovirus in 
immunosuppressed patients was presented at the 2015 BMT Tandem Meeting.(78, 79)  This 
retrospective study of 14 patients ([ADDRESS_329863]) with Norovirus documented the impact of nitazoxanide was 100 mg PO BID 
for ages 1 to 4 years, 200 mg PO BID for age 4 to 11 years, a nd 500 mg PO BID for greater than 
11 years. 4 patients received  500 mg PO BID for 5 -8 days (Mean duration 4.[ADDRESS_329864] on chemo/immunotherapy and [ADDRESS_329865] patients were on immunosuppressive therapy 
and 5 had documented GVHD.  Therapy resulted in improvements in diarrhea, nausea, and 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           36 
CONFIDENTIAL  
 abdominal pain within 2 -4 days (median 2 days).  Clearance of stool virus was variable. Two of 
[ADDRESS_329866] became negative on stool study within 5 -14 days of treatment (1 
unknown duration). Among patients treated after HSCT 4 of 9 had persistent viral shedding, 2  
received drug until death (1 adenovirus, 1 congestive heart failure) both were treated greater than 
[ADDRESS_329867] patie nt with clinical resolution but 
persistent viral shedding stopped treatment, resulting in recurrence of clinical symptoms. This 
patient responded clinically to reinstitution of therapy within 2 days but continued to shed virus. 
UGI endoscopy/ colonoscopy w ere performed in 5 pts at the time of infection, all showed 
inflammation/edema but no GVHD was seen on histology.  
 
Clinical Experience with Nitazoxanide Used for Greater than [ADDRESS_329868] been 3 studies  (n=505)  using nitazoxanide along or in combinat ion with interferon 
for the treatment of hepatitis C for 3 -10 months and one study of prolonged nitazoxanide for 
patients with AIDS and Cryptosporidiosis who were given 1 -1528 days (median 62 days) of 
nitazoxanide.89-[ADDRESS_329869] adverse events (72%) were mild and 
deemed unrelated to the nitazoxanide. None of the deaths or other serious adverse events (life -
threatening or requiri ng hospi[INVESTIGATOR_059]) was reported to be related to the use of nitazoxanide. 
Twenty -seven non -serious adverse events were considered possibly related to the use of the 
study drug. Twenty of these events were associated with the digestive tract (nausea, vomit ing, 
diarrhea, abdominal pain and dyspepsia). Other events possibly related to treatment were allergic 
reaction (n = 2), rash (n = 1), yellowish discoloration of the sclera (n = 2), and discoloration of 
urine (n = 2). Each of these events was transient in nature resolving on treatment or upon the 
discontinuation of treatment. In the 3 HCV studies, were attributed to the peginterfron and/or the 
ribavirin without apparent enhancement of the incidence in those patients who received 
nitazoxanide.89-[ADDRESS_329870] (nausea, vomiting, 
diarrhea , abdominal pain and dyspepsia). Other events possibly related to trea tment were allergic 
reaction (n = 2), rash (n = 1), yellowish discoloration  of the sclera (n = 2), and discoloration  of 
urine (n = 2). Each of these events was transient in nature resolving on treatment or upon the 
discontinuation of treatment. In the 3 HC V studies, were attributed to the peginterfron and/or the 
ribavirin without apparent enhancement of the incidence in those patients who received 
nitazoxanide.89-91 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329871] s.  
Given the safety of prolonged therapy with nitazoxanide  (89-92), lack of interactions with common 
post-transplant me dications, putative antiviral activity and prolonged duration of viral shedding 
we are assessing [ADDRESS_329872] s with chronic Norov irus 
infection with and without treatment.  
 
There are 2 arms  of the study:  
 
Nitazoxanide Arm : All subjects age ≥ 12 years:  500 mg (one tablet) nitazoxanide by [CONTACT_270630] 28 consecutive days.  
 
Placebo Arm:  All subjects age ≥ 12 years:  Placebo  (one tablet) by [CONTACT_270631] 28 consecutive days.  
2.3 Potential Risks and Benefits  
2.3.1 Potential Risks  
There are a number of potential risks associated with this study.  Risk is primarily derived from 
the study agent and the protocol -mandated p rocedures.   
 
Risks Associated with Nitazoxanide :  As outlined in the package insert for the nitazoxanide, the 
compound has been extensively studied and utilized clinically in a wide range of clinical settings 
including limited data in transplant recipi[INVESTIGATOR_841] s. The safety of nitazoxanide was evaluated in 2177 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329873] common adverse reactions were abdominal pain, 
headache, chromaturia and nausea  (>2%). Safety data were analyzed separately for 280 HIV -
uninfected subjects’ ≥[ADDRESS_329874] of adverse reactions spontaneously reported with nitazoxanide  
Tablets which were not included in clinical trial listings:  
 
Gastrointestinal disorders: diarrhea, gastroesophageal reflux disease .  
Nervous System disorders: dizziness . 
Respi[INVESTIGATOR_696], thoracic and mediastinal disorders: dyspnea .  
Skin and subcutaneous tissue disorders: rash, urti caria.  
 
Risks Associated with Protocol -Mandated Procedures : 
Blood Samples:  Drawing blood from a vein may cause local pain, bruising, occasional 
light-headedness, fainting, and very rarely, infection at the site of the 
blood draw.  
Buccal  Swabs:  Buccal  swab s may cause discomfort, irritation, or a gagging  sensation .  
Stool Collection:  Providing a stool specimen  might make the subject  feel embarrassed.  
Urine Test:  Female who could become pregnant, providing urine for a pregnancy test 
might feel embarrassed.  
Questionnaires:  Completion of  a questionnaire and the questions might make the subject 
feel uncomfortable or upset.  
Others:  
Pregnancy:  There are no data with this drug  in pregnant women to inform a drug -associated risk. 
No teratogenicit y or fetotoxicity was observed in animal reproduction studies with 
administration of nitazoxanide to pregnant rats and rabbits during organogenesis at expo sures 30 
and 2 times, respectively, the exposure at the maximum recommended human dose of 500 mg 
twice daily based on body surface area (BSA).   
In the U.S. general population, the estimated background risk of major birth defects and 
miscarriage in clinical ly recognized pregnancies is 2% to 4% and 15% to 20%, respectively.   
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           39 
CONFIDENTIAL  
 Breach of Confidentiality:  Instances like lost or stolen laptops storing participant information, 
lost or stolen thumb drives, paperwork with subject PHI left unsecured may result in bre ach in 
confidentiality.  
 
Unknown risks: Nitazoxanide and protocol mandated procedures may hav e risks previously 
unknown.  
2.3.[ADDRESS_329875] of care provided to 
patients with Norovirus (i.e. ant imotility agents and hydration) . 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           40 
CONFIDENTIAL  
 3 OBJECTIVES  
3.1 Study Objectives  
A. Primary Objective:   
1. To assess the clinical efficacy  of nitazoxanide for the management of acute and 
chronic Norovirus in transplant recipi[INVESTIGATOR_840].  
 
B. Secondary Objective s 
1. To assess virologic efficacy  of nitazoxanide  
2. To assess the safety  of nitazoxanide for the  management of acute and chronic 
Norovirus in transplant recipi[INVESTIGATOR_840].  
C. Exploratory Objectives  
1. To assess initial clinical improvement  in Norovirus Disease through [ADDRESS_329876] been conducted to establish the optimal endpoint for assessing novel drugs for 
the treatment of Norovirus in immunosuppressed  subjects.  Further, there are no published FDA 
guidance documents to inform optimal endpoint selection for this indication. (1)  Available 
literature and expert opi[INVESTIGATOR_270563].  
3.2.[ADDRESS_329877]  and will be 
defined as:  
a. Cessation of vomiting and,  
b. No stools classified by [CONTACT_270614] (Type 6 or 7)  
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329878] negative viral load through 180 days.  
2. The change in viral titer between Day 1 and 180 . 
Safety  
3. Incidence of unsolicited non -serious adverse events (see section 9 for details) through 
60 days.  
4. Incidence of laboratory adverse events (WBC, Hemoglobin, Platelet Count, 
Creatinine, Alkaline Phosphatase, ALT, AST, BUN and Bilirubin) through 60 days.  
5. Incid ence of protocol -specified serious adverse events (see section 9 for details) 
through 60 days.  
6. Incidence of Hospi[INVESTIGATOR_151400] 60 days.  
 
3.2.3 Exploratory  Outcome Measures  
Clinical Improvement;  
1. Time from randomization  to initial clinical improvement in Norovirus disease 
through [ADDRESS_329879] 48 hours, as defined by:  
a. 50% reduction in number of epi[INVESTIGATOR_261635],  
b. Improvement in PO intake, as judged by [CONTACT_20608],  
c. 50% reduction in the number of  epi[INVESTIGATOR_270564] 6 or 7 bowel movements.  
2. Time from randomization  to initial cessation of vomiting through Day 180 (recurrent 
vomiting will be considered disease recurrence unless determin ed to be due to another 
etiology [i.e. GVHD]).  
3. Time from randomization  to subject report of no loss of appetite that is maintained for 
48 hours through Day 180 (measure will be first time that the subject reports that they 
have no “loss of appetite” on the ir daily diary).  
4. Time from first dose to initial cessation of diarrhea through Day 180 classified by [CONTACT_270632] 6 or 7 bowel movements (recurrent diarrhea will be 
considered disease recurrence unless determined to be due to another etiology [i.e. 
GVHD]).  
5. Time from randomization  to 50% reduction in the amount of antimotility agents 
utilized by [CONTACT_270617] 180  
6. Number of days of diarrhea through Day s 28 and 180 . 
7. Number of stools classified by [CONTACT_270618] 6 or 7 bowel 
movements through Day 28. 
8. Number of days of IV hydration or total parenteral nutrition (TPN) therapy through 
Day 28 . 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           42 
CONFIDENTIAL  
 9. Total number of days  of hospi[INVESTIGATOR_270522] s 28 and 180 . 
10. Change in patient -reported quality of life as measured by [CONTACT_270619] -5 (global) and 
IBSQOL  (diarrhea specific ) [adult] or EuroQOL -5 Peds (global) and PedsQL GI 
Module  [children]  from baseline to Day 180 . 
11. Change in patient -reported physical function as measured by [CONTACT_270633] (Adult)  Pediatric Global Health (Peds)  from baseline to Day 180 . 
12. Change in patient -reported emotional distress as measured by [CONTACT_270634], Anxiety, Fatig ue (Adult and Peds)  from baseline to Day 180.  
13. Change in patient -reported gastrointestinal symptoms as measured by [CONTACT_270635] (Adult and Peds)  symptoms (6 of 8 subscales)  from baseline to Day [ADDRESS_329880] and will be defined as cessation of vomiting and no stools 
classified by [CONTACT_270614] (Type 6 or 7) from the total 
population compared to  the subgroup of subjects who do not report chromaturia 
(discoloration of urine) based on unsoli cited self -reporting.   
16. Incidence of  unsolicited non -serious adverse events (see section 9 for details) through 
60 days,  laboratory adverse events (WBC, Hemoglobin, Platelet count, Creatinine, 
Alkaline Phosphatase, ALT, AST, BUN and Bilirubin) through 60 d ays, protocol -
specified serious adverse events (see section 9 for details) through 60 days, 
and Hospi[INVESTIGATOR_151400] 60 days  from the total population compared to  the 
subgroup of subjects who do not report chromaturia (discoloration of urine) based on 
unsolicited self -reporting.  
 
 
Virologic Improvement:  
17. Time to ≥ [ADDRESS_329881] negative viral load through 180 days and the 
change in viral titer between Day 1 and 180  from the total population compared to  the 
subgroup of subjects who do not report chromaturia (discoloration of urine) based on 
unsolicited self -reporting.  
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           43 
CONFIDENTIAL  
  
Immunologic Response:  
22. Change in Norovirus -specific serum and stool  IgA, IgM  and IgG between Day 1 and 
Day 28 and 60  (stool only) . 
23. Association  between change in total lymphocyte count and T cell subsets at Day 1 
and 180 and clinical resolution of Norovirus symptoms.  
24. Association  between change in total lymphocyte count and T cell subsets at Day  1 
and 180 and undetectable quantitative norovirus PC R. 
25. Association  between change in Norovirus -specific serum  and stool  IgA, IgM  and IgG 
from  Day 1 to Days 28 and 60  (stool only) and clinical resolution of Norovirus 
symptoms.  
26. Association  between change in Norovirus -specific serum  and stool  IgA, IgM  and IgG 
from  Day 1  to Days 28 and 60 (stool only) and undetectable quantitative Norovirus 
PCR.  
 
Pharmacokinetics and Dose Response:  
27. For subjects consenting to PK draws, concentrations of nitazoxanide metabolites 
(tizoxanide and tizoxanide glucuronide) [ADDRESS_329882] dose on Day 7 and 
10 minutes before the second dose on Day 21.   
Natural History of Disease:  
28. Time to a llograft rejection as per each center team  
29. Time to allograft loss as reported to UNOS.  
30. Time to death.   
31. Time to withdrawal from the study because of intolerance or drug related adverse 
events.  
32. Correlation of secretor status as defined by [CONTACT_270636], separately , and 
clinical resolution  of Norovirus as defined by [CONTACT_53229] . 
 
 
 
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           44 
CONFIDENTIAL  
 4 STUDY DESIGN  
The study will be a phase 2 multi -center double -blind placebo -controlled study of the efficacy 
and safety of nitazoxanide for the treatment of solid organ and hematopoietic stem cell transplant 
recipi[INVESTIGATOR_270565]. The stu dy will involve approximately 
160 subjects randomly assigned (1:1) to nitazoxanide or placebo. The study duration is [ADDRESS_329883] negative viral load through 180 days and by 
[CONTACT_270637] 1 and 180; safety  of nitazoxanide  that will 
assessed by [CONTACT_270638] . 
 
There are 2 arms of the study:  
 
Nitazoxanide Arm:  All subjects age ≥ 12 years:  500 mg (one tablet) nitazoxanide by [CONTACT_270630] 56 consecutive d oses. 
 
Placebo Arm:  All subjects age ≥ 12 years:  Placebo (one tablet) by [CONTACT_270631] 56 consecutive d oses. 
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           45 
CONFIDENTIAL  
 5 STUDY ENROLLMENT AND WITHDRAWAL  
Approximately 160 males and females  ≥ [ADDRESS_329884] Inclusion Criteria  
Subjects should meet all of the following inclusion criteria  
1. Male or female age ≥ [ADDRESS_329885] result for Norovirus within 14 days of enrollment that is obtained as part of 
routine clinical care using a Norovirus testing available to the site.  
4. Active GI symptoms (diarrhea or vomiting) that, in the opi[INVESTIGATOR_17439], are seco ndary 
to Norovirus.#  
5. Willing and able to provide written informed consent and assent before initiation of any 
study procedures, consistent with local IRB policy.  
6. Subjects must be of non -childbearing potential or if of childbearing potential, must be 
using an effective method of birth control or must be abstinent.  
• Non-childbearing potential is defined as surgically sterile or postmenopausal for > 
one year.  
• Effectiv e methods of birth control include the use of hormonal or barrier birth control 
such as implants, injectable contraceptives, combined oral contraceptives, intrauterine 
devices [IUDs]  or condoms with spermicidal agents during study period.  Female 
subjects must be using an effective method of birth control or practice abstinence and 
must agree to continue such precautions during the study and for 30 days after the 
Day 28 study visit.  
• A woman is eligible if she is monogamous with a vasectomized male. This sub ject is 
considered low risk and not required to use contraception.  
7. Agrees to complete all screening requirements, study visits and procedures.  
 
 
 
 
 
# Patients must have active diarrhea, which is defined as at least [ADDRESS_329886] 2 
weeks prior to enrollment per patient report.  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329887] Exclusion Criteria  
Subjects meeting any of the exclusion criteria at baseline will be excluded from study 
participation  
1. Other identified infectious causes of diarrhea at screening *.  
2. Any condition that would, in opi[INVESTIGATOR_270566], place the subject at an 
unacceptable risk of injury or render the subject unable to meet the requirements of the 
protocol.   
3. Subjects receiving oral or intravenous immunoglobulin therapy concurrentl y or in the [ADDRESS_329888] at 
screening/enrollment/Day 1.  
 
Co-enrollment in other studies is allowed if none of the above exclusion criteria are met.  
*Alternative diagnosis requiring treatment would be considered a co -infection ; if the testing is 
positive for a pathogen that the PI [INVESTIGATOR_270567], they may be included 
but the PI [INVESTIGATOR_022]/her designee must document that the positive test is not clinically significant, 
does not require treatment and is not causing the symptoms making the patient eligible for 
enroll ment.  
 
5.3 Treatment Assignment Procedures  
5.3.1 Randomization Procedures  
Enrollment of subjects will be done online using the enrollment module of AdvantageEDCSM. 
Approximately 160 subjects will be randomized into two treatment groups:  active nitazoxanide 
and plac ebo with equal allocation (1 to 1 randomization) after providing consent and 
confirmation of eligibility based on the study inclusion and exclusion criteria.  
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           47 
CONFIDENTIAL  
 The study will use a stratified, permuted block randomization scheme. Permuted block 
randomizati on is used to avoid the potential for serious imbalance in the number of participants 
assigned to each group, an imbalance that can occur in the simple randomization procedures.  
 
Stratification will be by:   
 
• Duration of Symptoms:  onset of Norovirus -assoc iated symptoms (diarrhea, 
nausea  and/or abnormal appetite) < 14 days vs. ≥ 14 days  
• Transplant Type:  solid organ vs. hematopoietic stem cell transplant  
• Age Range:  pediatric (12 -17 years) vs. adult ≥ [ADDRESS_329889].  
5.3.2 Masking Procedures  
All subjects will take either nitazoxanide or matching placebo twice daily for 56 doses .  The 
placebo will be manufactured by [CONTACT_270612], L.C., Ltd . to match the appearance (color, size, with 
“CTM” imprints) of the active compound and will be dispensed in identical bottles.  Bottles will 
be labeled in such a way that it will not be obvious to the care team or the subject which arm 
they have been randomized to.  Bottles will be delivered to the site p re-filled containing either 
nitazoxanide or placebo and will have a unique number.  At the time of randomization, the 
unique number will be assigned to the individual subject.  No member of the study team will be 
aware of the arm that the subject has been assigned to unless the site PI [INVESTIGATOR_270568] (see section 5.3.4).    
 
Refer to the MOP for unblinding procedures, including emergency unblinding procedures  
(Section 5.2  of MOP ). 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329890] be recorded in 
the case report forms (CRFs).  
 
The reasons, migh t include, but are not limited to the following:  
• Subject no longer meets eligibility criteria  
• Subject withdraws consent  
• Subject not able to comply with study procedures  
• Subject becomes noncompliant  
• Evidence of toxicity including study drug -related AE/SAE, laboratory abnormality, 
intercurrent illness, or other medical condition or situation occurs that continued 
participation in the study would not be in the best interest of the subject.   
• Medical disease or condition, or new clinical finding (s) for which co ntinued 
participation, in the opi[INVESTIGATOR_202378], interfere with the subject's successful completion of this study, or interfere with 
the evaluation of responses  
• Subject lost to follow -up 
• Decision by [CONTACT_243278]’s best medical interest.  
• Decision by [CONTACT_270639]  
• Decision by [CONTACT_31665] (IRB/IEC) to stop or cancel the study  
• Determined by a physician’s discretion to require ad ditional therapy not indicated in the 
protocol to ensure subject’s  health and well -being  (or treatment failure, if applicable)  
 
The investigator should be explicit regarding study  follow -up (e.g. safety follow -up) that might 
be carried out despi[INVESTIGATOR_122748].  If the subject 
consents, every attempt will be made to follow all AEs through resolution.   The procedures that 
collect safety  data for the purposes of research must be inclusive in the original informed consent 
or the investigator may seek subsequent informed consent using an IRB/IEC -approved consent 
form with the revised procedures.  
 
The investigator will inform the subject tha t already collected data will be retained and analyzed 
even if the subject withdraws from th is study .  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329891]’s condition becomes stable.  
Subjects who request to withdraw their consent after study treatment from further participation in 
the study will be reminded of the importance of continuing the study for safety evaluations and 
will be encouraged to complete the Early Termination Visit if they choose not to complete the 
remaining study visits. The Early Termination Visit procedures are li sted in Section 7. 4. Subjects  
who choose to decline continuation in study participation will no longer be contact[CONTACT_51095] -
up.  
 
If a subject is withdrawn at any time due to an AE, the event will be followed until it is resolved 
or in the opi[INVESTIGATOR_8598] e Investigator is determined medically stable with the consent from the 
subject. The site PI [INVESTIGATOR_270569].  If the PI [INVESTIGATOR_270570], they will request unblinding by [CONTACT_270640].  Clinical failure is not an acceptable reason to request unblinding.   
Refer to the MOP and the DMID policy “Unblinding Individual Part icipants in DMID Clinical 
Research ,” the current policy is available at https://www.niaid.nih.gov/research/dmid -data-
management .  
 
In the case of subjects who fail to appear for a follow -up safety assessment, extensive effort (i.e., 
three documented contact [CONTACT_92238], e -mails, etc., made on separate occasions and 
followed by a certified letter) will be made to locate or  recall them, or at least to determine their 
health status.  Although the subject is not obliged to give reasons for withdrawing early, the 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329892]’s rights. These efforts will be documented in the subject’s records.  
5.3.5 Termination of Study  
The study will be terminated if the DSMB determines that the study should be terminated based 
on safety concerns.  If the study is terminated, the DSMB will be permitted to all ow the 
longitudinal monitoring phase of the study to proceed.  DMID and/or the IND holder may 
terminate the study at their sole discretion . Although the sponsor had every intention of 
completing this trial, it reserves the right to terminate this trial at any time for clinical or 
administrative reasons. Reasons for termination include, but not limited to, study closure due to 
DSMB review and recommendation and at the discretion of DMID.  
 
If the study is prematurely terminated by [CONTACT_78269], any regulatory authority, or the 
investigator for any reason, the investigator will promptly inform the study subjects and assure 
appropriate therapy or follow -up for the subjects, as necessary. The investigator will provide a 
detailed written explanation of the terminat ion to the IRB/IEC . 
 
 
5.3.[ADDRESS_329893] clinical appointments will be adjusted to 
coincide with their research visit windows to ensure convenience.  In addition, the subjects will 
be compensated for their research study visit.  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           51 
CONFIDENTIAL  
 6 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT  
6.[ADDRESS_329894] Description  
Nitazoxanide is a synthetic antiprotozoal agent for oral administration.  It is designated 
chemically as 2-acetyl oxy-N- (5-nitro -2-thiazolyl) benzamide. The molecular formula is 
C12H9N3O5S and the molecular weight is 307.3.  The placebo will look identical to nitazoxanide, 
and will have the same inactive ingredients ( described in section 6. 1.2). 
6.1.[ADDRESS_329895] from DMID, the study products  (nitazoxanide and placebo) will be shipped to 
the following address:   
DMID Clinical Materials Services (CMS)   
Fisher BioServices  
[ADDRESS_329896]  
Germantown, MD [ZIP_CODE]  
Phone: 240 -477-1350  
Fax: 240 -477-1360  
Email: [EMAIL_1395]  
Study product s, nitazoxanide 500mg tablets  and matching placebo will be shipped from DMID 
CMS to investigational site upon request and approval by [CONTACT_122830].  
6.1.2 Formulation, Packaging, and Labeling  
 
Nitazoxanide Tablets  
Nitazoxanide will be supplied as a 500 mg round, yellow, film -coated tablet with “CTM” 
imprint , manufactured by [CONTACT_270612], L.C. Per the package insert, inactive ingredients include: 
maize starch, pregelatinized corn starch, hydroxypropyl methylcellulose, sucr ose, sodium starch 
glycollate, talc, magnesium stearate, soy lecithin, polyvinyl alcohol, xanthan gum, titanium 
dioxide, FD&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, and 
FD&C Blue No. 2 Aluminum Lake.  
 
Placebo Tablets  
Placebo will be  supplied as a matching tablet of the active drug which will also be a round, 
yellow, film -coated tablet with “CTM” imprint .  Ingredients include : lactose monohydrate, 
magnesium stearate,  talc, soy lecithin, polyvinyl alcohol, xanthan gum, titanium dioxide , FD&C 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           52 
CONFIDENTIAL  
 Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, and FD&C Blue No. [ADDRESS_329897] will be packaged in two 60cc identical containers each containing 30 tablets. 
Each  container will also be labeled in compliance with appli cable regulatory requirements, 
including the FDA -required cautionary statement “Caution : - New drug -Limited by [CONTACT_270641].”    
 
6.1.[ADDRESS_329898] be stored at 25 °C (77 °F); excursions  are 
permitted to 15 -30°C (59 -86°F). [See US P Controlled Room Temperature].  
The temperature of the storage unit must be manually recorded daily (excluding non -business 
days and holidays, as applicable) and continuously monitored and recorded during the course of 
this trial per the participating site standard operatin g procedures (SOPs), and documentation will 
be maintained. If the temperature fluctuates outside of the required range, the affected study 
product(s) must be quarantined at the correct storage temperature and labeled as ‘Do Not Use’ 
(until further notice).  The participating site’s research pharmacist must alert the site principal 
investigator [INVESTIGATOR_32528], if the temperature fluctuates outside of the required range. In 
the event the temperature fluctuates outside of the required range, including ac cidental deep -
freezing or disruption of the cold chain, the affected study product(s) must not be administered. 
The site principal investigator [INVESTIGATOR_270571] [EMAIL_5255]  for further instructions 
before any additional study product are administered . Based on the information collected, DMID 
and/or the manufacturer will determine whether the affected study prod uct(s) can be used. If it 
cannot be used, the site will receive specific instructions on how to return the affected study 
product(s) to the DMID CMS or destroy it on site.  
For subjects in the hospi[INVESTIGATOR_307], the participating sites will maintain a temperature l og to record 
temperature once per day in the room where the study products  are stored for the period that the 
patient is in the hospi[INVESTIGATOR_307] . 
 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           53 
CONFIDENTIAL  
 6.2 Dosage, Preparation and Administration of Study 
Intervention/Investigational Product  
Nitazoxanide (administered orall y as one 500 mg tablet) or placebo (administered orally as a 
matching tablet) twice daily with food for [ADDRESS_329899] under state 
and local rules and regulations.  
 
6.3 Modification of Study Intervention/Investigational Product for a 
Participant  
There will be no modification of the dose of nitazoxanide during the [ADDRESS_329900]’s discontinuation of study treatment will be determine d by [CONTACT_270642].  
 
6.4 Accountabil ity Procedures for the Study Intervention/Investigational 
Product(s)  
Study product will be stored and shipped from the DMID contract repository, Fisher 
BioServices, to the Clinical Sites. Once received, study product will be stored in and dispensed 
by [CONTACT_156979].  
Used/opened product will be counted and disposed in accordance with site’s SOPs with two staff 
members  (two research pharmacists or a research pharmacist and /or a study team member ) 
present co -signing and verifying the count  (see MOP for additional detail) .  In addition, this 
verification form will be added to the protocol file so that DMID monitors can verify when at the 
sites for a routine IMV.  In addition, used/opened product can also be retained until monitored 
and released fo r disposition, as applicable.  
The [LOCATION_002] Food and Drug Administration (FDA) requires accounting for the disposition 
of all investigational products. The Investigator is responsible for ensuring that a current record 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329901] to inspection by a regulatory 
agency (e.g., FDA) at any time. An assigned Study Monitor will review the pharmacy records.  
 
Unused investigational product will be stored at 25°C (77 °F); excursions permitted to 15 -30°C 
(59-86°F) [See US P Controlled Room Temperature] in the Investigational Pharmacy until 
monitored and released for disposition as applicable. At study completion or termination, all 
unused investigational product will be d isposed in accordance with the MOP following complete 
drug accountability and monitoring.  Final disposition of the unused study product will be 
determined by [CONTACT_270643].  
6.[ADDRESS_329902] Compliance with Study 
Intervention/Investigational Product  
Subjects will be requested to bring study drug with them to all visits during the Treatment Phase.  
Remaining pi[INVESTIGATOR_270572].  If 
subjects forget to bring in their study drug or they lose their container, subject interview and 
study diary will be used to confirm medication adherence.  
6.6 Concomitant Medications/Treatments  
Subjects may receive any therapy that is deemed approp riate to treat the signs and symptoms of 
Norovirus after randomization at the discretion of their treating provider except for nitazoxanide  
and oral immunoglobulin. This can include:  
 
• Intravenous immunoglobulin  
• Changes in immunosuppression  
• Anti-motil ity agents  
 
Any treatment utilized should be included on the concomitant medications at the time of 
enrollment. Any concomitant medication pre - or post -randomization that is being used to treat 
the signs or symptoms of Norovirus should be marked as such on  the Case Report Form  for the 
entire duration of the study .  Likewise, any change to immunosuppressive therapy would have a 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           55 
CONFIDENTIAL  
 note in the Case Report Form noting if the change was made because of elevated drug levels, for 
treatment of Norovirus or for other purposes.  Concomitant medications will be collected through 
visit 12 (Day 180 after initial dose of study treatment) or early termination, whichever occurs 
first. If the Investigator learns that the subject has taken a prohibited medication (see 
inclusion/ exclusion criteria) prior to the last dose, the Inves tigator will contact [CONTACT_270644]’s continuation in the study.  
 
Medications that might interfere with the evaluation of the investigational prod uct should not be 
used unless absolutely necessary.  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           56 
CONFIDENTIAL  
 7 STUDY SCHEDULE  
The study will need to enroll 160 subjects who meet inclusion and exclusion criteria and agree to 
participate in the study (Section 5.1, 5.[ADDRESS_329903] Exclusion Criteria ).  
Upon enrollment in the study, subjects will be randomized  into two treatment groups:  a ctive 
nitazoxanide and placebo:  
 
a. Nitazoxanide Arm:  All subjects age ≥ 12 years:  500 mg (one tablet) nitazoxanide by 
[CONTACT_270613] 56 consecutive d oses. 
b. Placebo Arm:  All subjects age ≥ 12 years:  Placebo (one tablet) by [CONTACT_270645] 56 consecutive doses.  
Randomization will be stratified by [CONTACT_551] (adult vs. pediatric), chronicity of Norovirus -
associated symptoms (acute vs. chronic) a nd transplant type (HSCT vs. SOT) as follows:  
 
• Duration of Symptoms:  onset of Norovirus -associated symptoms (diarrhea, nausea    
and/or abnormal appetite) <  14 days vs. ≥ 14 days  
• Transplant Type:  solid organ vs. hematopoietic stem cell transplant  
• Age Ran ge:  pediatric (12 -17 years) vs. adult ≥ [ADDRESS_329904]’s record and then the full dose will be re -administered one time only 
per scheduled dose. All subjects must have therapy discontinued after taking [ADDRESS_329905]  Diary . 
If symptoms recur after discontinuing therapy, subjects can resume any therapy at the discretion 
of the principal investigator [INVESTIGATOR_022]/her designee with the exception of nitazoxanide.  
Nitazoxanide can be used after Day 28 if the local PI [INVESTIGATOR_270573] s evere or life -threatening disease.  Although 
nitazoxanide can be used if it is felt critical to the subjects care, its use should be avoided until 
Day 180 whenever felt to be safe to do so by [CONTACT_24099].  Any use of nitazoxanide beyond Day 
28 will be documented on the concomitant medication form and prescribed from commercial 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329906] 2 phases:  
1. Treatment Phase  (Study Day  1-28) 
2. Longitudinal Monitoring Phase  (Study Day 29 -180) 
7.1 Screening/Baseline/Treatment Phase  
Any subject ≥ [ADDRESS_329907] for Norovir us within 7 days as part of routine clinical care will be approached 
to participate in the study.  Once consent is obtained, then laboratory testing and medical history 
will be reviewed to determine eligibility unless local IRB waiver allows to review data  prior to 
consent.  Assessment required for eligibility may not be measured more than twice.  
a. Screening/Enrollment/Baseline  
• Consent/Assent will be reconfirmed with eligible subjects, consistent with local 
IRB policy for consent and assent of subjects.  
• Subject and their chart will be reviewed to collect a medical history, concurrent 
medications . 
• Urine pregnancy test will be obtained from women of childbearing potential. 
Results must be known and negative prior to dosing.  
• WBC, TLC (Total Lymphoc yte Count) Hb, Platelets (Derived from Complete 
Blood Count -within 3 days  of enrollment ). 
• Creatinine, Alk Phos, AST, ALT, BUN, Bilirubin  (Derived from Complete 
Metabolic Panel -within 3 days  of enrollment ). 
• T Cell Subsets will be drawn unless CBC shows an ALC <100.   
• Samples to be sent to the central laboratory are collected and processed:  
▪ Buccal swab and saliva samples for secretor assay . 
▪ Stool for quantitative Norovirus RT -PCR and sequencing . 
▪ Stool for other pathogen testing . 
▪ Stool for Norovirus -specific IgA, IgG, and IgM studies . 
• Serum for quantitative Norovirus -specific IgA, IgG, and IgM and total IgG . 
• Randomization . 
• Vital signs will be obtained ( pulse, temperature, BP, respi[INVESTIGATOR_1516], height and 
weight).  
• Weekly Recall Packet will be administe red.  
• Detailed Subject Reported Outcome and Severity Score Assessment . 
• Physical examination will be performed.  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           58 
CONFIDENTIAL  
 • Plastic bag with two [ADDRESS_329908] (nitazoxanide or placebo) will  be given  by 
[CONTACT_3476] .   
 
The study product (nitazoxanide or placebo) will be taken by [CONTACT_270646] 28 days.  
 
Subjects will be given a paper diary (to inquire about symptoms and severity along with overall 
well-being) that will be completed daily, at the time of study product dosing.  The time of study 
product dosing will also be recorded. This will be completed o n a daily basis through day 28.  
The pack of paper diary along with instructions that is given at enrollment will cover t he entire 
study period.   
 
The stool sample must have been p roduced within [ADDRESS_329909] would be encouraged to provide another sample within the visit 
window and if not, a rectal swab may be used  for virus detection.  
 
b. Study Day 7 ± 3 days  
• Collection and review of completed diary pages . 
• WBC, TLC, Hb, Platelets (Derived fro m Complete Blood Count ).  
• Creatinine, Alk Phos, AST, ALT, BUN, Bilirubin  (Derived from Complete 
Metabolic Panel ).   
• Pi[INVESTIGATOR_270574].  
• Samples of stool  (collected at home or at clinic)  to be sent to the central 
laboratory are collected and processed:  
▪ Stool for quantitative Norovirus RT -PCR and sequencing . 
▪ Stool for other pathogen testing; stool will be stored for later testing 
and this assay will not be performed for formed stool after Day 1.   
▪ Nitazoxanide PK drawn [ADDRESS_329910] takes his/her dose, for subjects 
consenting to this optional assessment .  The time of the blood draw and the time 
of the previous dose will be recorded.  
▪ Vital signs  (temperature, BP, respi[INVESTIGATOR_1516] , weight and pulse ) will be obtained . 
▪  Weekly Recall Packet will be administe red (Table 5). 
▪ Collect concurrent medications . 
▪ Inquiry about hospi[INVESTIGATOR_270575] . 
▪ Assess for adverse events.  
 
c. Study Day 14 ± 3 days :  Virtual Visit  
• Team to call subject  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           59 
CONFIDENTIAL  
 • Review of completed diary pages . 
• Subject to collect stool sample and store in freezer  until day 28 study visit  
• Weekly Recall Packet will be administe red (Table 5) . 
• Collect concurrent medications . 
• Inquiry about hospi[INVESTIGATOR_270575] . 
• Assess for adver se events . 
 
d. Study Day 21 ± 3 days - Virtual Visit except for patients who agree to optional PK study  
• Team to call subject  not enrolled in the PK Sub Study (those patients will have in 
person visit)  
• Review of completed diary pages . 
• Subject to collect stool sample and store in freezer  until day 28 study visit . 
• For patients in the PK Sub Study:  
▪ Samples  of stool  to be sent to the central laboratory are collected and 
processed:  
o Stool for quantitative Norovirus RT -PCR and sequencing . 
o Stool for other pathogen testing; stool will stored for later testing 
and this assay will not be performed for formed stool after Day 1.  
▪ Nitazoxanide PK drawn [ADDRESS_329911] takes his/her dose, 
for subjects consenting to this optional assessment.  The time of the blood 
draw and the time of the previous dose will be recorded.  
• Weekly Recall Packet will be administe red (Table 5)  
• Collect concurrent medications . 
• Assess  for adverse events . 
• Inquiry about hospi[INVESTIGATOR_270575] . 
 
e. Study Day 28  + [ADDRESS_329912] dose and return the residual medications and bottles on Study Day 60.  
• Collection and review of completed diary pages . 
• WBC, TLC, Hb, Platelets (Derived from Complete Blood Count ). 
• Creatinine, Alk Phos, AST, ALT, BUN, Bilirubin (Derived from  Complete 
Metabolic Panel ).   
• Samples  of stool  (collected at home or at clinic)  to be sent to the central 
laboratory are collected and processed:  
▪ Stool for quantitative Norovirus RT -PCR and sequencing . 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           60 
CONFIDENTIAL  
 ▪ Stool for other pathogen testing; stool will stored for later testing and 
this assay will not be performed for formed stool after Day  1. 
▪ Stool Norovirus -specific IgA, IgG, and IgM studies . 
• Serum for quantitative Norovirus -specific IgA, IgG, and IgM and total IgG . 
• Vital signs will be obtained ( temperature, BP, pulse, respi[INVESTIGATOR_270576] ). 
• Weekly Recall Packet will be administe red (Table 5) . 
• Detailed PROs packet will be collected (Table 5) . 
• Collect concurrent medications . 
• Assess for adverse events . 
• Physical examination will be performed . 
• Inquiry about hospi[INVESTIGATOR_270575] . 
• Pi[INVESTIGATOR_270577]-over pi[INVESTIGATOR_270578] .  
 
Instructions will be given to s ubject s for the Longitudinal Monitoring Phase diary  (Diary 2 9-180 
days)  at the Day [ADDRESS_329913] s can resume any therapy at the discretion 
of the principal investigator [INVESTIGATOR_022]/her designee.  Additional stool specimens should be collected 
prior to initiation of therapy for testing in the central la b, including stool for quantitative 
Norovirus  PCR, sequencing and other pathogen testing  when feasible . 
 
e. Study Day 35  ± 3 days: Telephone Call for an update to health status  and reminder 
for appointment  
• Collect concurrent medications . 
• Assess for adverse events .  
• Inquiry about hospi[INVESTIGATOR_270575] . 
• Weekly Recall packet will be administered by [CONTACT_270647] . 
 
f. Day 53  ± 7 days -Telephone Call for an update to health status and reminder for 
appointment  
• Weekly Recall  packe t will be administered by [CONTACT_270647] . 
• Appointment r eminder  for the next scheduled visit . 
 
g. Study Day 60 ± 14 days : Option to do as a virtual visit or in person visit.  Must be in 
person if medication not collected on day 28 visit.  
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           61 
CONFIDENTIAL  
 • A pi[INVESTIGATOR_270579] 28  
visit.  
• Review of completed diary pages . 
• Subject to collect stool sample and store in freezer  until day 120 or 180 study 
visit. 
▪ Samples  of stool  to be sent to the central laboratory are collected and 
processed  (if in person visit) : 
▪ Stool for quantitative Norovirus RT -PCR and sequencing . 
▪ Stool for other pathogen testing; stool will stored for later testing and 
this assay will not be performed for formed stool after Day 1.  
▪ Stool Norovirus -specific Ig A, IgG, and IgM  studies . 
• Daily Diary  and Detailed PROs packet will be collected (Table 5)   
• Weekly Recall Packet will be administe red (Table 5)  
• Collect concurrent medications . 
• Inquiry about hospi[INVESTIGATOR_270575] . 
• Assess for adverse events . 
h. Study Day 11 3 ± 7 days -Telephone call for update to health status and reminder for 
appointment  
• Weekly Recall  packet will be administered by [CONTACT_270647] . 
• Appointment r eminder  for the next scheduled visit . 
 
i. Study Day 120 ± 14 days : Option to do as a virtual visit or in person visit 
• Review of completed diary pages . 
• Subject to collect stool sample and store in freezer until day 180 study visit.  
• Samples  of stool   to be sent to the central laboratory are collected and processed (if 
in person visit) : 
▪ Stool for quantitative Norovirus  RT-PCR and sequencing . 
▪ Stool for other pathogen testing; stool will stored for later testing and 
this assay will not be performed for formed stool after Day 1.  
▪ Stool Norovirus -specific Ig A, IgG, and IgM  studies . 
• Daily Diary  and Detailed PROs packet  will b e collected (see Table 5) . 
• Weekly Recall Packet will be administe red (Table 5)  
• Collect concurrent medications . 
• Inquiry about hospi[INVESTIGATOR_270580] . 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           62 
CONFIDENTIAL  
 j. Study Day 173 ± 7 days -Telephone call for update to health status and reminder for 
appointment  
• Weekly Recall  Packet will be administered by [CONTACT_270647] . 
• Appointment r eminder  for the next scheduled visit . 
k. Study Day 180 ± 14 days  
• Collection and review of completed diary pages . 
• WBC, TLC (Total Lymphocyte  Count) Hb, Platelet s (Derived from Complete 
Blood Count ).  
• Creatinine, Alk Phos, AST, ALT, BUN, Bilirubin  (Derived from Complete 
Metabolic Panel . 
• T Cell Subsets will be drawn unless CBC shows an ALC <100.   
• Samples  of stool  (collected at home or at clinic)  to be sent to the central
 laboratory are collected and processed:  
▪ Stool for quantitative Norovirus  RT-PCR and sequencing  
▪ Stool for other pathogen testing; stool will stored for later testing and 
this assay will not be performed for formed stool after Day 1.  
▪ Stool Norovirus -specific Ig A, IgG, and IgM  studies  
• Serum for quantitative Norovirus -specific IgA, IgG, and IgM and tota l IgG.  
• Vital signs  (temperature, BP, pulse, respi[INVESTIGATOR_270576])  will be obtain ed. 
• Daily Diary  and Detailed PROs packet will be collected (see Table 5) . 
• Weekly Recall Packet will be administe red (Table 5)  
• Collect concurrent medications . 
• Inquiry about ho spi[INVESTIGATOR_270580] . 
7.[ADDRESS_329914] s will be followed weekly while on study medication (visits on study Day 1, 7, 14, 21 
and 28) and will be called [ADDRESS_329915] laboratory assessments ( WBC  with total 
lymphocyte count) , Hb, Platelets -derived from  complete blood count and Creatinine, Alk Phos, 
AST, ALT, BUN, Bilirubin -derived from comprehensive metabolic panel) on study Day 1, 7, [ADDRESS_329916] s develop recurrent diarrheal symptoms between visits, 
they should alert the study team, provide a sample of stool for central assessment and assessment 
locally.  Likewise, if they develop adverse events  between visits, they should alert the study 
team.  More frequent evaluation can be done  at the clinician’s discretion. (Please refer to 
Appendix A and Section 7 for details of study evaluations at each visit ) 
DMID  Protocol 16-0092  Version  4.0.21.Jan 2020  
 
 
DMID/NIAID/NIH           [ADDRESS_329917] on study Day 180 ± [ADDRESS_329918] should be followed until resolution of the event. ( Please refer to Appendix A and Section  
7 for details of study evaluations at final visit ) 
7.[ADDRESS_329919]. ( Please refer to Appendix  A for details of study 
evaluations at each visit ) 
7.[ADDRESS_329920] vita l signs , assessment 
for adverse events  and review the patient diary  and weekly PRO packet ; laboratory assessments 
will only be collected if standard of care labs are ordered by [CONTACT_3476].  Likewise, if they 
develop adverse events  between visits, they should alert the study team.  More frequent 
evaluation can be done at the clinician’s discretion.  (Please refer to Appendix A for details of 
study evaluations at each visit ) 
DMID Protocol [ADDRESS_329921] 2019  
 ________________________________ ________________________________ ________________________________ ___  
 
64 
 8 STUDY PROCEDURES/EVALUATIONS  
8.1 Clinical Evaluations  
1. Medical History  
2. Physical Exam  
3. Vital Signs including weight  
4. Review of Concurrent Meds  
5. Assessment for adverse events  
6. Daily  and Recall  Diary (See Appendix C) 
7. Weekly Patient Reported Outcomes Tool (See Appendix C) 
 
To minimize missing diary data, we have added a recall diary protocol, administered by [CONTACT_270648] , which can be used to offset any missing daily diary 
data. In a subset of participants enrolled in Irritable Bowel Syndrome Outcome Study, IBSOS, 
prospective daily diary was aggregated across 7 days and served as the “gold standard” by [CONTACT_270649] -of-period self -report ed recall of symptoms over the past 7 days.94  The 
participant groups’ mean level of symptom severity based on weekly recall were within one 
point of each other for the core symptoms in this trial: diarrhea frequency and consistency 
[Bristol Stool Scale], urgency, and abdominal pain.  If at all, participants were likely to over -
estimate their symptoms on recall which would potentially favor our placebo condition.  Because 
this prospective study, included participants who were already monitoring daily sympto ms as 
part of a clinical trial, we recommend our participants continue to monitor daily during 
assessment periods in case the act of daily monitoring itself influences recall at one week.  We 
will consider 80% compliance across the monitoring period accept able [missing no more than 
1.5/7 days per week over the 8 weeks].   While we will not exclude patients,  who are below this 
complianc e for any monitoring period , we will conduct a sensitivity analysis comparing those 
with few missing values to those with gr eater than 2 missing values per week.  
 
A schematic of diary and PRO data collection is listed on the next page.   
 
8.2 Laboratory  Evaluations  
8.2.1 Clinical Laboratory Evaluations  
1. Complete Blood Count with Differential:  This assay will be done in the individual site ’s 
laboratory using standard methodology.  Normal ranges for the key components of the 
complete blood count (white blood cell count, neutrophil count, lymphocyte count, 
eosinophil count, monocyte, hemoglobin, hematocrit, mean corpuscular volume, and platel et 
count) will be obtained for each site. Assessment of these lab values will be conducted as 
DMID Protocol [ADDRESS_329922] of care by [CONTACT_270650],  but only white blood cell count, 
hemoglobin and platelet count will be utilized for safety outcomes.  
Comprehensive Metabolic Panel:   This assay will be done in the individual site’s laboratory 
using standard methodology.  Normal ranges for the comprehensive metabolic panel 
(sodium, potassium, bicarbonate, chloride, blood urea nitrogen, creatinine, glucose,  calcium, 
albumin, total protein, alkaline phosphatase, alanine amino -transferase, aspartate amino -
transferase, and bilirubin) will be obtained for each site.  Assessment of t hese lab values will 
be conducted as per described in Section 9.[ADDRESS_329923]:   This assay will be done in the individual site’s laboratory using 
standard methodology and must utilize an FDA -approved, cleare d, or licensed test system.  
3. T-Cell Subsets:   This assay will be done in the individual site’s laboratory using standard 
methodology to provide absolute number and % of CD3+, CD4+ and CD8+ cells.  
4. Stool for Pathogen Screen:   This assay will be performed in the Diagnostic Infectious 
Diseases Testing Laboratory (Cincinnati Children’s Hospi[INVESTIGATOR_29349] (CCHMC, 
Cincinnati, OH) which will be provided a 1-gram  aliquot of stool from the Jiang Laboratory.  
Day 1 stool specimen  and non -formed stool samples from subsequent visits will be screened 
for additional pathogens (Bacteria - Campylobacter (jejuni, coli and upsaliensis), 
Clostridium difficile (Toxin A/B), Plesiomonas shigelloides, Salmonella species, Yersinia 
enterocolitica , Vibrio species (parahaemolyticus, vulnificus and cholerae), Diarrheagenic 
E.coli/Shigella including, Enteroaggregative E. coli (EAEC), Enteropathogenic E. coli 
(EPEC), Enterotoxigenic E. coli (ETEC), Shiga -like toxin -producing E. coli (STEC), 
Shigella/En teroinvasive E. coli (EIEC); Parasites - Cryptosporidium, Cyclospora 
cayetanensis, Entamoeba histolytica, Giardia lamblia; Viruses - Adenovirus F40/41, 
Astrovirus, Norovirus GI/GII, Rotavirus A, Sapovirus (I, II, IV and V)) using the  FDA -
cleared FilmArray system from BioFire Diagnostics (bioMerieux, Marcy l’Etoile, [LOCATION_009]).  
After collection in the stool hat, the subjects can wipe down and disinfect the outside of the 
container and place it in a bag for transport then refrigerate until  they come to their visit 
with the research staff. The sample must have been p roduced within [ADDRESS_329924] 2019  
 ________________________________ ________________________________ ________________________________ ___  
 
66 
   
Table 5:  Protocol PRO Completion Guide  
Phase  Treatment  Post-treatment monitoring  Unsche
duled 
Visit  Early 
Termin
ation 
Visit  
Assessment 
Time Point  Screen  
Enroll  
Day 1  Day 7  
(±3 d)  Day 
14₩ 
(±3 d)  Day 
21₩ 
(±3d)  Day 28  
(+3 d) Day 
35 (± 
3d) *Day 
53 
(±7d) ₩Day 
60 
 (±14 d)  *Day 
113 
 ±7d ₩Day 
120 
 (±14 d)  *Day 
173 
 ±7d Day 180 
(±14 d)    
Daily Diary    Days  
1-[ADDRESS_329925] 
week 
before 
term 
Weekly Recall/ 
Phone Packet  X X X X X X X X X X X X X X 
  
Detailed PROs 
Packet  X       X    X  X  X   X 
  
Daily Diary: To be completed by [CONTACT_270651].  Diary 1 -28 days; Diary 29 -180 days   See MOP for details.  
Weekly Recall Packet :  To be completed by [CONTACT_464].  See MOP for details.  
Detailed PROs Packet:  To be completed by [CONTACT_464].  This will include  PROMIS and QOL Questionnaires. See MOP for details.  
*Phone call -Appointment reminder and Weekly Recall Packet to be completed  
₩Can be Virtual Visits 
DMID  Protocol 16-[ADDRESS_329926] 2019  
 
 
 
67 8.2.2 Special Assays or Procedures  
1. Stool for Norovirus  Assays:   These assays will be performed in the Jiang Laboratory 
(CCHMC, Cincinnati, OH).  Bulk stool samples are collected from subjects and aliquoted 
on site into cryovials. Aliquots are frozen at < -70°C before shipment to the Jiang Lab.  One-
gram  bulk stool ali quots are necessary for the following assays.  
a. Norovirus  Quantitative RT -PCR (qRT -PCR):   Stool suspensions (10% w/v) will be 
prepared in sterile water. Viral RNA will be purified from the clarified extracts using the 
QiaAmp Viral Mini kit (Qiagen) according  to the manufacturer’s instructions. The viral 
RNA will be eluted in a final volume of 60ul. Each sample will be tested in triplicate 
using the TaqMan Fast Virus 1 -Step Master Mix (Applied Biosystems). GI NoVs are 
amplified with forward primer – QNIF4 5’CG C TGG ATG CGN TTC CAT, reverse 
primer – NV1LCR 5’CCT TAG ACG CCA TCA TTT AC, and probe – NV1LCpr 
5’VIC -TGG ACA GGA GAY CGC RAT CT -MGBNFQ, while GII NoVs are amplified 
with forward primer – QNIF2d 5’ATG TTC AGR TGG ATG AGR TTC TCW GA, 
reverse primer – Cog2R  5’TCG ACG CCA TCT TCA TTC ACA, and probe – RING2 
5’6-FAM -TGG GAG GGC GAT CGC AAT CT -MGBNFQ. Real -time RT -PCR will be 
performed using the [ADDRESS_329927] Real -time PCR System (Applied Biosystems). All samples 
will be compared among each other, as well as against  known GI and GII positive 
controls for relative Ct values.  
Stool  samples  will  be  processed  for  extraction  of  norovirus  RNAs.  RT -PCR  will  
be  performed  via  a  standard  procedure  using  primers  targeting  the  RNA -dependent  
RNA  polymerase  gene  of  norovirus  genome.  This  will  result  in  a  319 -nucleotide  
fragment  as  PCR  products.  PCRs  will  contain  40  cycles  of  amplifications;  a  
positive  and  negative  control  will  be  included  to  make  sure  PCR  being  wo rking.  
As  explained  above,  stool  sampling  will  be  performed  according  to  an  SOP;  there  
is  no  approaches  at  the  laboratory  level  to  account  for  sampling  error.  The  PCR  
product  of  norovirus  genome  fragment  will  be  sequenced  at  CCHMC’s  DNA  
Sequencing  Core  Facility  equipped  with  state -of-the-art  capi[INVESTIGATOR_270581]  
(Sanger  Sequencing).  
b. Norovirus  Genotypi[INVESTIGATOR_007]:   Once NoV -positive samples have been identified by [CONTACT_16641] -PCR, 
routine RT -PCR and sequencing can be employe d to identify genotype. This 
amplification uses a set of primers (p289H,I/p290H,I,J,K) designed to detect all NoV 
genotypes. PCR products are run on an agarose gel and visible bands at the correct size 
are cut from the gel, purified, and sequenced. Sequenc es are compared to published NoV 
sequences with known genotypes downloaded from GenBank to determine genotype.  
c. Norovirus  Phylogenetic Analysis:   After sequencing RT -PCR products from subjects 
over the course of the study to determine genotype, as described  above, sequences from 
the same subject over time will be compared to identify mutations. Various analyses can 
be performed to assess sequences changes over time.  
DMID  Protocol 16-[ADDRESS_329928] 2019  
 
 
 
68 2. Stool for Norovirus -Specific Immunoglobulin Studies:   These assays will be performed in 
the J iang Laboratory (CCHMC, Cincinnati, OH).  Bulk stool samples are collected from 
subjects and aliquoted on site into cryovials. Aliquots are frozen at < -70°C before shipment 
to the Jiang Lab.  One-gram  bulk stool aliquots are necessary for the following ass ays.  For 
stool Norovirus -specific IgA, IgM and IgG studies, a 96 -well microtiter plates are coated 
with rabbit antibody specific to Noroviruses overnight at 4 °C. Following a wash the plates 
are blocked with 5% nonfat dry milk. For Norovirus -specific Igs, purified Norovirus P -
particles (PP) are then added. After incubation 1 hour at 37°C, dilutions of subject 10% 
stool suspensions are added and the plates are incubated at 37°C for 1 hour. Horseradish 
peroxidase conjugated goat anti -human Ig antiserum is the n added to each plate. After 
incubation the wells are washed and TMB substrate solution is added to each well followed 
by [CONTACT_270652]. The reaction is stopped by [CONTACT_1121] 1M 
Phosphoric Acid.  Plates are read using an EIA spectra r eader (at a wavelength of 450 nm 
according to manufacturer’s instructions). All assays will include positive and negative 
control stool.  
3. Stool Pathogen Screen: The Stool Pathogen Screen will utilize the BioFire FilmArray 
Gastrointestinal Panel to screen for a range of pathogens ( Campylobacter (C. jejuni/C. 
coli/C. upsaliensis ),Clostridium difficile (C. difficile ) toxin A/B,  Plesiomonas 
shigelloides,  Salmonella,  Vibrio (V. parahaemolyticus/V. vulnificus/ V. cholerae ), including 
specific identificati on of Vibrio cholerae,  Yersinia enterocolitica,  Enteroaggregative 
Escherichia coli (EAEC),  Enteropathogenic Escherichia coli (EPEC),  Enterotoxigenic 
Escherichia coli (ETEC) lt/st, Shiga -like toxin -producing Escherichia coli (STEC) stx1/stx2 
(including spec ific identification of the E. coli O157serogroup within STEC),  Shigella / 
Enteroinvasive Escherichia coli (EIEC),  Cryptosporidium,  Cyclospora 
cayetanensis,  Entamoeba histolytica,  Giardia lamblia (also known as G. intestinalis and G. 
duodenalis ), Adenovirus F 40/41,  Astrovirus,  Norovirus GI/GII,  Rotavirus A,  Sapovirus 
(Genogroups I, II, IV, and V)). The samples are placed in Cary -Blair. Test is performed 
according to manufacturer ’s instructions. Once completed, the results are reviewed for 
intern al contro ls and possible pathogen detection. The internal controls must be positive for 
the run to pa ss. If controls fail, the sample s is retested with a new pouch. Any unusual 
pathogens detected will be brought to the attention of the Director and study PI.  
4. Serum for  Immunoglobulin Assays:   These assays will be performed in the Jiang Laboratory 
(CCHMC, Cincinnati, OH).  For these assays, at least 4, [ADDRESS_329929] tubes and serum is processed and aliquoted into 
cryovials at the sites  and frozen at < -70°C before shipment to the Jiang Lab.  
a. Quantitative Total IgG Level:   Total IgG levels are also measured using a similar EIA 
method. Instead of coating Norovirus -specific antibodies to the microtiter plates, anti -IgG 
antibodies are used fo r the initial coating before addition of subject serum samples. 
Similar to above, horseradish peroxidase conjugated anti -human Ig antiserum is added to 
each plate before TMB substrate and phosphoric acid addition and measurement. Known 
DMID  Protocol 16-[ADDRESS_329930] samples compared to the standards.  
b. Norovirus -Specific Serum IgA, IgM and IgG:   96-well microtiter plates are coated with 
rabbit antibody specific to Noroviruses overnight at 4 °C. Follo wing a wash the plates are 
blocked with 5% nonfat dry milk. For Norovirus -specific Igs, purified Norovirus P -
particles (PP) are then added. After incubation 1 hour at 37°C, subject serum samples are 
added and the plates are incubated at 37°C for 1 hour. Ho rseradish peroxidase conjugated 
goat anti -human Ig antiserum is then added to each plate. After incubation the wells are 
washed and TMB substrate solution is added to each well followed by [CONTACT_270653]. The reaction is stopped by [CONTACT_270654] 1M Phosphoric Acid.  Plates are 
read using an EIA spectra reader (at a wavelength of 450 nm according to manufacturer’s 
instructions). All assays will include positive and negative control serum.  
 For the NoV -specific ELISAs, they will be performed  for subjects after the sample           
genotypi[INVESTIGATOR_24008]. Since we are interested in the antibody responses in each 
subject, the antigens in the ELISAs will match their genotypes. The ELISA SOPs ( see 
MOP ) gives the example of our NoV GII.4 P -domain protein as the antigen that we make 
in-house but also states that other genotypes may be used as long as the protein 
concentration has already been determined for the antigen.  
5. Buccal Swab/Saliva for Secretor Status Phenotype and Genotype:   These ass ays will be 
performed in the Jiang Laboratory (CCHMC, Cincinnati, OH).  5 -10 mL of saliva will be 
collected in a sterile cup and aliquot into 5 1mL tubes which can then be frozen at < -70°C C 
before being shipped to the Jiang Lab.  Buccal swab will be colle cted by [CONTACT_270655].  This should provide enough buccal cells for the analysis. 
Swabs are stored in 1 mL distilled water in the swab container and can be sealed then frozen 
at <-70°C before shipment to the Jiang Lab.  
Both p henotypic and genotypic evaluation will be performed to compare results of the two 
methods. In the case of discordant results, for this trial, the results from the phenotypic 
method will be used to classify secretor status.  
a. Secretor Status Phenotypi[INVESTIGATOR_007]:   The secretor status of individual subjects will be 
determined based on the detection of histo -blood group antigens (HBGAs) for the 
secretor antigens (Leb, Ley, H types) vs. the non -secretor antigens (Lea and Lex) in their 
saliva. In this assay, boiled human saliva samples are diluted and used to coat wells of a 
96-well EIA plate in duplicate. The HBGAs present in a sample are determined by [CONTACT_270656] a panel of monoclonal antibodies specific to each individual HBGA. A set of saliva 
samples with known HBGA p rofiles are used as positive and negative controls, including 
at least one positive and one negative control sample for each assay. An OD result >0.[ADDRESS_329931] isotope 
determines if a sa mple is positive for a particular HBGA.  
b. Secretor Status Genotypi[INVESTIGATOR_007]:  A FUT2 genotypi[INVESTIGATOR_270582] -PCR (SSP -PCR) is based on single nucleotide polymorphisms (SNPs) of the 
FUT2 gene. Primers covering three major mutations are synth esized [wild -type 385A (5’ -
DMID  Protocol 16-[ADDRESS_329932] 2019  
 
 
 
70 AGGAGGAATACCGCCACAT), mutated 385T (5’ -GAGGAGGAATACCGCCACT), 
wild-type 428G (5’ -GCTACCCCTGCTCCTGG), mutated 428A (5’ -
CGGCTACCCCTGCTCCTA), wild -type 571C (5’ -TAGGGGTCCATGTTCGCC), and 
mutated 571T (5’ -GTAGGGGTCCATGTTCGCT)].  An ant isense primer (5’ -
GGCTGCCTCTGGCTTAAAG) is paired with FUT2 wild -type and mutated sense 
primers. DNA is extracted from buccal cells in saliva samples. DNA amplification is 
carried out using the following program: 95°C for 2 min, 10 cycles of 95°C for 20 sec , 
66°C for 1 min, and 70°C for 1 min; then 20 cycles of 95°C for 20 sec, 62°C for 1 min, 
and 72°C for 1 min; and a final extension at 72°C for 5 min. The human growth hormone 
gene is used as PCR internal control.  
6. Nitazoxanide Blood Levels for Pharmacokinetic Assessments:   First 20% of the subjects 
who consent (20% convenience sample) will be asked to pro vide PK samples. After 20% 
sample requirements have been met, NU team will notify sites as to no longer ask subject to 
participate in providing  this sample.  
All samples are de -identified with only study assigned numbers. This assay will be 
conducted by [CONTACT_270657], Wavre, Belgium who is the only company that assesses 
nitazoxanide blood levels.  Whole blood sample will be centrifuged (At 1500 g during 10 
minutes at 4°C) within maximum 30 min after blood collection. Blood collection has to be 
performed in Li Hep polyproprylene collection tube. 2 aliquots of around 400µL of plasma 
will be sufficient for tizoxanide determination. A maximum of 486 days has been validated 
for the long term storage of plasma samples below -20°C. Therefore, it’s recommended to 
ship samples to the bioanalytical laboratory after maximum [ADDRESS_329933] to the Jiang lab 
and then onto SGS for testing per Romark, L.C. approved protocol.  
 
8.2.3 Specimen Preparation, Handling, and Shippi[INVESTIGATOR_270583]  (Table 6) . Local laboratories should 
analyze specimens on the day of specimen collection.  
 
Specific instructions will be provided to subjects about specimen handling at home and 
transportation to the study site (outlined in the MOP). The sites may call the subject s the night 
before the in -person visit to remind the subjects  to bring in the samples with them.  
 
 
  
DMID  Protocol 16-[ADDRESS_329934] 2019  
 
 
 
71 Table 6: Specimen Collection, Preparation, Processing and Storage  
Sample Collection 
Schedule for 
Assays  Objective  Study Day  Collection 
Tube  Processed  
Assayed* Processing / 
tubes 
needed  Use as  Storage  
Blood for Serum  
Ig studies  
(NoV -specific IgA, IgG, 
and IgM and total IgG)  Exploratory  1, 28  10mL Gold 
tube Sites  
Jiang Lab  1mL aliquots in 
2mL vials  
2 x 1mL 
required  Frozen  Samples will be shipped to 
Jiang Lab.  
Future Use  180 10mL Gold 
tube Sites  
Jiang Lab  1mL aliquots in 
2mL vials  
2 x 1mL 
required  Frozen  Samples will be shipped to 
Jiang Lab  
Saliva  
Saliva for Secretor Status 
Phenotype and Genotype  Exploratory  1 Sterile Cup  Sites  
Jiang Lab  1mL aliquots in 
2mL vials  
5 x 1mL 
required  Frozen  All samples will be 
shipped to Jiang Lab.  
Buccal Swab  for 
Secretor Status 
Phenotype and Genotype  Exploratory  1 1 swab in 
1mL distilled 
water  No processing  
Jiang Lab  1 swab in 1mL 
distilled water  Frozen  All samples will be 
shipped to Jiang Lab.  
Stool  
NoV Viral Load by [CONTACT_16641]-
PCR  Secondary  1, 7, 14, 21, 28, 
60, 120, 180, and 
with recurrent 
diarrhea  1g aliquots  Sites  
Jiang Lab  1g aliquots  
2 x 1g required  Frozen  Samples will be shipped to 
Jiang Lab.  
Ig studies  
(NoV -specific IgA, IgG, 
and IgM  Exploratory  1, 28, 60  1g aliquots  Sites  
Jiang Lab  1g aliquots  
2 x 1g required  Frozen  Samples will be shipped to 
Jiang Lab.  
Future Use  14, 120, 180  1g aliquots  Sites  
Jiang Lab  1g aliquots  
2 x 1g required  Frozen  Shipped to Jiang Lab  
NoV RT -PCR and 
Sequencing  Exploratory  1, 28, 60  1g aliquots  Sites  
Jiang Lab  1g aliquots  
1 x 1g required  Frozen  Samples will be shipped to 
Jiang Lab.  
Future Use  7, 14, 21, 120, 
180, and with 
recurrent diarrhea  1g aliquots  Sites  
Jiang Lab  1g aliquots  
1 x 1g required  Frozen  Samples will be s hipped to 
Jiang Lab  
Pathogen Screen 
(BioFire)  Exploratory  1, 180 (all 
subjects) also 7, 
14, 21, 28, 60, 
120, and with 
recurrent diarrhea 
if unformed stool 
on study day  1g aliquots  Sites  
Mortensen Lab  1g aliquots  
1 x 1g required  Frozen  Samples will be shipped to 
Jiang Lab -will provide stool 
aliquots to Mortensen Lab 
([ADDRESS_329935], ML 1010, 
Cincinnati, OH [ZIP_CODE]) as 
requested when ready to 
perform assay.  
Backup Specimen  Exploratory 
and Future 
Use 1, 7, 14, 21, 28, 
60, 120, 180, and 
with recurrent 
diarrhea  1g aliquots  Sites  
Jiang Lab  1g aliquots  
[ADDRESS_329936]. Xi Jason Jiang’s  laboratory at Cincinnati 
Children’s Hospi[INVESTIGATOR_29349]. Northwestern will provide the sites with key required study 
consumables (e.g. blood and stool collection tubes), shippi[INVESTIGATOR_270584] -paid 
shippi[INVESTIGATOR_270585]. Jiang’s laboratory   
Jiang Lab  
Attn: Ming Tan , PhD  
Division of Infectious Diseases, S8.[ADDRESS_329937]  
Cincinnati, OH [ZIP_CODE]  
 
 
In addition, blood collected for the PK testing perfor med will be stored and sent to SGS 
Biopharma SA, Wavre, Belgium for t esting ; samples for PK testing will be sent to SGS 
Biopharma once per year . 
 
Frozen samples will be batched and shipments to the central laboratory will  occur at minimum 
every other month after communication with [CONTACT_265139]’s study coordinator. All residual 
specimens will remain in the Jiang Laboratory until the end of the study. At this time unused 
sample aliquots will be returned to the NUCTC laboratory for banking. Detailed instructions for 
sample preparation, handling, storage and shipment are included in the protocol -specific Manual 
of Procedures.  
 
DMID  Protocol 16-[ADDRESS_329938] for mu ltiple myeloma is 87.1% (95% CI 84.8 -89.1%); 1 year survival for 
acute myeloid leukemia is 75.4% (95%CI 70.2 -79.8%), 72.5% (95%CI 70.6 -74.2%), and 64.8% 
(95%CI 63.1 -66.3%) for autologous, allogeneic (HLA -identical), and allogeneic (matched 
unrelated), resp ectively.93 
  
For SOT, the rate of survival and hospi[INVESTIGATOR_270586], the 
indication for transplantation and the type of organ transplanted (living vs. deceased donor).  For 
patients treated at Northwestern, the 1 year  survival rate is 98.3% for kidney transplant, 87.2% 
for liver transplant and 95.7% for pancreas transplant.  Admission data is typi[INVESTIGATOR_270587] 
30 days for transplant and greatly falls off after 30 days.  At Northwestern, the rate of 30-day 
hospi[INVESTIGATOR_270588] 28% and 13% for deceased and living donor kidney transplantation and 31% 
and 54% for deceased and living donor kidney transplantation.  
 
The safety of nitazoxanide  will be assessed by [CONTACT_270658] e events, laboratory adverse events  and serious adverse events . We observe the 
following safety parameters:  Laboratory values, clinical assessments and subject complaints as 
collected on the subject diary.  
 
The safety follow -up period for nitazoxanide will be through day [ADDRESS_329939] 2019  
 
 
 
74 An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of medicinal (inve stigational) 
product.  The occurrence of an AE may come to the attention of study personnel during study 
visits and interviews of a study recipi[INVESTIGATOR_12189], or upon review by a study 
monitor  
 
Unsolicited clinical AEs are those non serio us AEs that are not being collected as clinical 
outcome measures. For this study, unsolicited clinical AEs to be captured on the appropriate case 
report form, will be only those clinical AEs that meet either of the following criteria  through 60 
days : 
• Resul t in modification in the administration of the study drug (nitazoxanide or 
placebo).  
• Result in discontinuation of the study drug (nitazoxanide or placebo).  
 
The following solicited safety laboratory parameters will be assessed on Day 7, 28 and 60: 
WBC, Hem oglobin, Platelet count, Creatinine, Alkaline Phosphatase, ALT, AST, BUN and 
Bilirubin. Additional laboratory parameters performed as part of the CBC and complete 
metabolic panel results need to be recorded in the source document with the evaluation of the  site 
physician. Those additional laboratory value will need to be reported as AE only if clinically 
significant and not attributable to Norovirus infection or underlying SOT/HSCT medical 
conditions.    
 
Abnormal values observed in the clinical laboratory a ssessment that are conducted by [CONTACT_270659], will be reported as AE only if the site physician assess that the 
laboratory value is clinically significant and not attributable to Norovirus infection or underlying 
SOT/HSCT medi cal conditions. The evaluation should be recorded in the source documents.  
 
Laboratory AEs will be reported as defined in section 9.2. 3. 
 
Information to be collected for these unsolicited clinical AEs and laboratory AEs includes event 
description, time of onset, clinician’s  assessment of severity, relationship to study product 
(assessed only by [CONTACT_8703] a diagnosis - a licensed study 
physician listed on the Form FDA 1572 as the site principal investigator [INVESTIGATOR_11637]-investigator ), and 
time of resolution/stabilization of the event.  These events occurring while on study must be 
documented appropriately regardless of relationship will be followed to adequate resolution.  
 
Any medical condition that is present at the time that the subject is screened should be 
considered as baseline and not reported as an AE.  However, if it deteriorates at any time during 
the study, it should be recorded as an AE as defined above.  
 
DMID  Protocol 16-[ADDRESS_329940] 2019  
 
 
 
75 Severity of Event:   Unsolicited clinical AEs (as defi ned above)  and all protocol specified SAEs  
will be assigned the severity level of Grade 3.  Laboratory AEs will be assessed by [CONTACT_270660] a protocol defined grading system (Appendix B).   
 
Relationship to Study Products:   The clinician’s assessmen t of an AE's relationship to test 
article (study drug) is part of the documentation process, but it is not a factor in determining what 
is or is not reported in the study.  If there is any doubt as to whether a clinical observation is an 
AE, the event shou ld be reported.  AEs must have their relationship to study product assessed 
using the terms:  related or not related.  In a clinical trial, the study product must always be 
suspect.  To help assess, the following guidelines are used.  
 
• Related  – There is a reasonable possibility that the study product caused the adverse event. 
Reasonable possibility means that there is evidence to suggest a causal relationship between 
the study product and the adverse event.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
product caused the event.  
9.2.2 Serious Adverse Events  
 
Hospi[INVESTIGATOR_270589].  
 
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either 
the site principal investigator [INVESTIGATOR_10157], it results in any of the following outcomes through Day 
60: 
• Death,  
• A life -threatening adverse event *, 
• A persisten t or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or  
• A congenital anomaly or birth defect , 
• Important medical events that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_059], may be c onsidered serious when, based upon appropriate medical 
judgment, they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
 
 
DMID  Protocol 16-[ADDRESS_329941] 2019  
 
 
 
76 * Life -threatening adverse event. An adverse event is considered “life -threatening” if, in the 
view of either the investigator or sponsor, its occurrence places the patient or subject at 
immediate risk of death.  It does not include an adverse event that, had it occurred in a more 
severe form, might have caused death.  
 
Unexpected:  An adverse reaction, the nature or severity of which is not consistent with the 
applicable product information (e.g. IB for an unapproved investigational medicinal product).  
SAEs  will be:  
• Assessed by a licensed study physician listed on the Form FDA 1572 as the site principal 
investigator [INVESTIGATOR_11637] -investigator.  
• Recorded on the appropriate SAE form and CRF.  
• Followed through resolution or stabilization by a study physician licensed to  make 
medical diagnoses and listed on the Form FDA 1572 as the site principal investigator [INVESTIGATOR_119251]-investigator.  
• Reviewed and evaluated by [CONTACT_4318] (periodic review), DMID, and the IRB.  
 
9.2.[ADDRESS_329942] Values or 
Abnormal Clinical Findings  
 
The site principal investigator [INVESTIGATOR_29353] -investigator is responsible for recording all 
AE/SAEs that are observed or reported during this trial, regardless of the relationship to study 
product.  AE/SAEs, abnormal laboratory test values, or abnormal clinical findings will be 
collected, assessed, documented, reported, and followed appropriately.  
 
The criteria for an abnormal laboratory test finding being classified as an AE are any of the  
follow ing and will be documented on the AE form : 
• Test result is associated with a sign or symptom , and/or  
• Test result requires additional diagnostic testing , and/or  
• Test result requires a medical or surgical intervention , and/or  
• Test result leads to a change in stu dy dosing outside of the protocol defined dosing or 
discontinuation from the study treatment , and/or  
• Test result requires significant additional treatment, i.e. addition of new medication, 
significant increase in dose of current medication  
 
Baseline clinic al labs performed on Day 1 (screening/enrollment visit) might fall outside of the 
normal range. Laboratory values in all subsequent visits for subjects in which baseline clinical 
labs results fall outside the normal range will be considered adverse events only if there is a 
worsening in the grading of the event (e.g., value that on screening falls within grade 1, and 
subsequently on grade 2 will be considered AE; value that on both screening and on subsequent 
testing fall within grade 2 will not be consider ed AE).  
DMID  Protocol 16-[ADDRESS_329943] a clinically significant worsening and not 
attributable to Norovirus infection or underlying SOT/HSCT medical conditions will be reported 
as AEs.  
 
The protocol defined  grading system is used to determine the cut off point for reporting. As such, 
laboratory results that are abnormal according to the local laboratory reference range but not 
considered a Grade 1 abnormality, will not be considered laboratory AEs. Those eve nts will be 
followed -up clinically at the discretion of the study site physician.  
9.3 Reporting Procedures  
9.3.1 Serious Adverse Events  
Any AE that meets a protocol -specified  serious criterion  (see section 9.2. 2) through  Day [ADDRESS_329944] 
be submitted immediately (within 24 hours of site awareness ) on an SAE form to the DMID 
Pharmacovigilance Group, at the following address:  
 
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS ) 
[ADDRESS_329945]. Suite 650  
Bethesda , MD 2081 7, [LOCATION_003]  
SAE Hot Line: 1 -[PHONE_889] (US) or 1 -[PHONE_1728] (outside US)  
SAE FAX Phone Number: 1 -[PHONE_1729] (US) or 1 -[PHONE_891] (outside US)  
SAE Email Address: [EMAIL_1393]  
 SAEs will be followed until satisfactory resolution or until the PI [INVESTIGATOR_12749] -Investigator deems the 
event to be chronic or the subject to be stable  
In addition to  the SAE form, selected SAE data fields must also be entered into 
AdvantageEDCSM. Please see the protocol -specific MOP for details regarding this procedure.  
Other supporting documentation of the eve nt may be requested by [CONTACT_154385].  
The site will send a copy of the SAE report(s) to the ISM (as deemed necessary) when they are 
provided to the DMID Pharmacovigilance Group.  The DMID Medical Monitor and DMID 
Clinical Pro ject Manager will be notified of the SAE by [CONTACT_71500].  
The DMID Medical Monitor will review and assess the SAE for regulatory reporting and 
potential impact on study subject safety and protocol conduct.  
DMID  Protocol 16-[ADDRESS_329946], the site 
principal investigator [INVESTIGATOR_29353] -investigator will report the event to the DMID 
Pharmacovigilance Group.  
SAEs will be reported to the IRB in accordance with IRB policy.  
Note:  Hospi[INVESTIGATOR_270590].  
9.3.2 Regulatory Reporti ng for Studies Conducted Under 
DMID -Sponsored IND  
Following notification from the site principal investigator [INVESTIGATOR_29353] -investigator , 
DMID, the Investigational New Drug (IND) sponsor, will report any suspected adverse reaction 
that is both serious  and unexpected.  DMID will report an adverse event as a suspected adverse 
reaction only if there is evidence to suggest a causal relationship between the drug and the 
adverse event.  DMID will notify FDA and all participating site principal investigators (i .e., all 
principal investigators to whom the sponsor is providing drug under its IND(s) or under any 
principal investigator’s IND(s) in an IND safety report of potential serious risks from clinical 
trials or any other source, as soon as possible, but in no  case later than 15 calendar days after the 
sponsor determines that the information qualifies for reporting as specified in 21 CFR Part 
312.32.  DMID will also notify FDA of any unexpected fatal or life -threatening suspected 
adverse reaction as soon as poss ible, but in no case later than 7 calendar days after the sponsor’s 
initial receipt of the information.  Relevant follow up information to an IND safety report will be 
submitted as soon as the information is available.  Upon request from FDA, DMID will submi t to 
FDA any additional data or information that the agency deems necessary, as soon as possible, 
but in no case later than [ADDRESS_329947].  
All serious events designated as “not related” to study product(s), will be reported to the FDA at 
least annually in a summary format.  
9.3.[ADDRESS_329948]’s 
permission all protocol -required samples will be obtained,  and the subject will continue to be 
followed for safety for the duration of this trial . Efforts will be made to follow all pregnancies 
reported during the course of this trial to pregnanc y outcome pe nding the subject’s permission.  
DMID  Protocol 16-[ADDRESS_329949] study 
procedure through  resolution even if this extends beyo nd the study -reporting period. Resolution 
of an AE is defined as the return to pretreatment status or stabilization of the condition with the 
expectation that it will remain chronic. Follow -up procedures, evaluations, and outcomes will be 
recorded on the a ppropriate data collection form.  
 
9.5 Halting Rules  
Further enrollment will be halted for DSMB review/recommendation if any of the following are 
reported  through Day 60 : 
• Two or more  subject s experience a study product -related SAE.  
• ≥4 subjects  experience the same severe (Grade 3) study product -related unsolicited  AE 
until 80 subjects enrolled  or ≥5% or more subjects  experience the same severe (Grade 3) 
study product -related unsolicited  AE after [ADDRESS_329950] been enrolled . 
• ≥4 subjects  experience the same severe (Grade 3) study product -related safety laboratory 
AE until 80 subjects enrolled  or ≥5% or more subjects  experience the same severe (Grade 
3) study product -related safety laborato ry AE  after [ADDRESS_329951] been enrolled . 
Further enrollment will be halted for DSMB review/recommendation if the ratio of each clinical 
adverse outcome incidence rate per subject between the study arms is  two or higher through Day 
180: 
• Death:  Minimum o f 4 or more subjects experience death in all study arms . 
• Hospi[INVESTIGATOR_059]:  Minimum of 10 or more subjects experience hospi[INVESTIGATOR_270591] . 
• Graft rejection:  Minimum of 5 or more subjects experience graft rejection in all study 
arms . 
• Graft loss :  Minimum of 5 or more subjects experience graft loss in all study arms  
• Renal insufficiency, defined as a 20% or greater increase in serum creatinine relative to 
screening/enrollment/baseline value:  Minimum of 10 or more subjects experience renal 
insuffi ciency in all study arms . 
 
DMID retains the authority to suspend additional enrollment and study interventions/  
administration of study product during the entire study, as applicable.  
 
 
DMID  Protocol 16-[ADDRESS_329952] 2019  
 
 
 
80 9.6 Safety Oversight (ISM plus SMC or DSMB)  
9.6.[ADDRESS_329953] , the principal investigator (PI) will identify a physician with 
relevant expertise, to act as a Secondary Medical Assessor (SMA ). The SMA will examine a 
subject and/or medical records and provide a medical assessment (or second medical opi[INVESTIGATOR_1649]) to 
the DMID of the safety event in question. The PI [INVESTIGATOR_270592], a summary of the 
event and include the PI [INVESTIGATOR_270593] s.   
 
Note: In the case that DMID has requested this type of evaluation multiple times, DMID may 
request the site(s) identify a SMA to assist DMID with safety oversight.   
9.6.[ADDRESS_329954] (DSMB)  
Safety oversight will be conducted by a DSMB that is an independent group of experts that 
monitors subject safety and advises DMID.  The DSMB members will be separate and 
independent of study personnel participating in this trial and should not have scientific, financial 
or other conflict of int erest related to this trial.  The DSMB will consist of members with 
appropriate expertise to contribute to the interpretation of the data from this trial.  
 
The DSMB will operate under the rules of a DMID -approved charter that will be written at the 
organiz ational meeting o f the DSMB. Procedures for DSMB reviews/meetings will be defined in 
the charter. Reports may include enrollment and demographic information, medical history, 
concomitant medications, physical assessments, clinical laboratory values, dosing  compliance, 
and solicited and unsolicited AE/SAEs.   The DSMB will review SAEs on a regular basis and ad 
hoc during this trial. The DMID Medical Monitor and the ISM (as deemed necessary) will be 
responsible for reviewing SAEs in real time.  
 
 The DSMB will  review and discuss study data:  
 
• At the following enrollment milestones with the relevant percentage of patients 
completing Day 60 of the study: 25% (N=40), 50% (N=80), 75% (N=120);the DSMB 
will review available safety data through Day [ADDRESS_329955] nitazoxanide retreatment data .   
• Final review meeting: [ADDRESS_329956] 
summary format.  The DSMB may be asked to provide recommendations in response to 
questions posed by [CONTACT_122830].  
• Ad hoc review: may be in response to a safety issue such as a halting rule being met.  
DMID  Protocol 16-[ADDRESS_329957] 2019  
 
 
 
81  
(Enrollment will be m onitored to ensure there is a DSMB review each year of the study during 
active enrollment.  In the case one of the enrollment milestones has not be met and a review has 
not occurred within the previous [ADDRESS_329958] the DSM B review the study for 
safety.)  
  
The DSMB may also be convened for an ad hoc meeting. An Ad hoc meeting is an unplanned 
meeting that is called for a specific purpose such as when a study halting rule is met.   The 
meeting can be requested by [CONTACT_270661] (such as the 
PI, DSMB, DMID, industry collaborator).   In the case of an ad hoc meeting, the DSMB may 
request special reports on an as -needed basis.   
 
If the study is discontinued, subjects will not receive study product and , follow -up visits for 
safety would continue.  
 
Additional data may be requested by [CONTACT_4318], and interim statistical reports may be generated 
as deemed necessary and appropriate by [CONTACT_122830]. The DSMB may receive data in aggregate and 
presented by [CONTACT_2939]. The DS MB may also be provided with expected and observed rates 
of the expected AEs in an unblinded fashion, and may request the treatment assignment be 
unblinded for an individual subject if required for safety assessment. The DSMB will review 
grouped and unblin ded data in the closed session only. As an outcome of each review/meeting, 
the DSMB will make a recommendation as to the advisability of proceeding with study 
investigational product  (as applicable), and to continue, modify, or terminate this trial . 
 
DMID  Protocol 16-[ADDRESS_329959] protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet sponsor, ICH/GCP guidelines and applicable regulations, and that this trial is 
conducted in accordance with the protocol, protocol -specific MOP and applicable sponsor 
standard operating procedures.  DMID, the sponsoring agency, or its designee will conduct  site-
monitoring visits as detailed in the clinical monitoring plan.  
Site visits will be made at standard intervals as defined by [CONTACT_149098].  Monitoring visits will include, but are not limited to, review of 
regulatory files, accountability records, CRFs, source data (paper and electronic), audit trails, 
ICFs, medical and laboratory reports, and protocol and GCP compliance.  Site monitors will 
have access to the study site, study personnel, and all study docume ntation  according to the 
DMID -approved site monitoring plan.  Study monitors will meet with site principal investigators 
to discuss any problems and actions to be taken and document visit findings and discussions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
DMID  Protocol 16-[ADDRESS_329960] at t he 5% two -sided level of significance.  
11.2 Sample Size Considerations  
Sample size calculations assume a 50% reduction in the median duration of diarrhea for the 
nitazoxanide -treated group compared to those receiving placebo. The median diarrhea duration 
for th e placebo group is assumed to be 135 days, while the median diarrhea duration for the 
treatment group is assumed to be 67.5 days. Given these assumptions, a sample size of 64 
subjects in each arm (128 total) is required to achieve 90% power using the Log -Rank test. 
Accounting for a 20% attrition rate, final sample size will be 80 in each arm (160 total).  
 
Though discouraged, the protocol allows for subjects in either study group to receive additional 
nitazoxanide after [ADDRESS_329961] study outcomes (longest time to clinical resolution of diarrhea) will be the 
most likely to receive additional trea tment.  Subjects receiving additional treatment will be 
imputed as having the worst outcome (time to resolution censored at 180 days). Accounting for 
this imputation method, the power attained for the primary comparison was computed via 
simulation (R versi on 3.0.3).  Estimated power is displayed in the following table, varying the 
proportion of subjects in each study group who receive additional treatmen t 
 
  Proportion Receiving Additional Treatment in the Placebo Group  
  0% 5% 10% 15% 20% 25% 30% 
Proportion 
re-treated in 
the 
nitazoxanide 
Group  0% 91.3%  91.6%  91.7%  91.6%  91.8%  92.0%  92.3%  
5% 91.4%  91.5%  91.6%  91.2%  91.2%  91.8%  92.5%  
10% - 91.5%  92.0%  91.2%  91.8%  91.2%  92.2%  
15% - - 90.7%  90.7%  91.0%  91.6%  91.8%  
20% - - - 87.3%  87.1%  87.0%  87.7%  
25% - - - - 74.0%  73.9%  75.2%  
30% - - - - - 40.0%  40.9%  
 
DMID  Protocol 16-[ADDRESS_329962] 2019  
 
 
 
84 For example, if 15% of placebo subjects receive nitazoxanide, and 5 -10% of subjects in the 
nitazoxanide -treated group receive additional treatment, the power is estimated to be 91.2%.  
Note that implausible scenarios (where substantially more nitazoxanide subjects receive 
additional treatment than do placebo subjects) have been omitted from the table.  
11.[ADDRESS_329963] 
deviation or inter -quartile range. Summary statistics for discrete data will include absolute and 
relative frequencies and confidence intervals where appropriate.  
 
In presenting statistical inferences, the statistical claim (i.e. null and al ternative hypotheses) will 
be clearly stated, the method used for hypothesis testing will be described and appropriately 
referenced, and the assumptions underlying the methods will be validated.  
 
More details of the analyses to be performed will be include d in a separate Statistical Analysis 
Plan.   
 
11.4.2  Analysis Populations  
The safety population (grouped by [CONTACT_147246]) will include all subjects who are 
randomized, have received at least one dose of study treatment and have at least one safety 
assessment.  
DMID  Protocol 16-[ADDRESS_329964] 2019  
 
 
 
85 The modified intent -to-treat (mITT) population includes all randomized subjects who received at 
least one dose of assigned study drug . Analyses are performed according to randomized 
treatment assignment, not the treatment received.  
The per -protocol (PP) population will include all subjects who met all inclusion /exclusion 
criteria, complied with the assigned study product, complied with the daily diary, and were 
followed up until resolution of symptoms, or completed [ADDRESS_329965] if he/she takes at least 
75% of the scheduled doses through [ADDRESS_329966] is considered to be compliant with the daily diary if he/she is missing n o more than 
1.5/7 days per week over the 8 weeks.  
11.4.3  Efficacy Analyses  
[IP_ADDRESS]  Analysis of Primary Outcome Measure  
The primary efficacy outcome measure is the time from randomization to initial clinical 
resolution of Norovirus for at least [ADDRESS_329967]  and will be defined as:  
a. Cessation of vomiting and  
b. No stools classified by [CONTACT_270614] (Type 6 or 7)  
 
The primary efficacy outcome measure will be assessed in the mITT population. Subjects who 
receive additional treatment with nitazoxanide other than their assigned study product will be 
considered censored at [ADDRESS_329968] to take into account the 
stratification at ra ndomization. Estimates for median time to resolution and corresponding 95% 
confidence intervals will be reported for each treatment arm.  
We will consider 80% compliance across the monitoring period acceptable [missing no more 
than 1.5/7 days per week over an 8 week period]. While we will not exclude patients, who are 
below this compliance for any monitoring period, we will conduct a sensitivity analysis 
comparing those with few missing values to those with [ADDRESS_329969] t o missing data  for the primary endpoint, the primary analysis will be handled as 
follows:  
• Data that are missing after a subject has reached clinical resolution will not affect the 
primary time to event analysis and therefore will be ignored  
• Subjects who dr op out, are lost to follow -up, withdraw consent, or otherwise stop 
completing daily diary entries before clinical resolution will be censored on the day of their 
last completed diary  
• Subjects with a gap in outcome data prior to clinical resolution will be handled depending 
on their last completed diary entry and their next completed diary entry:  
▪ If the last completed diary entry and the next completed diary entry have the same 
outcome (i.e., they are still symptomatic on both days or they have no symptoms 
on both days), then the gap will be imputed with the same outcome  
▪ If this imputation results in the subject being defined as having clinical resolution 
during this gap, their time to resolution will be the median of the interval  
• If the last completed diary entry and the next completed diary entry have different 
outcomes (i.e., the last one is symptomatic and the next one is asymptomatic, or vice 
versa), then the gap will be imputed with a symptomatic outcome (no resolution)  
 
The above method will be consider ed primary and additional methods such as worst case 
scenario or best case scenario may be explored as supportive analyses to assess robustness of 
results.  
 
[IP_ADDRESS]  Analysis of Secondary Efficacy Outcome Measures  
All secondary efficacy outcome measures will be ass essed in the mITT and PP populations 
separately.  
 
The secondary efficacy outcome measures are as follows:  
1. The time from the randomization to first negative viral load  through [ADDRESS_329970] 2019  
 
 
 
87  
Secondary o utcome measure 2 will be assessed using analysis of covariance (ANCOVA) 
adjusting for baseline viral titer.  
[IP_ADDRESS]   Sensitivity Analysis of Primary and Secondary Efficacy Outcome Measures  
As a sensitivity analysis, all primary and secondary efficacy analyses wil l be conducted among 
the subgroup of subjects who do not report chromaturia (discoloration of urine) based on 
unsolicited self -reporting, in order to help determine if knowledge of this side effect may have 
impacted these outcomes.  
11.4.[ADDRESS_329971] 95% confidence intervals of AEs in aggregate, as well as by 
[CONTACT_270662], will be computed. The number of SAEs will be reported by a detail ed 
listing showing the type, MedDRA coding, relevant dates (treatment dosing dates and AE onset 
and resolution dates), severity, relatedness, and outcome for each event.  
 
[IP_ADDRESS] Analysis of Secondary Safety Outcome Measures  
Safety outcome measures will be analyzed in the safety analysis population.  
 
The safety outcome measures are as follows:  
1. Incidence of unsolicited non -serious adverse events through 60 days.  
2. Incidence of laboratory adverse events (WBC, Hemoglobin, Platelet count, Creatinine, 
Alkaline P hosphatase, ALT, AST, BUN, and Bilirubin) through 60 days.  
3. Incidence of protocol -specified serious adverse events (see section 9.2. 3 for details) 
through 60 days.  
4. Incidence of hospi[INVESTIGATOR_151400] 60 days.  
 
For all safety outcome measures above, the proportion of subjects with events will be presented 
by [CONTACT_166884]. Point estimates for proportions and difference in proportions along 
with the corresponding 95% confidence intervals will be report ed. A Barnard’s exact test at the 
5% two -sided level of significance level will be used for the comparisons of proportions between 
treatment arms.  
11.4.5  Exploratory Analyses  
The exploratory outcome measures are as follows:  
Clinical Improvement;  
1. Time from random ization to initial clinical improvement in Norovirus disease 
through [ADDRESS_329972] 48 hours, as defined by:  
[CONTACT_122851] 16-[ADDRESS_329973] 2019  
 
 
 
88 a. 50% reduction in number of epi[INVESTIGATOR_261635],  
b. Improvement in PO intake, as judged by [CONTACT_20608],  
c. 50% reduction in the nu mber of epi[INVESTIGATOR_270594] 6 or 7 bowel movements and,  
2. Time from randomization to initial cessation of vomiting through Day 180 
(recurrent vomiting will be considered disease recurrence unle ss determined to be 
due to another etiology [i.e. GVHD]).  
3. Time from randomization to subject report of no loss of appetite that is 
maintained for 48 hours through Day 180 (measure will be first time that the 
subject reports that they have no “loss of appet ite” on their daily diary).  
4. Time from randomization to initial cessation of diarrhea through Day 180 
classified by [CONTACT_270618] 6 or 7 bowel movements (recurrent 
diarrhea will be considered disease recurrence unless determined to be due  to 
another etiology [i.e. GVHD]).  
5. Time from randomization to 50% reduction in the amount of antimotility agents 
utilized by [CONTACT_270617] 180. 
6. Number of days of diarrhea through Day s 28 and 180 . 
7. Number of stools classified by [CONTACT_270618] 6 or 7 bowel 
movements through Day 28.  
8. Number of days of IV hydration or total parenteral nutrition (TPN) therapy 
through Day 28.  
9. Total number of  days of hospi[INVESTIGATOR_270522] s 28 and 180 . 
10. Change in patient -reported quality of life as measured by [CONTACT_270619] -5 (global) 
and IBSQOL  (diarrhea specific ) [adult] or Euro QOL -5 Peds  (global) and PedsQL 
GI Module  [children]  from baseline to Day 180.  
11. Change in patient -reported physical function as measur ed by [CONTACT_270663] (Adult) Pediatric Global Health (Peds)  from baseline to Day 
180. 
12. Change in patient -reported emotional distress as measured by [CONTACT_270634], Anxiety, Fatigue (Adult and Peds)  from baseline to Day  180. 
13. Change in patient -reported gastrointestinal symptoms as measured by [CONTACT_270635] (Adult and Peds)  symptoms (6 of 8 subscales)  from baseline to Day 
180. 
14. The effect of co -pathogens, as determined by [CONTACT_270664], 
on the primary outcome measure  
15. Time from randomization until initial clinical resolution of Norovirus symptoms 
for at least [ADDRESS_329974] and will be defined as c essation of vomiting and no 
stools classified by [CONTACT_270614] (Type 6 or 7) from the 
DMID  Protocol 16-[ADDRESS_329975] 2019  
 
 
 
89 total population compared to  the subgroup of subjects who do not report 
chromaturia (discoloration of urine) based on unsolicited self -reporting.   
16. Incidence of  unsolicited non -serious adverse events (see section 9 for details) 
through 60 days,  laboratory adverse events (WBC, Hemoglobin, Platelet count, 
Creatinine, Alkaline Phosphatase, ALT, AST, BUN and Bilirubin) through 60 
days,  protocol -specified serious adverse events (see section 9 for details) through 
60 days, and  Hospi[INVESTIGATOR_151400] 60 days  from the total population compared 
to the subgroup of subjects who do not report chromaturia (discoloration of 
urine) based on unsolicited self -reportin g. 
 
 
Virologic Improvement:  
17. Time to ≥ [ADDRESS_329976] negative viral load through 180 days and the 
change in viral titer between Day 1 and 180  from the total population compared 
to the subgroup of subjects who do not report chromaturia (discoloration of urine) 
based on unsolicited self -reporting.  
 
Immunologic Response:  
22. Change in Norovirus -specific serum and stool IgA, IgM  and IgG between Day 1 
and Day 28 and 60  (stool only) . 
23. Association between change in total lymphocyte count and T cell subsets at Day 1 
and 180 and clinical resolution of symptoms.  
24. Association between change in total lymphocyte count and T cell subsets at Day 1 
and 180 and undetectable quantitative Norovirus PCR.  
25. Association between change in Norovirus -specific serum and stool IgA, IgM  and 
IgG at from  Day 1 to Days 28 and 60 (stool only) and clinical resolution of 
symptoms.  
26. Association bet ween change in Norovirus -specific serum and stool IgA, IgM  and 
IgG from  Day 1  and Days 28 and 60  (stool only) and undetectable quantitative 
Norovirus PCR.  
 
Pharmacokinetics and Dose Response:  
DMID  Protocol 16-[ADDRESS_329977] 2019  
 
 
 
90 27. For subjects consenting to PK draws, concentrations of nitazoxan ide metabolites   
(tizoxanide and tizoxanide glucuronide) [ADDRESS_329978] dose on Day 7 and 
10 minutes before the second dose on Day 21.  
 
Natural History of Disease:  
28. Time to allograft rejection as per each center team . 
29. Time to graft loss as reported to UNOS.  
30. Time to death.   
31. Time to withdrawal from the study because of intolerance or drug related adverse 
events.  
32. Correlation of secretor status as defined by [CONTACT_270636], separately 
and clinical resolution of Norovirus as defined by [CONTACT_53229] . 
 
 
Clinical Improvement:  
For exploratory outcomes [ADDRESS_329979] ratio and 95% 
confidence interval. If baseline demographic variables are shown to be unbalanced among the 
treatment groups, those variables will be adjusted in the Cox model.  
 
For exploratory outcomes [ADDRESS_329980] 
will be considered.  
 
For exploratory outcomes 10-13, subjects will complete Detailed PRO and S ymptom Severity 
questionnaires at each visit to track changes over time in each of the psychosocial and QOL 
constructs.  An ANCOVA model will be fit using the two groups as the between -subjects factor, 
time as the within -subjects factor and baseline scores  as a covariate. In addition, groups will be 
compared on unadjusted change over time using a mixed -design analysis of variance (ANOVA) 
model with all times, including baseline, as a repeated measures factor. Of interest is whether 
DMID  Protocol 16-[ADDRESS_329981] 2019  
 
 
 
91 there are statistically s ignificant pairwise contrasts between the groups on unadjusted change 
between baseline and subsequent time points, and on adjusted change (controlling for baseline).   
 
For exploratory outcome 14, a Cox proportional hazards model will be utilized to determi ne the 
effect of the presence or absence of co -pathogens at any time point on the time to clinical 
resolution of Norovirus symptoms for at least 48 hours through Day 180. A binary covariate 
representing the presence or absence of co -pathogens will be inclu ded in the model. As an 
alternative, if it is determined that subjects’ co -pathogen status changes often throughout the 
study, the effect may be considered as a time -varying covariate.  
 
For exloratoy outcome 15,16 -please see section [IP_ADDRESS]  
 
Virologic Im provement:  
For exploratory outcomes 17-19, analysis of Norovirus sequencing data, mutations will be 
compared between the nitazoxanide and placebo treatment groups. Non -
synonymous/synonymous (dN/dS) mutation analysis will be performed for each subject to 
determine whether selection is occurring within the polymerase, as well as Viral Epi[INVESTIGATOR_270595] (VESPA) and Random Effects Likelihood and Fixed Effects 
Likelihood (REL and FEL) methods to perform site -specific analyses a nd to identify trends 
within the nitazoxanide treatment group and differences between the treatment and placebo 
groups.  
 
For exploratory outcome 20, a Cox proportional hazards model will be utilized to determine the 
effect of the presence or absence of co-pathogens at any time point on the time to first negative 
viral load through 180 days. A binary covariate representing the presence or absence or co -
pathogens will be included in the model. As an alternative, if it is determined that subjects’ co -
pathog en status changes often throughout the study, the effect may be considered as a time -
varying covariate.  
 
For exploratory outcome 21, please see section [IP_ADDRESS]  
 
Immunologic Response:  
For stool immunoglobulin testing, Day [ADDRESS_329982] -treatment level.  The proportion of subjects 
with ≥4 -fold rise in Norovirus -specific Ig titers from Day 1 will be assessed at each follow -up 
time point comparing the nitazoxanide tr eatment group to the placebo group.  
 
Serum Immunoglobulin Testing (Serum total Ig and Norovirus -specific levels):  Day 1 will 
assess baseline values, Day 28 will assess end of treatment levels.  The proportion of subjects 
with ≥[ADDRESS_329983] to difference in changes of Norovirus -specific serum  and stool  IgA, 
IgM and IgG between Day 1 and Day 28  and between Day 1 and Day 60  (for s tool only) . A 
mixed effects model will then be used to compare the treatment and placebo groups with respect 
to difference in the changes of Norovirus -specific serum  and stool  IgA, IgM  and IgG, which will 
use the longitudinal data observed at all three time points.  
 
For exploratory outcomes 23-26, a Fisher’s Z -transformation will be applied to the Pearson 
correlations between change in total lymphocyte count and T cell subsets at Day [ADDRESS_329984].  
 
Pharmacokinetics and Dose Response:  
For exploratory outcome 27, plasma concentrations of nitazoxanide metabolites in subjects 
consenting for PK blood draws at two time points will be described an d summarized. Descriptive 
statistics (e.g. n, mean, standard deviation, % CV, median, and range) will be calculated for each 
sampling time.  
 
Cox proportional hazard regression models will be used to examine the dose response 
relationship of Day [ADDRESS_329985] 48 hours 
through Day 180. Additional analyses of PK endpoints may be described in the SAP.  
 
 
Natural History of Diseas e: 
Exploratory outcomes 28-[ADDRESS_329986] 2019  
 
 
 
93 12 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research records in compliance 
with ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of 
confidentiality of subjects. Each site will permit authorized representatives of the DMID, its 
designees, and appropriate regulatory agencies to examine (and when required by [CONTACT_1289], 
to copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of 
the study safety and progress. These representatives will be permitted access to all source data  
and source documents , which include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office 
charts, laboratory notes, memoranda, subjects’ memory aid or evaluatio n checklists, pharmacy 
dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_12192], microfiches, photographic negatives, microfilm 
or magnetic media, x -rays, and subject  files and records kept at the pharmacy, at the laboratories, 
and medico -technical departments involved in the clinical trial.  
 
 
DMID  Protocol 16-[ADDRESS_329987] igational site is responsible for conducting routine quality control (QC)  and quality 
assurance (QA) activities to internally monitor study progress and protocol compliance.   Each 
site Principal Investigator [INVESTIGATOR_270596] -related source data/source 
documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection 
by [CONTACT_3482]. Each site Principal Investigator [INVESTIGATOR_270597].  
 
DMID -designated clinical monitors will verify the clinical trial data are generated, documented 
(recorded), and reported in compliance with the protocol, Good Clinical Practice standards, and 
the applicable regul atory requirements.   Clinical monitoring reports will be submitted to DMID.  
 
The Statistical and Data Coordinating Center (SDCC) will implement quality control procedures 
beginning with the data entry system; database quality control checks will be impleme nted. Any 
missing data or data anomalies will be communicated to the site(s) for clarification and 
resolution . 
DMID  Protocol 16-[ADDRESS_329988] 2019  
 
 
 
95 14 ETHICS/PROTECTION OF HUMAN SUBJECTS  
14.[ADDRESS_329989]  
The site principal investigator (PI) will ensure that this trial is conducted in full confor mity with 
principles of the Belmont Report:  Ethical Principles and Guidelines for the Protection  of Human 
Subjects of Research ( National Commission for the Protection of Human Subjects of Biome dical 
and Behavioral Research [April 18, 1979 ]) and codified i n [ADDRESS_329990]  
Each site principal investigator [INVESTIGATOR_270598]/her  research site(s), and send  supporting documentation to the DMID before initiating 
recruitment of subjects .  The investigator will submit applicable information to the IRB/IEC on 
which it relies for the review , to conduct the review in accordance with 45 CFR 46, ICH E6 
GCP, and as applicable , 21 CFR 56 (Institutional Review Boards) and 21 CFR 50 (Protection of 
Human Subjects) , other federal, state, and local regulations.  The IRB/IEC must  be registered 
with OHRP [ OHRP -only or OHRP/FDA ] as applicable to the research.  DMID  must receive the 
documentation that verifies IRB/IEC -approval for  this protocol, associated inform ed consent 
documents, and upon request any recruitment material and handouts or surveys intended for the 
subjects , prior to the recruitment and enrollment of subjects.     
Any amendments to the protocol or consent materials will be approved by [CONTACT_1201]/IEC before 
they are implemented.  IRB/IEC review and approval will occur at least annually throughout the  
enrollment and follow -up of subjects, and may cease if annual review is no longer required by 
[CONTACT_5279] .  The investigator will notify the IR B/IEC of deviations from the protocol 
and reportable SAEs, as applicable to the IRB/IEC policy.  
Each institution engaged in this research will hold a current Federalwide  Assurance (FWA) 
issued by [CONTACT_28820] (OHRP) for federally  funded research.  
 
 
 
 
DMID  Protocol 16-[ADDRESS_329991] 2019  
 
 
 
96 14.3 Informed Consent Process  
 
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial participation.  Before any study procedures 
are performed, informed consent will be obtained and documented.  Subjects will receive a 
concise and focused presentation of key information about the clinical trial, verbally and with a 
written consent form. The explanation will be organized, and presented i n lay terminology and 
language that facilitates understanding why one might or might not want to participate.  
An investigator or designee will describe the protocol to potential subjects face -to-face. The key 
information about the purpose of the study, the  procedures and experimental aspects of the study, 
risks and discomforts, any expected benefits to the subject, and alternative treatment will be 
presented first to the subject.   
Subjects will also receive an explanation that the trial involves research, and a detailed summary 
of the proposed study procedures and study interventions/products.  This will include aspects of 
the trial that are experimental, the probability for random assignment to treatment groups, any 
expected benefits, all possible risks (i ncluding a statement that the particular treatment or 
procedure may involve risks to the subject or to the embryo or fetus, if the subject is or may 
become pregnant, that are currently unforeseeable), the expected duration of the subject’s 
participation in  the trial, alternative procedures that may be available and the important potential 
benefits and risks of these available alternative procedures.  
Subjects will be informed that they will be notified in a timely manner if information becomes 
available tha t may be relevant to their willingness to continue participation in the trial. Subjects 
will receive an explanation as to whether any compensation and any medical treatments are 
available if injury occurs, and, if so, what they consist of, or where further  information may be 
obtained. Subjects will be informed of the anticipated financial expenses, if any, to the subject 
for participating in the trial, as well as any anticipated prorated payments, if any, to the subject 
for participating in the trial. They will be informed of whom to contact (e.g., the investigator) for 
answers to any questions relating to the research project.  
Information will also include the foreseeable circumstances and/or reasons under which the 
subject’s participation in the trial may  be terminated. The subjects will be informed that 
participation is voluntary and that they are free to withdraw from the study for any reason at any 
time without penalty or loss of benefits to which the subject is otherwise entitled.   
The extent of the c onfidentiality of the subjects’ records will be defined, and subjects will be 
informed that applicable data protection legislation will be followed. Subjects will be informed 
that the monitor(s), auditors(s), IRB, NIAID, and regulatory authority(ies) will be granted direct 
access to the subject’s original medical records for verification of clinical trial procedures and/or 
data without violating the confidentiality of the subject, to the extent permitted by [CONTACT_270665] 16-[ADDRESS_329992] will be kept confidential, and, to 
the extent permitted by [CONTACT_29695]/or regulations, will not be  made publicly 
available and, if the results of the trial are published, the subject’s identity will remain 
confidential. Subjects will be informed whether private information collected from this research 
and/or specimens will be used for additional resear ch, even if identifiers are removed.    
Subjects will be allowed sufficient time to consider participation in this research trial, and have 
the opportunity to discuss this trial with their family, friends or legally authorized representative, 
or think about  it prior to agreeing to participate.  
Informed consent forms will be IRB -approved,  and subjects will be asked to read and review the 
consent form. Subjects must sign the informed consent form prior to starting any study 
procedures being done specifically for this trial.  
 
Once signed, a copy of the informed consent form will be given to the subject(s) for their 
records.  The subject(s) may withdraw consent at any time throughout the course of the trial.  
The rights and welfare of the subject(s) will be protected by [CONTACT_270666].  
Study personnel may employ recruitment efforts prior to obtaining study consent if a patient -
specific screening consent is on record or if the IRB has agreed that chart review is allowed 
without  a fully executed screening consent.  In cases where there is not a patient -specific 
screening consent on record, site Clinical staff  may pre -screen via chart review and refer 
potential subjects to the Research staff.  Research staff would obtain written c onsent per the 
standard informed consent process before conducting protocol -specific screening activities.  
New information will be communicated by [CONTACT_16541] [INVESTIGATOR_270599] r equirements.  The informed consent document 
will be updated,  and subjects will be re -consented per IRB requirements, if necessary.  Subjects 
will be given a copy of all informed consent forms that they sign.  
14.3.1  Informed Consent/Assent Process (in Case of a Mi nor)  
Investigators will follow IRB/IEC requirements for enrollment of minors in this study.  Minors 
will be informed about the study to the extent understandable to the minor.  Investigators or 
designee will conduct the consent process with the p arent(s)/l egal guardian , who  will be given an 
IRB/IEC -approved permission form, which may be referred to as a consent form, to read, review, 
and sign prior to any study procedures. The parent(s)/legal guardian will be provided meaningful 
study information including a statement that this study involves research,  the child may not 
benefit from the trial, and the study involves risk. The required elements will be clearly 
presented, including the purpose of the study, the experimental procedures, the potential risks 
DMID  Protocol 16-[ADDRESS_329993]’s parent( s)/legal guardian will be  allowed 
sufficient time to discuss questions with the investigator.   
The investigator or designee will describe  in simplified terms the details of the study 
intervention/product, study procedures, risks and discomforts, benefits, and other consent 
elements, as appropriate . A separate IRB/IEC -approved assent form will be used for the minor, 
who may read and sign the  form , or have it read to him/her  prior to participation in study 
procedures.   Assent may be obtained verbally or waived when approved by [CONTACT_1201]/IEC as 
appropriate to age.  If a child declines to participate in the trial when assent is required by [CONTACT_5040]/IEC, the subject will not be enrolled even though the parents have provided permission.   
To ensure that consent is an ongoing process throughout the subject’s participation in the study, 
the investigator and staff will review information as needed with th e subject and the 
parent(s)/legal guardian and confirm that assent and permission are continuing.  The permission 
and assent documents will be updated when new information is acquired that may impact the 
decision to continue in the study, and the subject’s  assent and the parent(s)/legal guardian’s 
permission will be obtained, as applicable.   
14.4 Exclusion of Women, Minorities, and Children (Special Populations)  
This trial will be inclusive of all subjects who are ≥ 12 years  of age and thus will follow all 
guidelines detailed in Subpart D – Additional Protections for Children Involved as Subjects in 
Research (45 CFR Part 46.401 -409) who meet the Subject Inclusion/Exclusion Criteria, 
regardless of religion, gender, or ethnic background.   
 
14.[ADDRESS_329994] by [CONTACT_3486], their staff, and 
the sponsor(s) and their agents. This confidentiality includes documentation, investigation data, 
subject’s clinical information, and all other informat ion generated during participation in the 
study. No information concerning the study or the data generated from the study will be released 
to any unauthorized third party without prior written approval of the DMID and the subject. 
Subject confidentiality w ill be maintained when study results are published or discussed in 
conferences.  The study monitor or other authorized representatives of the sponsor or 
governmental regulatory agencies may inspect all documents and records required to be 
maintained by [CONTACT_11168], including but not limited to, medical records (office, clinic, or 
hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this study. The clinical study site will permit 
access to such records.  
All records will be kept locked and all computer ent ry and networking programs will be carried 
out with coded numbers only and with password protected systems.  All non -clinical specimens, 
DMID  Protocol 16-[ADDRESS_329995] the site will be identified only by a coded 
number.  
 
The study m onitor, representatives from the NIH/DMID, representatives from Northwestern 
University and their affiliates, applicable regulatory authorities, such as the FDA and the IRB, 
representatives of Romark, L.C. , or other authorized representatives of the sponso r may inspect 
all documents and records required to be maintained by [CONTACT_093], including but not 
limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in 
this study.  The clinical study sites will permit ac cess to such records.  
 
To protect privacy, we have received a Certificate of Confidentiality.  With this Certificate, the 
researchers cannot be forced to release information that may identify the research subject, even 
by a court subpoena, in any federal, state, or local civil, criminal, administrative, legislative, or 
other proceedings.  The researchers will use the Certificate to resist any demands for information 
that would identify the subject, except as explained below.  
The Certificate cannot be used to resist a demand for information from personnel of the United 
States Government that is used for auditing or evaluation of federally funded projects, like this 
study, or for information that must be released in order to meet the requirements of t he Federal 
Food and Drug Administration (FDA).  
A Certificate of Confidentiality does not prevent the subject from voluntarily releasing 
information about themselves or their involvement in this research.  If any person or agency 
obtains a written consent t o receive research information, then the researchers may not use the 
Certificate to withhold that information.   
The Certificate of Confidentiality does not prevent the researchers from reporting without the 
subject’s consent, information that would identify the subject as a participant in the research 
project regarding matters that must be legally reported including : child and elder abuse, sexual 
abuse, or wanting to harm themselves or others.   
14.6 Study Discontinuation  
If the study is prematurely terminated by [CONTACT_78269], any regulatory authority, or the 
investigator for any reason, the investigator will promptly info rm the study subjects and assure 
appropriate therapy or follow -up for the subjects, as necessary. The investigator will provide a  
detailed written explanation of the termination to the IRB/IEC . If any subject’s private 
information will continue to be colle cted for this study, the IRB/IEC must approve a consent 
form with the study procedures, any risks and discomforts, and applicable elements, and the 
investigator or designee will re -consent the subjects as approved by [CONTACT_1201]/IEC.  
 
In the event that the stu dy is discontinued, subjects who were randomized to study drug can 
continue the use of the medication at the discretion of their clinician.  
DMID  Protocol 16-[ADDRESS_329996] to subjects for taking part in this tria l. 
Subjects may be compensated for their participation in this trial.  Compensation will be in 
accordance with the local IRB’s policies and procedures, and subject to IRB approval (no more 
than $25/visit).  
If it is determined by [CONTACT_270667] [INVESTIGATOR_270600] a subject as a result of the tests or treatments that are done for this trial, then referrals 
to appropriate health care facilities will be provided to the subject.  Study personnel will try to 
reduce, control, and treat any complications from this trial.  Immediate medical treatment may be 
provided by [CONTACT_16529], such as giving emergency medications to stop allergic 
reactions to the study drug.  No financial compensation will be provide d to the subject by [CONTACT_270668]  
 
14.[ADDRESS_329997] udies with the 
stored specimens, e.g., each  sample will be encoded (labeled) only with a barcode and a unique 
tracking number to protect the subject’s confidentiality.  
 
Subjects may be given the option to decide if they want their samples to be used for f uture 
research or have their samples destroyed at the end of the trial.  The subject’s decision can be 
changed at any time by [CONTACT_270669]’s in writing, and the unused identifiable 
samples will be destroyed.  However, if the subject originall y consents to future use and 
subsequently changes his/her decision, any data obtained prior to the withdrawal of consent may 
still be used for research . 
 
All sites will follow guidelines of local IRB offices in regard to  the need to obtain re -consent 
from minors for future use once they reach the age of consent.  Samples may be shared with 
investigators at the other participating sites or investigators at o ther institutions. Samples will not 
be sold or used directly for production of commercial product.  
 
 
DMID  Protocol 16-[ADDRESS_329998] KEEPI[INVESTIGATOR_114744], completeness, legibility, and timeliness of 
the data reported.  A ll source documents should be completed in a neat, legible manner to ensure 
accurate interpretation of data.  Black  or blue permanent  ink is required to ensure clarity of 
reproduced copi[INVESTIGATOR_014].  When making changes or corrections, cross out the original entry with a 
single line, and initial and date the change.  DO NOT ERASE, OVERWRITE, OR USE 
CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source data collection forms 
and maintained for recording data f or each subject enrolled in the study.  Data reported in the 
eCRF derived from source data collection forms should be consistent or the discrepancies should 
be explained.  
DMID  and/or its designee will provide guidance to the site principal investigators and other 
study personnel on making corrections to the data collection forms and eCRF.  
15.[ADDRESS_329999] maintain complete and accurate documentation for the study.  
The data coordinating center  for this  study will be responsible for data management, quality 
review, analysis, and reporting of the study data.  
 
Emmes  will serve as the Statistical and Data Coordinating Center for th is study and will be 
responsible for data management, quality review, analysi s, and reporting of the study data.  
15.2 Data Capture Methods  
Clinical data (including AEs, concomitant medications data) and clinical laboratory data will be 
entered into a 21 CFR Part 11 -compliant Internet Data Entry System (IDES) provided by [CONTACT_270670].  The d ata system includes password protection and internal quality checks, such as 
automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate.  
Clinical data will be entered directly from the source documents . 
15.3 Types of Data  
Data  for this study will inclu de safety, laboratory (immunologic and virologic), and patient 
reported outcome measures -patient diary  (safety, adverse events).  
 
DMID  Protocol 16-[ADDRESS_330000] 2019  
 
 
 
102 15.4 Timing/Reports  
 
A final clinical study report will be prepared following availability of all safety,  PK, and efficacy 
data.  See Section 9.6.[ADDRESS_330001]. Consents with future use provisions will be 
retained until all samples are used or destroyed.   All study  documents will be retained for a 
longer period, however, if required by [CONTACT_427]. No records will be destroyed without the 
written consent of the sponsor. It is the responsibility of the sponsor to inform the inve stigator 
when these documents no longer need to be retained.    
15.6 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical study protocol, Good Clinical 
Practice (GCP), or Manual of Procedures requirements.  The noncompliance may be either on 
the part of the subject, the investigator, or the study site staff.  As a re sult of deviations, 
corrective actions are to be developed by [CONTACT_3483].  
 
 
These practices are consistent with ICH E6:  
 
4.[ADDRESS_330002] be promptly reported to DMID, via 
The SDDC’s AdvantageEDCSM.  
 
All deviations from the protocol must be addressed in study subject source documents.  A 
completed copy of the DMID Pro tocol Deviation Form must be maintained in the regulatory file, 
as well as in the subject’s source document.  Protocol deviations must be sent to the local IRB 
per their guidelines.  The site PI/study staff is responsible for knowing and adhering to their IRB 
requirements.  
DMID  Protocol 16-[ADDRESS_330003] submitted for them to the National 
Library of Medicine’s PubMed Central ( http://www.ncbi.nlm.nih.gov/pmc/ ) an electronic 
version of their final, peer -reviewed manu scripts upon acceptance for publication, to be made 
publicly available no later than [ADDRESS_330004] be accessible to the public on PubMed C entral no later than 12 
months after publication.  
Refer to:  
• NIH Public Access Policy, http://publicaccess.nih.gov/  
• NIH Office of Extramural Research (OER) Grants and Funding, 
http://grants.nih.gov/grants/oer.htm  
As of January 2018, all clinical trials supp orted by [CONTACT_12242].gov, no later than [ADDRESS_330005] applied for certification of delayed posting.  
As part of the result posting a copy of this protocol (and its amendments) and a copy of the 
Statistical Anal ysis Plan will be posted on ClincialTrials.gov . 
For this trial  the responsible party is [DMID ] which will register the trial and post results.   
The responsible party [DMID ] to request certification of delayed posting.  
Refer to:  
• Public Law 110 -85, Section 801, Clinical Trial Databases  
• 42CFR11  
• NIH NOT -OD-16-[ADDRESS_330006] 2019  
 
 
 
104 17 LITERATURE REFERENCES  
1. Kaufman SS, Green KY, Korba BE. Treatment of Norovirus infections: moving antivirals 
from the bench to the bedside. Antiviral Res. 2014;105:80 -91. doi: 
10.1016/j.antiviral.2014.02.012. PubMed PMID: 24583027.  
2. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J 
Gastroenterol. 1997;32(9):920 -4. doi: 10.3109/00365529709011203. PubMed PMID: 
9299672.  
3. Bok K, Green KY. Noro virus gastroenteritis in immunocompromised patients. N Engl J Med. 
2012;367(22):2126 -32. doi: 10.1056/NEJMra1207742. PubMed PMID: 23190223.  
4. Ruvoen -Clouet N, Belliot G, Le Pendu J. Noroviruses and histo -blood groups: the impact of 
common host genetic polymo rphisms on virus transmission and evolution. Rev Med Virol. 
2013;23(6):355 -66. doi: 10.1002/rmv.1757. PubMed PMID: 23959967.  
5. Bresee JS, Marcus R, Venezia RA, Keene WE, Morse D, Thanassi M, et al. The etiology of 
severe acute gastroenteritis among adults vi siting emergency departments in the United 
States. J Infect Dis. 2012;205(9):1374 -81. doi: 10.1093/infdis/jis206. PubMed PMID: 
22454468.  
6. Boillat Blanco N, Kuonen R, Bellini C, Manuel O, Estrade C, Mazza -Stalder J, et al. Chronic 
Norovirus gastroenteritis i n a double hematopoietic stem cell and lung transplant recipi[INVESTIGATOR_841]. 
Transpl Infect Dis. 2011;13(2):213 -5. doi: 10.1111/j.1399 -3062.2010.[ZIP_CODE].x. PubMed 
PMID: 20804535.  
7. Echenique IA, Penugonda S, Stosor V, Ison MG, Angarone MP. Diagnostic yields in solid 
organ transplant recipi[INVESTIGATOR_270601]. Clin Infect Dis. 2015;60(5):729 -37. doi: 
10.1093/cid/ciu880. PubMed PMID: 25371488.  
8. Henke -Gendo C, Harste G, Juergens -Saathoff B, Mattner F, Deppe H, Heim A. New real -
time PCR detects prolonged Norovirus excr etion in highly immunosuppressed patients and 
children. J Clin Microbiol. 2009;47(9):2855 -62. doi: 10.1128/JCM.[ZIP_CODE] -09. PubMed 
PMID: 19625473; PubMed Central PMCID: PMC2738087.  
9. Kundu S, Lockwood J, Depledge DP, Chaudhry Y, Aston A, Rao K, et al. Next -gene ration 
whole genome sequencing identifies the direction of Norovirus transmission in linked 
patients. Clin Infect Dis. 2013;57(3):407 -14. doi: 10.1093/cid/cit287. PubMed PMID: 
23645848; PubMed Central PMCID: PMC3703108.  
10. Lee BE, Pang XL, Robinson JL, Bigam D, Monroe SS, Preiksaitis JK. Chronic Norovirus 
and adenovirus infection in a solid organ transplant recipi[INVESTIGATOR_841]. Pediatr Infect Dis J. 
2008;27(4):360 -2. doi: 10.1097/INF.0b013e31815f5b5a. PubMed PMID: 18316991.  
11. Robles JD, Cheuk DK, Ha SY, Chiang AK, Chan GC . Norovirus infection in pediatric 
hematopoietic stem cell transplantation recipi[INVESTIGATOR_840]: incidence, risk factors, and outcome. Biol 
Blood Marrow Transplant. 2012;18(12):1883 -9. doi: 10.1016/j.bbmt.2012.07.005. PubMed 
PMID: 22796532.  
12. Glass RI, Parashar UD, Es tes MK. Norovirus gastroenteritis. N Engl J Med. 
2009;361(18):1776 -85. doi: 10.1056/NEJMra0804575. PubMed PMID: 19864676; PubMed 
Central PMCID: PMC3880795.  
DMID  Protocol 16-[ADDRESS_330007] common 
strain of " Norwalk -like viruses" having a global distribution. J Infect Dis. 1999;179(6):1334 -
44. doi: 10.1086/314783. PubMed PMID: 10228052.  
14. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus 
classification and proposed strain nomenclature. Vi rology. 2006;346(2):312 -23. doi: 
10.1016/j.virol.2005.11.015. PubMed PMID: 16343580.  
15. Chan MC, Sung JJ, Lam RK, Chan PK, Lee NL, Lai RW, et al. Fecal viral load and 
Norovirus -associated gastroenteritis. Emerg Infect Dis. 2006;12(8):1278 -80. doi: 
10.3201/eid 1208.060081. PubMed PMID: 16965715; PubMed Central PMCID: 
PMC3291221.  
16. Teunis PF, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, et al. Norwalk virus: how 
infectious is it? J Med Virol. 2008;80(8):1468 -76. doi: 10.1002/jmv.[ZIP_CODE]. PubMed PMID: 
18551613.  
17. Stals A, Mathijs E, Baert L, Botteldoorn N, Denayer S, Mauroy A, et al. Molecular detection 
and genotypi[INVESTIGATOR_270602]. Food Environ Virol. 2012;4(4):153 -67. doi: 10.1007/s12560 -
012-9092 -y. PubMed PMID: 23412888.  
18. Mathijs E, Stals A, Baert L, Botteldoorn N, Denayer S, Mauroy A, et al. A review of known 
and hypothetical transmission routes for Noroviruses. Food Environ Virol. 2012;4(4):131 -52. 
doi: 10.1007/s12560 -012-9091 -z. PubMed PMID: 23412887.  
19. Dolin R, Blacklow NR, DuPont H, Formal S, Buscho RF, Kasel JA, et al. Transmission of 
acute infectious nonbacterial gastroenteritis to volunteers by [CONTACT_270671]. J Infect Dis. 1971;123(3):307 -12. PubMed PMID: 5111887.  
20. Green KY. Caliciviridae:  The Noroviruses. In: Knipe DM, Howley PM, editors. Fields 
Virology 6th Edition. Philadelphia: Wolters Kluwer; 2013. p. 582 -608. 
21. Tan M, Jiang X. Histo -blood group antigens: a common niche for Norovirus and rotavirus. 
Expert Rev Mol Med. 2014;16:e5. doi: 10.1017/erm.2014.2. PubMed PMID: [ADDRESS_330008] symptomatic 
GII.4 Norovirus infection. PLoS One. 2009;4(5):e5593. doi: 10.1371/journal.pone.00 [ZIP_CODE]. 
PubMed PMID: 19440360; PubMed Central PMCID: PMC2680586.  
23. Currier RL, Payne DC, Staat MA, Selvarangan R, Shirley SH, Halasa N, et al. Innate 
Susceptibility to Norovirus Infections Influenced by [CONTACT_270672]2 Genotype in a [LOCATION_002] 
Pediatric Population. C lin Infect Dis. 2015. doi: 10.1093/cid/civ165. PubMed PMID: 
25744498.  
24. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, et al. Human 
susceptibility and resistance to Norwalk virus infection. Nat Med. 2003;9(5):548 -53. doi: 
10.1038/nm860. Pu bMed PMID: 12692541.  
25. Nordgren J, Kindberg E, Lindgren PE, Matussek A, Svensson L. Norovirus gastroenteritis 
outbreak with a secretor -independent susceptibility pattern, Sweden. Emerg Infect Dis. 
2010;16(1):81 -7. doi: 10.3201/eid1601.090633. PubMed PMID: 20 031047; PubMed Central 
PMCID: PMC2874438.  
26. Han L, Kitova EN, Tan M, Jiang X, Pluvinage B, Boraston AB, et al. Affinities of human 
histo -blood group antigens for Norovirus capsid protein complexes. Glycobiology. 
DMID  Protocol 16-[ADDRESS_330009] 2019  
 
 
 
106 2015;25(2):170 -80. doi: 10.1093/glycob/cwu100.  PubMed PMID: 25395406; PubMed 
Central PMCID: PMC4351396.  
27. Wyatt RG, Dolin R, Blacklow NR, DuPont HL, Buscho RF, Thornhill TS, et al. Comparison 
of three agents of acute infectious nonbacterial gastroenteritis by [CONTACT_12783] -challenge in 
volunteers. J Infect Dis.  1974;129(6):709 -14. PubMed PMID: 4209723.  
28. Czako R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK. Serum 
hemagglutination inhibition activity correlates with protection from gastroenteritis in persons 
infected with Norwalk virus. Clin Vaccine Immunol . 2012;19(2):284 -7. doi: 
10.1128/CVI.[ZIP_CODE] -11. PubMed PMID: 22190401; PubMed Central PMCID: PMC3272916.  
29. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral 
immunity following Snow Mountain virus challenge. J Virol. 2005; 79(5):2900 -9. doi: 
10.1128/JVI.79.5.2900 -2909.2005. PubMed PMID: 15709009; PubMed Central PMCID: 
PMC548455.  
30. Chachu KA, LoBue AD, Strong DW, Baric RS, Virgin HW. Immune mechanisms 
responsible for vaccination against and clearance of mucosal and lymphatic No rovirus 
infection. PLoS Pathog. 2008;4(12):e1000236. doi: 10.1371/journal.ppat.1000236. PubMed 
PMID: 19079577; PubMed Central PMCID: PMC2587711.  
31. Saif MA, Bonney DK, Bigger B, Forsythe L, Williams N, Page J, et al. Chronic Norovirus 
infection in pediatric h ematopoietic stem cell transplant recipi[INVESTIGATOR_840]: a cause of prolonged 
intestinal failure requiring intensive nutritional support. Pediatr Transplant. 2011;15(5):505 -
9. doi: 10.1111/j.1399 -3046.2011.[ZIP_CODE].x. PubMed PMID: 21504523.  
32. Wingfield T, Gallimore CI, Xe rry J, Gray JJ, Klapper P, Guiver M, et al. Chronic Norovirus 
infection in an HIV -positive patient with persistent diarrhoea: a novel cause. J Clin Virol. 
2010;49(3):219 -22. doi: 10.1016/j.jcv.2010.07.025. PubMed PMID: 20863753.  
33. Kaplan JE, Gary GW, Baron R C, Singh N, Schonberger LB, Feldman R, et al. Epi[INVESTIGATOR_270603]. Ann Intern Med. 1982;96(6 Pt 1):756 -61. PubMed PMID: 6283977.  
34. Patel MM, Hall AJ, Vinje J , Parashar UD. Noroviruses: a comprehensive review. J Clin 
Virol. 2009;44(1):1 -8. doi: 10.1016/j.jcv.2008.10.009. PubMed PMID: 19084472.  
35. Trivedi TK, Desai R, Hall AJ, Patel M, Parashar UD, Lopman BA. Clinical characteristics of 
Norovirus -associated deaths:  a systematic literature review. Am J Infect Control. 
2013;41(7):654 -7. doi: 10.1016/j.ajic.2012.08.002. PubMed PMID: 23266383.  
36. Lee LY, Ison MG. Diarrhea caused by [CONTACT_270673][INVESTIGATOR_840]. Transpl Infect Dis. 
2014;16(3):347 -58. doi: 10.1111/tid.12 212. PubMed PMID: 24750282.  
37. Kaufman SS, Chatterjee NK, Fuschino ME, Morse DL, Morotti RA, Magid MS, et al. 
Characteristics of human calicivirus enteritis in intestinal transplant recipi[INVESTIGATOR_840]. J Pediatr 
Gastroenterol Nutr. 2005;40(3):328 -33. PubMed PMID: 157 [ZIP_CODE].  
38. Roddie C, Paul JP, Benjamin R, Gallimore CI, Xerry J, Gray JJ, et al. Allogeneic 
hematopoietic stem cell transplantation and Norovirus gastroenteritis: a previously 
unrecognized cause of morbidity. Clin Infect Dis. 2009;49(7):1061 -8. doi: 10.1086/60 5557. 
PubMed PMID: 19705974.  
39. Roos -Weil D, Ambert -Balay K, Lanternier F, Mamzer -Bruneel MF, Nochy D, Pothier P, et 
al. Impact of Norovirus/sapovirus -related diarrhea in renal transplant recipi[INVESTIGATOR_270604] 16-[ADDRESS_330010] 2019  
 
 
 
107 for diarrhea. Transplantation. 2011;92(1):61 -9. doi: 10.1097/TP.0b013e31821c9392. 
PubMed PMID: 21555974.  
40. Schorn R, Hohne M, Meerbach A, Bossart W, Wuthrich RP, Schreier E, et al. Chronic 
Norovirus infection after kidney transplantation: molecular evidence for immune -driven viral 
evolution. Clin Infect Dis. 2010;51(3):307 -14. doi: 10.1086/653939. PubMed PMID: 
20575662.  
41. Simon A, Schildgen O, Maria Eis -Hubinger A, Hasan C, Bode U, Buderus S, et al. Norovirus 
outbreak in a pediatric oncology unit. Scand J Gastroenterol. 2006;41(6):693 -9. doi: 
10.1080/003655 20500421694. PubMed PMID: 16716968.  
42. Alkhouri N, Danziger -Isakov L. Norovirus and severe chronic gastroenteritis in pediatric 
stem cell transplantation: the plot thickens. Pediatr Transplant. 2011;15(7):671 -2. doi: 
10.1111/j.1399 -3046.2011.[ZIP_CODE].x. PubMed P MID: 21736680.  
43. Doshi M, Woodwell S, Kelleher K, Mangan K, Axelrod P. An outbreak of Norovirus 
infection in a bone marrow transplant unit. Am J Infect Control. 2013;41(9):820 -3. doi: 
10.1016/j.ajic.2012.10.025. PubMed PMID: 23415769.  
44. Lemes LG, Correa TS, Fiaccadori FS, Cardoso D, Arantes Ade M, Souza KM, et al. 
Prospective study on Norovirus infection among allogeneic stem cell transplant recipi[INVESTIGATOR_840]: 
prolonged viral excretion and viral RNA in the blood. J Clin Virol. 2014;61(3):329 -33. doi: 
10.1016/j.jcv.2 014.08.004. PubMed PMID: 25171964.  
45. Schwartz S, Vergoulidou M, Schreier E, Loddenkemper C, Reinwald M, Schmidt -Hieber M, 
et al. Norovirus gastroenteritis causes severe and lethal complications after chemotherapy 
and hematopoietic stem cell transplantation. Blood. 2011;117(22):5850 -6. doi: 
10.1182/blood -2010 -12-325886. PubMed PMID: 21487110.  
46. Chehade H, Girardin E, Delich V, Pascual MA, Venetz JP, Cachat F. Acute Norovirus -
induced agranulocytosis in a pediatric kidney transplant recipi[INVESTIGATOR_841]. Transpl Infect Dis. 
2012;14(4):E27 -9. doi: 10.1111/j.1399 -3062.2012.[ZIP_CODE].x. PubMed PMID: 22676808.  
47. Engelen MA, Gunia S, Stypmann J. Elimination of Norovirus in a chronic carrier under 
immunosuppression after heart transplantation --effect of everolimus. Transpl Int. 
2011;24(11):e102 -3. doi: 10.1111/j.1432 -2277.2011.[ZIP_CODE].x. PubMed PMID: 21880072.  
48. Westhoff TH, Vergoulidou M, Loddenkemper C, Schwartz S, Hofmann J, Schneider T, et al. 
Chronic Norovirus infection in renal transplant recipi[INVESTIGATOR_840]. Nephrol Dial Transplant. 
2009;24(3):1051 -3. doi: 10.1093/ndt/gfn693. PubMed PMID: 19073655.  
49. Lee L, Ho B, Lapin B, Ladner DP, Ison MG. Norovirus Infection in the Solid Organ 
Transplant Recipi[INVESTIGATOR_841].  World Transplant Congress; San Francisco, [LOCATION_004]2014.  
50. Ye X, Van JN, Munoz FM, Revel l PA, Kozinetz CA, Krance RA, et al. Noroviruses as a 
Cause of Diarrhea in Immunocompromised Pediatric Hematopoietic Stem Cell and Solid 
Organ Transplant Recipi[INVESTIGATOR_840]. Am J Transplant. 2015. doi: 10.1111/ajt.[ZIP_CODE]. PubMed 
PMID: 25788003.  
51. Kele B, Lengyel G, D eak J. Comparison of an ELISA and two reverse transcription 
polymerase chain reaction methods for Norovirus detection. Diagn Microbiol Infect Dis. 
2011;70(4):475 -8. doi: 10.1016/j.diagmicrobio.2011.04.002. PubMed PMID: 21767704.  
DMID  Protocol 16-[ADDRESS_330011] 2019  
 
 
 
108 52. Atmar RL, Neill FH, Le Guya der FS. Detection of human caliciviruses in fecal samples by 
[CONTACT_270674]-PCR. Methods Mol Biol. 2011;665:39 -50. doi: 10.1007/978 -1-[ZIP_CODE] -817-1_3. PubMed 
PMID: 21116794.  
53. Hochleitner BW, Bosmuller C, Nehoda H, Fruhwirt M, Simma B, Ellemunter H, et al. 
Increased tacro limus levels during diarrhea. Transpl Int. 2001;14(4):230 -3. doi: 
10.1007/s0014710140230. PubMed PMID: 11512055.  
54. Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y. Cytochrome 
P450 3A4 and P -glycoprotein activity and assimilation of tacr olimus in transplant patients 
with persistent diarrhea. Am J Transplant. 2005;5(6):1383 -91. doi: 10.1111/j.1600 -
6143.2005.[ZIP_CODE].x. PubMed PMID: 15888045.  
55. Ebdrup L, Bottiger B, Molgaard H, Laursen AL. Devastating diarrhoea in a heart -
transplanted patient. J  Clin Virol. 2011;50(4):263 -5. doi: 10.1016/j.jcv.2010.11.007. PubMed 
PMID: 21126906.  
56. Florescu DF, Hermsen ED, Kwon JY, Gumeel D, Grant WJ, Mercer DF, et al. Is there a role 
for oral human immunoglobulin in the treatment for Norovirus enteritis in 
immunoco mpromised patients? Pediatr Transplant. 2011;15(7):718 -21. doi: 10.1111/j.1399 -
3046.2011.[ZIP_CODE].x. PubMed PMID: 21883746.  
57. Florescu DF, Hill LA, McCartan MA, Grant W. Two cases of Norwalk virus enteritis 
following small bowel transplantation treated with ora l human serum immunoglobulin. 
Pediatr Transplant. 2008;12(3):372 -5. doi: 10.1111/j.1399 -3046.2007.[ZIP_CODE].x. PubMed 
PMID: 18221419.  
58. Chen Z, Sosnovtsev SV, Bok K, Parra GI, Makiya M, Agulto L, et al. Development of 
Norwalk virus -specific monoclonal antibodies  with therapeutic potential for the treatment of 
Norwalk virus gastroenteritis. J Virol. 2013;87(17):9547 -57. doi: 10.1128/JVI.[ZIP_CODE] -13. 
PubMed PMID: 23785216; PubMed Central PMCID: PMC3754140.  
59. White CA, Jr. Nitazoxanide: a new broad spectrum antiparasitic  agent. Expert Rev Anti 
Infect Ther. 2004;2(1):43 -9. PubMed PMID: 15482170.  
60. Basu PP, Rayapudi K, Shah NJ, Krishnaswamy N, Brown RS. Effects of triple -drug therapy 
with nitazoxanide, high -dose ribavirin and peginterferon -alpha -2a in patients with chronic 
hepatitis C. Hepatol Res. 2013;43(6):589 -95. doi: 10.1111/hepr.[ZIP_CODE]. PubMed PMID: 
23228134.  
61. Doumbo O, Rossignol JF, Pi[INVESTIGATOR_93350] E, Traore HA, Dembele TM, Diakite M, et al. 
Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic 
infections associated with acquired immunodeficiency syndrome in tropi[INVESTIGATOR_270605]. Am J 
Trop Med Hyg. 1997;56(6):637 -9. PubMed PMID: 9230795.  
62. Rossignol JF, Abaza H, Friedman H. Successful treatment of human fascioliasis with 
nitazoxanide. Trans R Soc Trop M ed Hyg. 1998;92(1):103 -4. PubMed PMID: 9692168.  
63. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by [CONTACT_270675] E. dispar: a randomized, double -blind, placebo -controlled study of 
nitazoxanide. J Infect Dis . 2001;184(3):381 -4. doi: 10.1086/322038. PubMed PMID: 
11443569.  
DMID  Protocol 16-[ADDRESS_330012] 2019  
 
 
 
109 64. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by [CONTACT_270676]: a prospective randomized, double -blind, placebo -controlled study of Nitazoxanide. J 
Infect Dis. 2001;1 84(1):103 -6. doi: 10.1086/321008. PubMed PMID: 11398117.  
65. Rossignol JF, Hidalgo H, Feregrino M, Higuera F, Gomez WH, Romero JL, et al. A double -
'blind' placebo -controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea 
in AIDS patients i n Mexico. Trans R Soc Trop Med Hyg. 1998;92(6):663 -6. PubMed PMID: 
10326116.  
66. Romero Cabello R, Guerrero LR, Munoz Garcia MR, Geyne Cruz A. Nitazoxanide for the 
treatment of intestinal protozoan and helminthic infections in Mexico. Trans R Soc Trop Med 
Hyg.  1997;91(6):701 -3. PubMed PMID: 9580117.  
67. Abaza H, El -Zayadi A, Kabil SM, Rizk H. Nitazoxanide in the treatment of Patients with 
intestinal protozoan and helminthic infections: A Report on 546 Patients in Egypt. Curr Ther 
Res. 1998;59:116 -21. 
68. Ortiz JJ, Ayou b A, Gargala G, Chegne NL, Favennec L. Randomized clinical study of 
nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in 
children from Northern Peru. Aliment Pharmacol Ther. 2001;15(9):1409 -15. PubMed PMID: 
11552913.  
69. Juan JO , Lopez Chegne N, Gargala G, Favennec L. Comparative clinical studies of 
nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and 
hymenolepi[INVESTIGATOR_270606]. Trans R Soc Trop Med Hyg. 2002;96(2):193 -6. 
PubMed PM ID: 12055813.  
70. Taubel J, Lorch U, Rossignol JF, Ferber G, Camm AJ. Analyzing the relationship of QT 
interval and exposure to nitazoxanide, a prospective candidate for influenza antiviral therapy -
-A formal TQT study. J Clin Pharmacol. 2014;54(9):987 -94. doi:  10.1002/jcph.300. PubMed 
PMID: 24691901.  
71. Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, et al. The anti -hepatitis C 
agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein 
kinase activated by [CONTACT_65752] -strand ed RNA activation. Gastroenterology. 2009;137(5):1827 -
35. doi: 10.1053/j.gastro.2009.07.056. PubMed PMID: 19664635.  
72. Rossignol JF, Abu -Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide for treatment of 
severe rotavirus diarrhoea: randomised double -blind placebo -controlled trial. Lancet. 
2006;368(9530):124 -9. doi: 10.1016/S0140 -6736(06)[ZIP_CODE] -1. PubMed PMID: 16829296.  
73. Rossignol JF, Elfert A, El -Gohary Y, Keeffe EB. Improved virologic response in chronic 
hepatitis C genotype 4 treated with nitazoxanide, pe ginterferon, and ribavirin. 
Gastroenterology. 2009;136(3):856 -62. doi: 10.1053/j.gastro.2008.11.037. PubMed PMID: 
19135998.  
74. La Frazia S, Ciucci A, Arnoldi F, Coira M, Gianferretti P, Angelini M, et al. Thiazolides, a 
new class of antiviral agents effective  against rotavirus infection, target viral morphogenesis, 
inhibiting viroplasm formation. J Virol. 2013;87(20):[ZIP_CODE] -106. doi: 10.1128/JVI.[ZIP_CODE] -13. 
PubMed PMID: 23926336; PubMed Central PMCID: PMC3807293.  
75. Rossignol JF. Nitazoxanide: a first-in-class broad -spectrum antiviral agent. Antiviral Res. 
2014;110:94 -103. doi: 10.1016/j.antiviral.2014.07.014. PubMed PMID: 25108173.  
DMID  Protocol 16-[ADDRESS_330013] 2019  
 
 
 
110 76. Rossignol JF, El -Gohary YM. Nitazoxanide in the treatment of viral gastroenteritis: a 
randomized double -blind placeb o-controlled clinical trial. Aliment Pharmacol Ther. 
2006;24(10):1423 -30. doi: 10.1111/j.1365 -2036.2006.[ZIP_CODE].x. PubMed PMID: 17081163.  
77. Siddiq DM, Koo HL, Adachi JA, Viola GM. Norovirus gastroenteritis successfully treated 
with nitazoxanide. J Infect. 2011 ;63(5):394 -7. doi: 10.1016/j.jinf.2011.08.002. PubMed 
PMID: 21839773; PubMed Central PMCID: PMC3368802.  
78. Morris J, Brown W, Morris CL. Nitazoxanide Is Effective Therapy For Norovirus 
Gastroenteritis After Chemotherapy and Hematopoietic Stem Cell Transplanta tion (HSCT).  
55th American Soceity of Hematology Annual Meeting; December 9, 2013; New Orleans, 
Louisiana2013. p. Abstract 4581.  
79. Morris J, Morris C. Nitazoxanide Is Effective Therapy for Norovirus Gastroenteritis after 
Chemotherapy and Hematopoietic Stem Cell Transplantation (HSCT).  2015 BMT Tandem 
Meetings; San Diego, [LOCATION_004]2015. p. Abstract 358.  
80. Freedman SB, Eltorky M, Gorelick M, Pediatric Emergency Research Canada Gastroenteritis 
Study G. Evaluation of a gastroenteritis severity score for use in o utpatient settings. 
Pediatrics. 2010;125(6):e1278 -85. doi: 10.1542/peds.2009 -3270. PubMed PMID: 20439605.  
81. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for 
clinical severity of diarrhoeal epi[INVESTIGATOR_1841]. Scand J Infect Dis.  1990;22(3):259 -67. doi: 
10.3109/00365549009027046. PubMed PMID: 2371542.  
82. Schnadower D, Tarr PI, Gorelick MH, O'Connell K, Roskind CG, Powell EC, et al. 
Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency 
department s. J Pediatr Gastroenterol Nutr. 2013;57(4):514 -9. doi: 
10.1097/MPG.0b013e31829ae5a3. PubMed PMID: 23676445; PubMed Central PMCID: 
PMC3788842.  
83. EuroQol G. EuroQol --a new facility for the measurement of health -related quality of life. 
Health Policy. 1990;16( 3):199 -208. PubMed PMID: 10109801.  
84. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel 
on Cost -effectiveness in Health and Medicine. JAMA. 1996;276(15):1253 -8. PubMed PMID: 
8849754.  
85. Patrick DL, Drossman DA, Frederick IO, D iCesare J, Puder KL. Quality of life in persons 
with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 
1998;43(2):400 -11. PubMed PMID: 9512138.  
86. Varni JW, Franciosi JP, Shulman RJ, Saeed S, Nurko S, Neigut DA, et al. PedsQL 
Gastrointestinal Symptoms Scales and Gastrointestinal Worry Scales in Pediatric Patients 
with Inflammatory Bowel Disease in Comparison with Healthy Controls. Inflamm Bowel 
Dis. 2015;21(5):1115 -24. doi: 10.1097/MIB.0000000000000351. PubMed PMID: 2579 3327.  
87. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of 
Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 
2001;39(8):800 -12. PubMed PMID: 11468499.  
88. Kahan BC, Morris TP. Improper analysis of trials randomised using stratified blocks or 
minimisation. Stat Med. 2012;31(4):328 -40. doi: 10.1002/sim.4431. PubMed PMID: 
22139891.  
DMID  Protocol 16-[ADDRESS_330014] 2019  
 
 
 
111 89. Rossignol JF, Elfert A, El -Gohary Y, Keeffe EB. Improved virologic response in chronic 
hepatitis C ge notype 4 treated with nitazoxanide, peginterferon, and ribavirin. 
Gastroenterology. 2009 Mar;136(3):856 -62. doi: 10.1053/j.gastro.2008.11.037. Epub 2008 
Nov 19.  
90. Rossignol JF, Elfert A, Keeffe EB. Treatment of chronic hepatitis C using a 4 -week lead -in 
with nitazoxanide before peginterferon plus nitazoxanide. J Clin Gastroenterol. 2010 
Aug;44(7):504 -9. doi: 10.1097/MCG.0b013e3181bf9b15.  
91. Rossignol JF, Kabil SM, El -Gohary Y, Elfert A, Keeffe EB. Clinical trial: randomized, 
double -blind, placebo -controlled stud y of nitazoxanide monotherapy for the treatment of 
patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2008 Sep 
1;28(5):574 -80. doi: 10.1111/j.1365 -2036.2008.[ZIP_CODE].x. Epub 2008 Jun 26.  
92. Rossignol JF. Nitazoxanide in the treatment of acquir ed immune deficiency syndrome -
related cryptosporidiosis: results of the [LOCATION_002] compassionate use program in 365 
patients. Aliment Pharmacol Ther. 2006 Sep 1;24(5):887 -94. 
93. Center for International Blood and Marrow Transplant, a contractor for the C.W . Bill Young 
Cell Transplantation Program operated through the U. S. Department of Health and Human 
Services, Health Resources and Services Administration, Healthcare Systems Bureau. U.S. 
Patient Survival Report, 2008 -2012. Data accessed: October 16, 2016.  
94. Lackner, J. M., Jaccard J., Keefer L, Firth R, Carosella AM, Sitrin M, Brenner D for the 
IBSOS Research Group. The accuracy of patient -reported measures for GI symptoms: a 
comparison of real time and retrospective reports. Neurogastroenterol Motil.  2014 Dec; 
26(12): 1802 -1811. PMID:  2542458  
95. Lee LY, Ladner DP, Ison MG.  Norovirus infection in solid organ transplant recipi[INVESTIGATOR_840]:  A 
single -center retrospective study.  Transplant Infect Dis.  2016;18:932 -938. 
96. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Pa rker MA, Stuart FP.  Alemtuzumab 
induction and prednisone -free maintenance immunotherapy in kidney transplantation:  
Comparison with basiliximab induction – long-term results.  Am J Transplant. 2005; 5: [ADDRESS_330015] 2019  
 
 
DMID/NIAID/NIH           112 
CONFIDENTIAL  APPENDIX A: Schedule of Events  
Phase  Treatment Phase  Longitudinal Monitoring Phase  
 
Procedure  Screen
/Enroll
/Day  
1 Day 7  
(±3 d)  Day 
14₩ 
(±3 d)  Day 
21₩ 
(±3d)  Day 28  
(+3 d) Day 
35 
(±3 
d) Day 
53 
( ± 
7d) Day 
60₩ 
(±14 
d) Day 
113 
 (± 
7d) Day 
120₩ 
(±14 d)  Da
y 
173 
( ± 
7d) Day 
180 
(±14 d)  Unsche
duled 
Visit  Early 
Termination 
visit 
Visit  01 02 03 04 05 06 07 08 09 10 11 12   
Consent1 X              
Urine Pregnancy2 X              
Blood Draw  22.5 
mL₱ 8.5 
mL3   18.5 
mL3       22.5 
mL3  22.5 mL3 
Pi[INVESTIGATOR_38950]   X   X   X10       
Vital Signs *  X X   X   X    X X X 
Medical History  X              
Physical Exam X    X          
Inquiry about 
hospi[INVESTIGATOR_270607]   X X X X  
X  X  X  X  X 
Collect Stool X8¶ X7¶ X7¶ X7¶ X87¶   X87¶  X7¶  X7¶ X7¶ X7¶ 
Buccal 
Swab/Saliva 
Collection  X              
Randomization  X              
Nitazoxanide PK4  4.[ADDRESS_330016] 2019  
 
 
DMID/NIAID/NIH           [ADDRESS_330017] or Review 
Daily Diary6  X X X X   X  X  X X X 
Phone Call    Xⱥ Xⱥ  X X Xⱥ X Xⱥ X    
1Consent/Assent must be obtained from eligible subjects, consistent with local IRB policy for consent and assent of subjects a nd must be obtained prior to any study procedures being performed  
[ADDRESS_330018] be known and negative prior to dosing.  
3Values obtained within 7 days of the study visit, if obtained for clinical indication, can be utilized during the treatment ph ase and within 14 days of the study visit for the longi tudinal monitoring phase.  Blood collection 
includes CBC, Complete Meti bolic Panel, & T Cell Subsets ( T cell subset will be drawn unless CBC shows an ALC<100 ). Serum for Ig studies on Days 28 & 180.  
[ADDRESS_330019]. Study drug ( Nitazoxanide or placebo ) given BID for 28 days.  
6 Diary recorded once a day during the treatment phase and once a day during the longitudinal monitoring phase.  Copi[INVESTIGATOR_270608].  One pack give an enrollment and additional 
copi[INVESTIGATOR_270609] 28.  
7 Stool for pathogen screen will not be performed for formed stool except on Day 1 and 180.  An aliquot will be retained for later testing if indicated.  Norovirus testing includes quantitative viral loa d at all time points.  
8 Sequencing at selected time points.  
10Day 60 pi[INVESTIGATOR_270610] 28.  
₩ Can covert to virtual visit  
DMID  Protocol 16-[ADDRESS_330020] 2019  
 
 
DMID/NIAID/NIH           114 
CONFIDENTIAL  § If diarrhea recurs after stoppi[INVESTIGATOR_270611], would have subject provide a stool specimen for pathogen screen and Norovirus PCR; therapy is at the discretion of the s ite.  
¥ The sample must have been produced within [ADDRESS_330021] it in a bag for   transport then refrigerate until they come to their visit with the research staff. Subjects would be encouraged to provide an other sa mple within the visit window and if not, rectal swab may be used for 
all assays related to stool collection .  
*Vital Signs include weight, Blood Pressure, Respi[INVESTIGATOR_1516], Pulse, Temperature and Height. Height is only measured at Screening /Enrollment/Baseline visit.  
#Derived from Complete Blood Count.  
€Derived from Complete Metabolic Panel.  
¶Specimen also stored for future use.  
₱Must be within [ADDRESS_330022] 2019  
 
 
DMID/NIAID/NIH           115 
CONFIDENTIAL  Appendix B: Laboratory  Reference Ranges  and Toxicity Grading  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Depending upon the lab used, references ranges, eligibility ranges and grading may be split out by [CONTACT_78471]/or age.  
[ADDRESS_330023] – upper limit of normal; LLN – lower limit of normal  Blood, Serum, or Plasma Chemistries1 Reference 
Range2 LO/
HI/
N3 Mild  
(Grade 1)  Moderate 
(Grade 2)  Severe  
(Grade 3)  
Creatinine (mg/dL)   HI >ULN - 1.[ADDRESS_330024]  >1.5 – 3.[ADDRESS_330025]  >3.[ADDRESS_330026]  
Blood Urea Nitrogen (BUN, mg/dL)   HI >ULN  - 26 27 - 31 >31 
Alkaline phosphatase (U/L)   HI >ULN – 2.[ADDRESS_330027]  >2.5 – 5.[ADDRESS_330028]  >5.[ADDRESS_330029] (U/L)   HI >ULN – 3.[ADDRESS_330030]  >3.0 – 5.[ADDRESS_330031]  >5.[ADDRESS_330032]  
ALT (U/L)   HI >ULN – 3.[ADDRESS_330033]  >3.0 – 5.[ADDRESS_330034]  >5.[ADDRESS_330035]  
Bilirubin, serum total (mg/dL)   HI >ULN – 1.[ADDRESS_330036]  >1.5 – 3.[ADDRESS_330037]  >3.[ADDRESS_330038] 2019  
 
 
DMID/NIAID/NIH           116 
CONFIDENTIAL  Hematology  Reference 
Range 4 LO/H
I/N5 Mild  
(Grade 1) 6 Moderate 
(Grade 2)  Severe  
(Grade 3)  
Hemoglobin  (g/dL)    LO <LLN – 10.0 <10.0 – 8.0 <8.0   
     
White Blood Cell Count (WBC, K/CUMM )   HI >ULN  - 15.00  15.00 - 20.00  >20.00   
 LO <LLN – 3.0 <3.0 – 2.0 <2.0 
Platelets (K/CUMM)   LO <LLN - 75 <75 - 50 <50 
 
Other Laboratory Parameters   LO 
/HI Test result is 
associated with a 
mild sign or 
symptom . Test result 
requires 
minimal, local 
or non -invasive 
intervention.  Test result requires an 
invasive medical or 
surgical intervention, or 
change in study dosing 
outside of t he protocol 
defined dosing or 
discontinuation from the 
study treatment, or 
addition of new 
medication.   
 
[ADDRESS_330039] – upper limit of normal; LLN – lower limit of normal  
 
 
 
DMID  Protocol 16-[ADDRESS_330040] 2019  
 
 
DMID/NIAID/NIH           117 
CONFIDENTIAL   
 Appendix C: Patient Diary Components  
 
Symptom Diary  
Bristol Stool Scale  Lewis SJ, Heaton KW (1997). "Stool form scale as a useful guide to 
intestinal transit time". Scand. J. Gastroenterol. 32 (9): 920 –4. 
doi:10.3109/[ADDRESS_330041] Scale (weekly 
diary only)  Public domain, http://www.parqol.com/page.cfm?id=87  
Watson, D., Clark, L. A., & Tellegen, A. (1988). Development and 
validation of brief measures of positive and negative affect: The 
PANAS scales. Journal of Psychology, 54(6), 1063 -1070.  
Other individual 
questions about 
diarrhea, nausea and 
abdominal pain  Additional items in daily/weekly symptom diary were either validated 
in [CONTACT_270679]’s NIH Trial or were arrived at with expert consensus 
with study investigators  
 
No copyright, [CONTACT_270679] is a Co -investigator on this trial  
Detailed Patient Reported Outcome a nd Severity Score Assessment  
PROMIS Short 
Forms -- Adults   
 
 
PROMIS measures in English and Spanish are publicly available 
without license, fee, or royalty.  
 
http://www.healthmeasures.net/explore -measurement -systems/promis ;  
 
https://www.ncbi.nlm.nih.gov/pmc/articl es/PMC2829758/  
 Depression  
Anxiety  
Fatigue  
Sleep Disturbance  
GI symptoms  
Physical function  
Fecal incontinence  
PROMIS Short -
Forms -- Pediatrics  
Depression  
Anxiety  
Fatigue  
EuroQOL -5D Validated general QOL measure, permission obtained and study 
registered with company http://www.euroqol.org/  
IBS-Quality of Life 
Scale  Validated GI specific QOL measure, Permission requested/study 
registered with ePROVIDE    
DMID  Protocol 16-[ADDRESS_330042] 2019  
 
 
DMID/NIAID/NIH           118 
CONFIDENTIAL  https://eprovide.mapi -trust.org/instruments/irritable -bowel -syndr ome-
quality -of-life 
 
PedsQL4  Validated general QOL measure for pediatrics, Permission 
requested/study registered with PEDSQL 
http://www.pedsql.org/pedsql13.html  
 
 